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Summary 
BACKGROUND:  
This PhD project is part of the research area concerning effects of endocrine disrupters at the 
National Food Institute at DTU in Denmark. Endocrine disrupting chemicals (EDCs) have proved 
to be important for improper development of the male reproductive organs and subsequent for the 
potential inability to reproduce. Most recently, it was found that combinations of chemicals - each 
at a concentration where the single compound gave no effect - led to significant effects in 
experimental animals. There is a need for more knowledge about the mechanisms behind the 
observed effects, to be able to detect effects and predict mixture effects. In addition, a new 
hypothesis have emerge concerning a potential role of exposure to endocrine disrupting chemicals, 
and the development of obesity and obesity related diseases.  
 
AIM:  
This PhD project aimed to gain more information regarding the mechanisms behind the effects of 
EDCs. The focus of the current project has been on the use of in vitro assays to investigate: 
• The endocrine disrupting potential of phytoestrogens (PEs) and mixtures of PEs  
• How PEs and mixtures of PEs affect pathways involved in the development of obesity 
• The use of in vitro metabolising systems in conection with in vitro testing of EDCs 
  
METHODS:  
Twelve dietary relevant phytoestrogens (PEs) either alone or in mixtures were analysed in a battery 
of in vitro bioassays designed to look for effects on: a) steroid hormone production in human 
adrenal corticocarcinoma cells (H295R steroid synthesis assay), b) aromatase activity in human 
JEG-3 choriocarcinoma cells, c) estrogenic activity using the human MCF-7 cell proliferation assay, 
d) interaction with the androgen receptor (AR) in a reporter gene assay, e) effects on adipogenesis 
in the 3T3-L1 preadipocyte cell line, and f) effect on PPAR α and γ using a transactivation assay.  
For the in vitro metabolism studies, ten selected EDCs: five azole fungicides, three parabens, and 
two phthalates, were tested in vitro in the T-screen assay to determine possible changes in the 
ability of the EDCs to bind to and activate the thyroid receptor (TR) after biotransformation. The 
two in vitro metabolising systems applied were human liver S9 mix and PCB-induced rat 
microsomes. The ability of the two selected in vitro metabolising systems to metabolise the ten test 
 5
Summary
compounds, as well as the evaluation of the endogenous metabolic capacity of the GH3 cells, 
applied in the T-Screen assay, were examined using LC-MS analysis 
 
RESULTS: 
The results showed that all the tested PEs and PE-mixtures increased estradiol production in the 
H295R cells. The mixture containing all tested PEs, as well as the isoflavonoids also decreased 
testosterone production in H295R cells, indicating an induced aromatase activity. Furthermore, 
many of the tested PE-mixtures significantly stimulated MCF-7 human breast adenocarcinoma cell 
growth, and induced aromatase activity in JEG-3 choriocarcinoma cells.  
In the PPAR transactivation assay, the different PE-mixtures had stronger effect on PPARγ than on 
PPARα, with some mixtures showing PPARγ agonistic effects while others had more PPARγ 
antagonistic effects. Furthermore, the tested single PEs, as well as mixtures of PEs had an inhibitory 
effect on lipid accumulation in vitro, although at higher concentrations than nutritionally relevant.  
 
In the in vitro metabolism studies no marked difference in the effects in the T-screen assay was 
observed between the parent compounds and the tested metabolic extracts. The GH3 cells 
themselves significantly metabolised the two tested phthalates, dimethyl phthalate (DMP) and 
diethyl phthalate (DEP). The two in vitro metabolizing systems tested gave an almost complete 
metabolic transformation of the tested parabens and phthalates, with a recovery rate of the parent 
compounds of less than 1%. However, a difference was found between the human S9 and rat 
microsome assay systems when looking at the metabolism of the azole fungicides. The PCB-
induced rat microsomes gave a statistically significant difference between the amount of parent 
compound before and after treatment with the microsomes for four out of the five azole fungicides 
tested. When using the human liver S9, no significant metabolic transformation of the azole 
fungicides was detected.  
 
CONCLUSIONS AND PERSPECTIVES:  
Overall, the results from the studies presented in this thesis support the evidence suggesting that 
nutrition relevant concentrations of PEs, both alone and in mixtures, induce various endocrine 
disrupting effects. The main effect seems to be an estrogenic effect mediated both at the receptor 
level as seen in the MCF-7 cell proliferation assay, but also at the level of steroid synthesis, as seen 
in the H295R cell assay. Additionally, many PEs, as well as mixtures of PEs have an inhibitory 
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effect on lipid accumulation in vitro, an effect that could involve the estrogen receptor, and also a 
result that could suggest a beneficial effect of PEs with regard to obesity. However, the role of the 
different players involved in adipogenesis and lipolysis is still not understood. Therefore, based on 
the current results, the influence of PEs on adipogenesis and their effects on the different pathways 
involved in the development of obesity and obesity related diseases remains unclear, and needs 
further investigation.  
Finally, the results and qualitative data from the in vitro metabolising studies show that an in vitro 
metabolising system using liver S9 mixtures or hepatic rat microsomes could be a convenient 
method for the incorporation of metabolic aspects into in vitro testing for endocrine disrupting 
effects. 
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Dansk resumé 
BAGGRUND:  
Dette Ph.d.-projekt er en del af den forskning indenfor hormonforstyrrende stoffer, der foregår på 
DTU, Fødevareinstituttet i Danmark. Hormonforstyrrende stoffer har gennem de senere år vist sig 
at have betydning for udviklingen af misdannelser af drengebørns kønsorganer og for deres senere 
eventuelle manglende evne til at reproducere sig. Senest har det vist sig, at kombinationer af 
kemikalier - hver ved en koncentration, hvor enkeltstoffet ikke gav nogen effekt - medførte 
markante effekter i dyreforsøg. Der er brug for mere viden om mekanismerne bag de observerede 
effekter, for bedre at kunne detektere og forudsige dem, bl.a. også, når det gælder effekter af 
kombinationer af flere stoffer. Derudover er der indenfor området hormonforstyrrende stoffer 
kommet et nyt emne på banen, nemlig hvorvidt hormonforstyrrende stoffer kan have indvirkning på 
fedmeparametre og dermed på udviklingen af fedme og fedme relaterede sygdomme.  
  
FORMÅL:  
Formålet med dette Ph.d.-projekt har været at udbygge vores viden omkring mekanismerne bag 
effekterne af hormonforstyrrende stoffer. Fokus i dette projekt har været på brug af in vitro assays 
til at undersøge: 
• De hormonforstyrrende egenskaber af phytoøstrogener og blandinger af phytoøstrogener 
• Hvordan phytoøstrogener og blandinger af phytoøstrogener påvirker signalveje involveret i 
udviklingen af fedme 
• Brugen af in vitro metaboliserings systemer i forbindelse med in vitro testning af 
hormonforstyrrende stoffer  
 
METODER:  
Tolv fødevare relevante phytoøstrogener enten alene eller i forskellige blandinger, blev analyseret i 
et batteri af in vitro bioassays (celleforsøg) designet til at undersøge efter effekter på: a) steroid 
hormon produktion i humane binyre corticocarcinoma celler (H295R steroid syntese assay’et), b) 
aromatase aktivitet i humane JEG-3 choriocarcinoma celler, c) østrogen aktivitet ved brug af det 
humane MCF-7 celle proliferations assay, d) interaktion med androgen receptoren (AR) i et 
reportergen assay, e) effekter på dannelsen af 3T3-L1 fedtceller samt f) påvirkningen af PPARα og 
γ receptorerne ved anvendelse af et transaktiverings assay. 
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Til in vitro metabolismestudierne blev ti udvalgte hormonforstyrrende stoffer: 5 azol fungicider, 3 
parabener og 2 phthalater, testet i T-screen assay’et, for at undersøge eventuelle ændringer i de ti 
stoffers evne at binde til og aktiverer thyreoidea hormon receptoren (TR) efter omdannelse/ 
metabolisering. De to in vitro metaboliseringssystemer, der blev anvendt, var human lever S9-miks 
samt PCB-inducerede rotte mikrosomer. De to metaboliseringssystemers evne til at nedbryde de ti 
hormonforstyrrende stoffer, samt evalueringen af den endogene metaboliske kapacitet af den GH3 
cellelinje, der anvendes i T-Screen assay’et, blev undersøgt ved af LC-MS analyse. 
 
RESULTATER: 
Resultaterne fra de undersøgte phytoøstrogener alene og i forskellige blandinger viste en øget 
østrogen produktion i H295R cellerne. Blandingen indeholdende alle 12 phytoøstrogener samt 
isoflavonoiderne gav også et signifikant fald i testosteron produktion, hvilket kunne tyde på en 
øgning af aromatase aktiviteten. Ydermere sås, at mange af de testede blandinger gav en signifikant 
stimulering af MCF-7 cellevæksten, samt en øget aromatase aktivitet i JEG-3 cellerne.  
Forsøgene, der undersøgte PPAR receptor aktivering, viste, at de forskellige blandinger af 
phytoøstrogener havde større effekt på PPAR gamma end på PPAR alpha. Endvidere havde både de 
testede enkeltstoffer samt phytoøstrogenblandingerne en hæmmende virkning på lipid-
akkumuleringen i 3T3-L1 celleforsøgene, dog ved højere koncentrationer end dem man finder i 
fødevarer. 
 
I in vitro metabolismestudierne sås ingen signifikant forskel på effekten af moderstofferne og 
effekten af de metabolske ekstrakter testet i T-screen assay’et. GH3 cellerne, som blev anvendt i T-
screen assay’et, var selv i stand til at metabolisere de to testede phthalater dimethyl phthalat (DMP) 
og diethylphthalat (DEP), hvorimod der ikke sås nogen signifikant omsætning af de andre 
teststoffer.  
De to anvendte in vitro metaboliseringssystemer gav en næsten fuldstændig metabolisering af de 
testede parabener og phthalater, med en genfindelsesprocent af moderstoffet på mindre end 1 %. 
Der blev fundet en forskel mellem metaboliseringen med det humane liver S9 og de PCB-
inducerede rotte mikrosomer, når det handlede om omdannelsen af azol fungiciderne. De PCB-
inducerede rotte mikrosomer gav en statistisk signifikant forskel mellem mængden af moderstof 
målt før og efter behandling med mikrosomerne, for fire ud af de fem testede azol fungicider. 
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Anvendelse af den humane liver S9-miks gav ingen signifikant omdannelse af de testede azol 
fungicider. 
 
KONKLUSIONER OG PERSPEKTIVER: 
Samlet set støtter resultaterne fra studierne præsenteret i denne afhandling vidnesbyrdet om, at 
phytoøstrogener både alene og i blandinger kan have forskellige hormonforstyrrende effekter. Den 
overordnede effekt ser ud til at være en østrogen effekt, medieret både via receptor aktivering, som 
det fremgår af MCF-7 celleforsøgene, men også via effekter på steroidsyntesen, som det ses af 
forsøgene med H295R cellerne. Endvidere har flere phytoøstrogener og blandinger af 
phytoøstrogener vist sig at have en hæmmende virkning på dannelsen af lipider og på fedtcelle 
differentiering i in vitro tests. Disse effekter kan muligvis involvere østrogeneceptoren og er 
desuden et resultat, der kunne tyde på en gavnlig effekt af phytoøstrogener med hensyn til 
udviklingen af fedme. Baseret på de aktuelle resultater, samt de mage forskellige mekanismer, der 
er involveret i dannelsen og nedbrydningen af fedt og fedtceller, så er phytoøstrogenernes rolle eller 
indvirkning på disse mekanismer dog fortsat uklar og yderligere studier er nødvendige, for at kunne 
sige noget mere konkret om phytoøstrogenernes eventuelle gavnlige indvirkning på f.eks. 
udviklingen af fedme. 
Endelig viser resultaterne samt de kvalitative data fra in vitro metabolismestudierne, at et in vitro 
system med brug af lever S9 eller rottelever mikrosomer kunne være en anvendelig metode i 
forbindelse med indkorporering af metabolisme i in vitro testning af hormonforstyrrende stoffer. 
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3,3’,5-triiodo-thyronine  
Thyroid hormone  
Thyroid hormone receptor  
Thyroid receptor  
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1 Introduction 
The overall purpose of this PhD project was broad, and aimed to gain more knowledge regarding 
the mechanisms of endocrine disruption chemicals (EDCs) using in vitro systems. Knowledge of 
the mechanisms of action of EDCs can help improve risk assessment, and mechanistic knowledge 
can be a key to understanding whether the effects are relevant to humans.  
 
This PhD project focused on studying compounds as well as mixtures of compounds from different 
groups or classes, which have previously been shown to have different endocrine disrupting 
properties. The groups of compounds investigated included phytoestrogens (PEs), pesticides, as 
well as a few parabens and phthalates. The main focus, however, has been on the PEs and different 
mixtures of PEs. 
 
The PhD project included two studies on mixtures of PEs. The first study examined the effects of 
mixtures of PEs on steroid hormone production, aromatase activity, estrogenic activity and 
interaction with the androgen receptor using a battery of in vitro assays. In the second study, 
mixtures of PEs as well as a few single PEs were examined for their effect on different obesity 
parameters in vitro. Specifically, the PEs were tested for their ability to affect the differentiation of 
preadipocytes into mature adipocytes as well as their ability to activate the peroxisome proliferator-
activated receptors (PPARs).  
 
Recently, studies conducted at the National Food Institute have shown that exposure to diisobutyl 
phthalate (DiBP) and butyl paraben during gestation resulted in significantly decreased plasma 
levels of insulin and leptin in rat foetuses. These results show that substances with known effects on 
steroid synthesis or estrogenic endpoints could have effects on other endocrine systems. In 
combination with the increasing number of published data this is supporting a new hypothesis 
correlating exposure to EDCs to the development of obesity. This new area of EDC research was 
one of the focus points in the current PhD project, with the overall aim of eventually gaining a 
better understanding of the mechanisms involved in the hypothesised link between EDCs and 
obesity.  
 
Another area of interest in the current PhD project was the use of in vitro metabolising systems in 
connection with in vitro testing for endocrine disruption. Lack of knowlege on metabolism of test 
 15
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substances is one of the reasons why in vitro research in risk assessment does not stand stronger in 
the regulation of chemicals. This is an area that has been almost absent in the initial tests of 
endocrine disruptors. In this PhD project, the metabolism or breakdown of 10 known endocrine 
disrupters was evaluated using different in vitro metabolising systems (e.g. liver S9 mix). 
Additionally, both the parent compounds as well as metabolic extracts were tested in an established 
in vitro assay (the T-screen assay) to compare potential effects between the effect of parent 
compound and metabolites in the selected in vitro assay. The intrinsic ability of the particular cells, 
applied in the selected in vitro assay, to metabolise the test compounds was also evaluated. 
 
 
The present PhD thesis is based on the work described in papers I to III, however my contribution 
to the work presented in the papers is different for the three papers. 
Regarding paper I: “Effects of nutrition relevant mixtures of phytoestrogens on steroidogenesis, 
aromatase, estrogen and androgen activity”, the different studies described in the paper were the 
result of a collaboration with multiple national partners. I was not involved in the initial planning 
and the design of the studies, but got involved after the studies had been performed and have written 
the paper describing the results from these different in vitro studies.  
 
Concerning paper II and III, I was involved in most of the work, from planning the studies to 
conducting the different laboratory work and analysing the data. As part of my PhD study I visited 
Professor Bruce Blumberg’s laboratory at the University of California, where I was taught the 3T3-
L1 adipocyte assay presented in paper III. However, a laboratory technician student and a master 
student performed the PPAR transactivation assay experiments presented in paper III, and a 
chemical engineer, in our division at the National Food Institute, conducted the LC-MS analyses 
presented in paper II. 
 
 
 
 
 
 
 16 
Introduction
2 Background 
EDCs are a structurally diverse class of synthetic and natural compounds. The EDCs do not 
adversely affect organisms in the traditional sense by directly damaging cellular or physiological 
processes, but instead interfere with the endocrine systems, either by mimicking hormones, by 
blocking their effects, or by interfering with their synthesis or excretion (1, 2). 
EDCs act through a variety of receptor-mediated and non-receptor-mediated mechanisms to 
modulate different components of the endocrine system. Receptor-mediated mechanisms have 
received the most attention and EDCs are typically identified as agonists or antagonists of 
endogenous hormone receptors. However, EDCs can act through multiple mechanisms of action 
such as hormone synthesis, transport, and metabolism (Figure1) (3).  
 
 
EDC
Biosynthesis 
of hormones
Metabolism Transport
Action  
(target tissues)
PXR (CYP3A)
AhR (CYP1A)
Steroid hormone receptors:
ER, AR, TR, …
SHBG
Steroidogenesis:
aromatase (CYP19), CYP17….
Excretion
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1- Endocrine disrupting chemicals (EDC) can exert their effect through a number of different mechanisms: They 
can mimic the biological activity of a hormone by binding to a cellular receptor (acting as an agonist or antagonist). 
They can bind to transport proteins in the blood, as a result altering the amounts of natural hormones that are present in 
the circulation. They can interfere with the metabolic processes in the body, affecting the synthesis, or breakdown rates 
of the natural hormones (Modified from Devillers, 2009 (2)).  
 
 
Although there is considerable information on the early molecular events involved in EDC 
response, we still need more knowledge concerning the relationship between those molecular events 
and adverse health effects. For many of the associations that have been found between exposure to 
EDCs and a variety of biological effects, the mechanisms of action are poorly understood. This 
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makes it difficult to distinguish between direct and indirect effects and between primary versus 
secondary effects of exposure to EDCs. It also means that caution is necessary when extrapolating 
from in vitro data to in vivo effects, and when extrapolating from experimental data to human or 
wildlife situations. Concerns regarding exposure to EDCs have primarily been related to adverse 
effects observed in wildlife, but increased incidences of malformations of the reproductive organs in 
newborn boys, early onset of puberty, as well as increased incidence of certain endocrine-related 
human diseases are also generating concern (3-5).  
EDCs include a variety of both natural compounds like phytoestrogens as well as man-made 
substances including pharmaceuticals and pesticides such as prochloraz and tebuconazole, as well 
as a number of industrial chemicals like polychlorinated biphenyls, and phthalates. Because EDCs 
consist of so many diverse compounds from many different sources, an exact level of EDC 
exposure is hard to give. The levels of exposure to EDCs also vary between people, it can differ 
over time, and different periods in life can be more sensitive to such exposure. The time period 
considered to be particular sensitive to EDC exposure is foetal development, and foetuses and 
infants as well as pregnant women are of special concern when it comes to risk assessment of 
EDCs.   
 
2.1 Mechanisms of Endocrine Disruption 
2.1.1 Receptor-mediated mechanisms  
The first characterised mechanism of action for endocrine disruptors was the ability to act directly 
as ligands for steroid hormone nuclear receptors (NRs), in particular estrogen, androgen, and 
thyroid hormone receptors. NRs are a class of proteins found within the interior of cells that are 
responsible for sensing the presence of hormones. In response, these receptors act together with 
other proteins to regulate the expression of specific genes (6). 
It has been observed that some effects of binding of hormone to the receptor occur within seconds 
or minutes, which is inconsistent with the genomic mechanism of nuclear receptor action, (genomic 
pathway: hormone binding to cytosolic receptors, subsequent modulation of gene expression 
followed by protein synthesis) and it is therefore believed that there are variants of nuclear receptors 
that are membrane associated instead of being located in the cytosol or nucleus (7, 8). The existence 
of a specific plasma membrane estrogen receptor has been known for many years, but in general the 
area of membrane associated NRs is still poorly understood (7, 9). 
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When a compound is bound to a receptor, it can have various effects. A substance that binds to a 
receptor and triggers a response is called an agonist. Agonists often mimic the action of the 
naturally occurring ligand, however, often with different potencies. In contrast to an agonist, an 
antagonist blocks the action of the agonist or natural ligand.  
Thus, receptors can be activated or inactivated by either endogenous (e.g., hormones and neuro-
transmitters) or exogenous (e.g., drugs) agonists and antagonists, resulting in stimulaton or 
inhibition of biological responses, respectively. The potency of an agonist is inversely related to its 
EC50 value. The EC50 can be measured for a given agonist by determining the concentration of 
agonist needed to elicit half of the maximum biological response of the agonist. The EC50 value is 
useful for comparing the potencies of drugs with similar efficacies producing physiologically 
similar effects. The smaller the EC50 value, the greater the potency of the agonist, and the lower the 
concentration required to elicit the maximum biological response. 
Studies have demonstrated that ligands can concurrently behave as agonist and antagonists at the 
same receptor, depending on effector-pathways or tissue type (10-12). Selective receptor 
modulators (SRMs) are receptor ligands that exhibit agonistic or antagonistic ability in a cell- and 
tissue dependent manner. An example of a SRM is tamoxifen, which is a selective estrogen receptor 
modulator that can activate or inhibit estrogen receptor action, acting as an agonist in some tissues 
and an antagonist in other tissues (13). 
The properties of SRMs are due in part to unique ligand-induced conformational changes in the 
hormone receptor that influence their abilities to interact with other proteins, such as co-activators 
and co-repressors. The relative balance of co-activator and co-repressor expression within a given 
target cell determines the relative agonist vs. antagonist activity of the SRMs. However, other 
factors, like cellular environment also play a critical role in determining the properties of the SRMs. 
Cellular signalling, for example, influences the activity and sub-cellular localization of co-activators 
and co-repressors as well as nuclear receptors and this contributes to gene-, cell-, and tissue-specific 
responses to SRM ligands (13). 
 
 
2.1.2 Non-receptor-mediated mechanisms  
Interference with steroidogenic enzymes and hormone transport 
The ability of xenobiotics to disrupt steroidogenesis and the mechanisms by which these 
compounds interfere with the function of steroidogenic enzymes are very complex. Nevertheless, 
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key enzymes involved in steroid hormone synthesis and metabolism are considered as important 
targets for EDCs. The cytochrome P450 enzymes responsible for the highly specific reactions in the 
steroid biosynthesis pathway are some of the molecular targets of interest, given their key role in 
the formation of various highly potent endogenous steroid hormones (Figure 2)  (14).  
The cytochrome P450 enzymes consist of several specific cytochrome P450 enzymes (CYPs), 
hydroxysteroid dehydrogenases (HSDs), and steroid reductases (15). The enzyme that has received 
the most attention with regard to endocrine disruptors is aromatase (CYP19) that converts 
androgens to estrogens (Figure 2). However, all the steroidogenic enzymes are potential targets for 
disruption and we, as well as others have previously shown that CYP17 could be involved in the 
endocrine disrupting effect of azole fungicides (16, 17).  
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     Figure 2 – The Steroid hormone synthesis pathway. Enzymes are highlighted in blue. 
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Another target for endocrine disrupters is binding proteins (Figure 1). In most vertebrate species, 
sex steroid hormones circulate in the plasma predominantly bound to a specific high-affinity sex 
hormone–binding globulin (SHBG) and low-affinity proteins such as corticosteroid-binding 
proteins and albumin (18). In the blood, typically 97% to 99% of total estrogens and androgens are 
carried bound to these proteins. Although the functions of the SHBG are not fully understood, 
SHBG is believed to be involved in regulating circulating endogenous sex steroids as well as 
cellular signal transduction to nuclear steroid receptors in sex steroid–sensitive tissues (19). 
Interestingly, binding proteins have been reported to bind several endocrine disruptors, including 
bisphenol A (BPA), 4-nonylphenol, and genistein (20, 21) and to alter the biological activity of 
natural and synthetic estrogens (22, 23). The consequence is that modulation of SHBG constitutes 
an indirect pathway for regulating steroid hormone action.  
 
Transgenerational consequences of EDC exposure 
Recent studies have demonstrated the ability of EDCs to have epigenetic effects (24-26). The term 
epigenetics is defined as the molecular phenomena that regulate gene expression without alterations 
in the DNA sequence (27). When these epigenetic changes occur during certain stages of 
development, they are permanent and can be inherited by the offspring. Epigenetics provides a 
framework to explain the source of variations between individual organisms (28) and also explains 
what makes cells, tissues, and organs different despite the identical nature of the genetic 
information in every cell in the body. The most studied epigenetic modification is DNA methylation 
of CpG nucleotides that are essential for mammalian development (29). In most studies, increased 
DNA methylation is associated with gene silencing, and decreased methylation is associated with 
gene activation. These epigenetic mechanisms can help explain the transgenerational effects 
observed for some hormonally active chemicals. Examples of this include exposure to 
diethylstilbestrol (DES) during pregnancy, which resulted in vaginal adenocarcinoma in female 
offspring in humans (30) and mice (31). Rats treated with the estrogenic pesticide methoxychlor or 
the antiandrogenic fungicide vinclozolin during pregnancy produced male offspring that had 
decreased sperm capacity and fertility, and the compromised fertility was passed on through the 
adult male germ line for four generations (26). The authors demonstrated altered patterns of DNA 
methylation in germ cells of generation two and three. Other environmental contaminants, such as 
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), polychlorinated biphenyls (PCBs), and phthalate 
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esters have also been found to affect the reproductive system or induce tumour development by 
altering DNA methylation, and steroid hormone metabolism and signalling (32-34). 
 
2.2 Methods for investigating EDCs in vitro  
Both in vivo and in vitro tests are presently being developed and proposed for the testing of 
endocrine disrupting activity of different compounds. The in vivo or animal tests are necessary 
because it is not possible to model the complex responses of a whole body to endocrine disrupters 
(EDs), including aspects like uptake, distribution and metabolism of compounds. However, despite 
limitations like the ones just mentioned, in vitro studies have many advantages. These include their 
relative low cost, the fact that they are less time consuming than in vivo studies, the possibility to 
test many compounds at several different concentrations and repeat the test several times, and their 
usefulness in getting mechanistic information. The fact that an in vitro test is generally studying one 
mechanism, isolated, without interference from the total connecting environment, like you have in a 
whole body organism, can be both an advantage and a limitation. Therefore, a single in vitro assay 
can never stand alone, but will require information from other studies to give a realistic or good 
picture of what is going on in an in vivo situation.   
Given the wide range of potential working mechanisms and sites of action of EDCs, different in 
vitro bioassays have been developed for the testing of EDCs:  
 
Examples of assays for testing endocrine disruption in vitro: 
 
• Binding assays (e.g., ERα) 
• Reporter gene assays (e.g., ER, AR, AhR) 
• Proliferations assay (e.g., E-screen and T-screen) 
• Induction/inhibition of enzymes (e.g., aromatase)  
• Production of steroid hormones (e.g., H295R steroidogenesis assay) 
 
With regard to endocrine disruption, only few of the available in vitro tests have currently 
completed the process of validation and have been adapted as OECD (Organisation for Economic 
Co-operation and Development) test guidelines. Therefore, they can not be used for regulatory 
purposes. However, they are still very important and useful tools in research and in understanding 
the mechanisms behind the effects of the different EDC compounds.  
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In the studies included in this PhD project, different in vitro assays have been used in the 
investigation of the selected test compounds. In the methods section, a short description will be 
given of each assay employed in this PhD project. 
 
2.3 The different groups of EDCs studied in this PhD project    
In this PhD project the different studies conducted have together investigated the endocrine 
disrupting potential of four groups of compounds: Phytoestrogens, azole fungicides, parabens and 
phthalates. The current section will give a short general description of these four groups of 
endocrine disrupting compounds.   
2.3.1 Phytoestrogens (PEs) 
PEs are a diverse group of naturally occurring plant compounds that have the ability to cause 
estrogenic or/and antiestrogenic effects because of their structural similarity with oestradiol (35). 
The broad classes of PEs includes the isoflavonoids (genistein, daidzein, formonetin, biochanin A, 
and equol) found predominantly in soy beans and red clover, the lignans (enterolactone, enterodiol, 
pinoresinol, lariciresinol, secoisolariciresinol, matairesinol) found particularly in flax seed and 
fruits, and the coumestans (e.g., coumestrol) found in red clover and a variety of other plants. 
Several of the PEs are ingested as precursors and then converted by the microflora in the 
mammalian gut. Lignans for instance, are metabolised by intestinal bacteria to form the mammalian 
lignans known as enterodiol and enterolactone (36). The major isoflavonoids daidzin and genistin 
are metabolised in mammals to form the active compounds daidzein and genistein. Daidzein is 
further metabolised to the compound equol (37). The extent of the metabolism of PEs by the 
intestinal bacteria appears to be highly variable among individuals and for example, only one-third 
to one-half of the population can metabolise the soy isoflavone daidzein to equol (38, 39).  
Many of the metabolites have been shown to have more pronounced effects compared to the parent 
compound (37, 40). Several in vivo studies indicate that PEs may elicit cancer-preventing effects in 
laboratory animals exposed to a cancer-inducing agent (37, 41, 42). Furthermore, epidemiological 
data suggest that a diet rich in PEs decreases the risk of breast cancer, among others based on the 
fact that the breast cancer incidence is much lower in Asian populations in comparison with 
Western populations (43). However, other studies, both animal and in vitro, have shown that the 
effects of PEs may increase cancer risk (44-47).  
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PEs are weak estrogens, but may also function as estrogen antagonists by blocking the binding of 
the much more potent endogenous estrogen to its receptor. In addition, it has been shown that PEs 
can affect the synthesis or metabolism of steroid hormones, for example by affecting aromatase 
activity. Aromatase activity is important for the balance between the endogenous testosterone and 
17ß-estradiol, and changes in this balance may be beneficial or adverse in relation to proliferation of 
e.g. breast cancer tumor cells as 17ß-oestradiol is considered the main determinant of proliferation 
of estrogen-dependent breast cancer cells (48). The major aromatase dependent estradiol synthesis 
occurs in the ovary in premenopausal women and in peripheral tissues in postmenopausal women 
(such as the adrenals) (49). Many papers refer to the inhibitory effects of PEs on the aromatase 
activity (40, 50-52), but it cannot be generalised that these compounds elicit inhibitory effects, and 
it has been found that some PEs in fact induce aromatase activity (53-55). The available literature 
provides conflicting findings as to the effects of PEs, which probably results from the multiple 
mechanisms of action of these compounds. The complexity of the influence of PEs at the cellular 
and molecular level is further increased by the fact that their effects are dependent on the dose, the 
class to which they belong, the presence or absence of endogenous estrogens, their different affinity 
for the estrogen receptor (ER) α and ERß, and the type of tissue or cell considered (52).  
2.3.2 Azole fungicides 
Pesticides are of great concern for potential adverse human health effects. The extensive use of 
pesticides leads to exposure risk of the general population and several studies have shown the 
presence of the pesticides and their residues in the environment, in food and in human tissues 
worldwide (56-58). Epidemiological research has indicated a causal connection between human 
exposure to pesticides and endocrine disrupting effects such as poor sperm quality (59) and 
increased incidence of cryptorchidism (60).  
One class of pesticides that has been studied extensively is the socalled azole fungicides. Based on 
their chemical structure, azole compounds are classified as triazoles and imidazoles; however, their 
antifungal activity is due to the same molecular mechanism.  
The azole fungicides are used agriculturally to control rust and mildew on fruit, vegetables, cereals 
and seeds, and in pharmaceutical applications for the treatment of local and systemic fungal 
infections, but also as drugs in tumour chemotherapy. Their antifungal activities are based on the 
disruption of fungal cell membranes by inhibiting fungal lanosterol-14α-demethylase (cyp51) (61). 
Cyp51 is evolutionarily conserved between plants, fungi, and animals and is critical for cholesterol 
synthesis and therefore steroid biosynthesis in animals (62). Besides Cyp51, triazoles also modulate 
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the gene expression and enzyme activity of multiple cytochrome P450 (CYP) and other metabolic 
enzymes in mammalian liver and other tissues (63-65), and the aromatase enzyme (Cyp19) is one of 
the cytochrome P450 monooxygenase enzymes that is inhibited by azoles (66-68). However, our 
own research on the imidazole fungicide prochloraz, as well as other studies on azole fungicides, 
indicates that azole fungicides have the ability to act through multiple mechanisms and to induce 
various endocrine disrupting effects (69, 70) 
2.3.3 Parabens  
Parabens are a group of alkyl esters of p-hydroxybenzoic acid and typically include methyl paraben, 
ethyl paraben, propyl paraben, butyl paraben, isobutyl paraben, isopropyl paraben, and benzyl 
paraben. The parabens or their salts are widely used as preservatives in cosmetics, toiletries, and 
pharmaceuticals. Additionally, methyl- and ethylparaben are permitted in certain foods in limited 
amounts. However, concern has been raised for the potential endocrine disrupting effects of 
parabens. They have been studied in a number of in vitro and in vivo systems, and many of the 
parabens have been shown to have weak estrogenic activity, and some, including butyl paraben, 
also caused reduction in testosterone levels and in sperm production in rats (71-75). However, the 
ability of parabens to activate the estrogen receptor may not be the main mechanism of action. 
Further endocrine disrupting activity has been demonstrated including the ability of parabens to 
antagonize AR-mediated events in androgen-responsive cells and to act as sulfotransferase enzyme 
(SULT) inhibitors, as well as the ability to impair mitochondrial function in rat hepatocytes (76).   
Possibly, the influence of parabens (together with other chemicals) on human tissues is wider than 
what has previously been anticipated and research is needed to establish how wide the implications 
may actually be (77).  
2.3.4 Phthalates 
Phthalates are esters of phthalic acid that have been used worldwide as plasticizers to impart 
flexibility, softness, and elasticity to otherwise rigid polymers such as PVC. Phthalates are found in 
industrial paints and solvents but also in toys, personal-care products, food packaging materials, and 
medical devices such as intravenous tubing and blood transfusion bags.  
Because phthalates are not covalently bound to the polymer matrix, they are highly susceptible to 
leaching. As a result, phthalates contaminate food, particularly meat and milk products, and are 
found nearly everywhere in interior environments. In addition, important routes of human exposure 
include dermal uptake from personal-care products and from plastic medical devices that come into 
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direct contact with biological fluids. Exposure to phthalates can occur in the developing foetus 
through the placenta-blood barrier and in postnatal stages during breast feeding or from toys and 
baby-care products (78).  
Studies in rodents exposed to certain phthalates, have shown that high doses caused changes in 
hormone levels and birth defects (79), and experimental studies with low doses of di(2-ethylhexyl) 
phthalate (DEHP) have demonstrated reproductive toxicity in male rodents (80, 81). Maternal urine 
levels of metabolites of DEHP have been reported to be associated with a higher risk of incomplete 
testicular descent for male human infants as well as being inversely correlated with the anogenital 
distance (AGD), an endpoint often measured in animal studies, where it has been found to be a 
sensitive marker for antiandrogenic influence during gestation (4, 82, 83).   
More recently, several studies have demonstrated a correlation between phthalates and metabolic 
disorders. In short- and long-term rodent studies, dose-related deregulation of levels of serum 
insulin, blood glucose, liver glycogen, and cortisol were observed (84, 85). In humans, the log-
transformed concentrations of several phthalate metabolites positively correlated with abdominal 
obesity and insulin resistance in adult males (86), and mono-ethyl-hexyl-phthalate MEHP), a 
metabolite of DEHP, has been found to interact with all three PPARs, which are known to play a 
role in lipid and carbohydrate metabolism (87).  
 
2.4 Evidence of a potential link between EDCs and development of obesity 
It is now well documented that numerous environmental chemicals can interfere with complex 
endocrine signalling pathways and cause adverse effects (88). The centre of attention for EDCs has 
earlier been on reproductive parameters and potential carcinogenic effects, but it is now broadened 
by the knowledge that multiple organ systems can be affected by EDCs. One of the new emerging 
effects or mode of action for EDCs is that exposure to EDCs may play a role in obesity.  
Much interest has focused on the need to incorporate healthy foods in our diets and more physical 
activity into our lifestyle. However, the prevalence of obesity is still rising and the exact cause of 
obesity is unclear. Today it is known that obesity is not simply a product of a too high caloric intake 
compared to the amount of calories burned. Although, it is a fact that fat cannot be accumulated 
without a higher caloric intake than expenditure, recent studies suggests the existence of chemicals 
that alter regulation of energy balance to favour weight gain and obesity (89). Nevertheless, the 
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relative contributions of environmental factors to the development of both obesity and obesity 
related diabetes are far from understood. 
A variety of factors controls the accumulation of fat and mobilisation of lipids from adipose storage 
depots. These include the hormonal regulation of appetite, glucose level, central control of basal 
metabolic rate, regulation of metabolic set points, and the number, size and metabolic activity of 
adipocytes. Furthermore, adipose tissues themselves function as endocrine organs and participate in 
the body’s feedback systems that help to fine tune appetite and satiety. Therefore, obesity is, among 
others thought to result from a prolonged disturbance in the regulation of energy metabolism in 
favor of triglyceride storage and adipocyte hypertrophy, as well as genetic factors known to impact 
hunger and satiety (89, 90). 
Although the evidence is still limited, accumulating data are pointing to the potential role of EDCs, 
either directly or indirectly in the pathogenesis of adipogenesis and diabetes, as well as in the 
development of obesity itself. Some of the research supporting this hypothesis describes excess 
weight gain in animals treated developmentally with certain EDCs, including diethylstilbestrol 
(DES) and BPA (91-93) as well as data from epidemiologic studies showing a possible association 
between serum dioxin levels and the onset and incidence rate of diabetes (94). Numerous 
chemicals/pharmaceuticals, used for instance in oncology, cardiology, immunology, and psychiatry, 
have weight gain as a side effect (89, 95). Furthermore, many synthetic chemicals are known to 
increase weight gain in animals, because they have especially been used by the livestock industry to 
promote animal fattening and growth (96, 97).   
Additionally, in one of our own studies, we found that DiBP, butylparaben, and rosiglitazone 
reduced plasma leptin and/or insulin levels in 21-day old male and female foetuses after exposure of 
pregnant rats from gestation day (GD) 7–21 (98). 
However, to confirm the hypothesis about EDCs and their effect on the development of obesity, an 
appropriate molecular target affecting regulation of adipose physiology must be found. Altered 
parameters of adipocyte biology that result in depot remodeling or gain of adipose mass leading to 
obesity would be a good confirmation of a link between EDCs and obesity. Furthermore, a 
corresponding dose-response relationship between perturbations and realistic environmental 
exposures is needed, as well as epidemiological data that establish a connection for a significant 
fraction of the population (99). 
Overall, the published studies so far, indicate that exposures to various EDCs may play a role in 
obesity and the complications connected to this, such as type 2 diabetes. However, since many 
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classes of chemicals maybe involved, the mode of action and the mechanisms behind are likely 
many and complex, acting through more than one pathway, and further research is required to 
elucidate all potential interactions between environmental substances and metabolic dysregulation 
(95). 
 
2.4.1 The major modes and mechanisms of actions involved in potential EDC induced 
obesity 
There are numerous potential targets for EDCs that can result in obesity. The mechanisms involved 
are very complex and not fully elucidated. Figure 3 shows schematically a simplification of the 
potential mechanisms involved in EDC induced obesity, as well as the different factors involved in 
these mechanisms. The suggested targets include ERs, the aryl hydrocarbon receptor (AhR) and 
PPARγ (100).  
The most described mechanisms involve activation of PPARγ, dysregulation of sex steroids, and 
interference with the programming of metabolic set points.  
At the basic level, the progression to obesity occurs when the adipocyte number and lipid content 
increases. A number of transcriptional regulators are critical with regards to the regulation of genes 
controlling intracellular lipid flux, and adipocyte proliferation and differentiation. Among these are 
nuclear hormone receptors, especially the PPARα, -β and –γ (Figure 9). The PPARs form 
heterodimers with the 9-cis retinoic acid receptor (RXR) and play a preeminent role, serving as 
metabolic ligand sensors for a variety of lipophilic hormones, dietary fatty acids and their 
metabolites (89, 90).  
Activation of the RXR-PPARα heterodimer promotes peroxisome proliferation and stimulates β-
oxidation of fatty acids (Figure 9). Therefore, xenobiotics that target PPARα usually act as lipid-
lowering agents (90). In contrast, activation of the RXR-PPARγ heterodimer favors lipid 
biosynthesis and storage and is essential for the differentiation of  pre-adipocytes (101). PPARγ 
agonists, such as the thiazolidinediones, rosiglitazone and pioglitazone, are potent insulin 
sensitizing pharmaceuticals used to improve glycemic control and serum triglycerides in diabetics. 
However, prolonged use of these drugs is associated with persistent weight gain (102).  
In addition to nutrition sensing NRs, such as PPARs, NRs for sex steroid hormones are also known 
to influence the development of adipose tissue. The hormones help to integrate metabolic functions 
among major organs that are essential for metabolically intensive activities, like foetal development.  
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Figure 3 Summary of effects of EDCs on the metabolic system. Schematic showing simplified complex interactions 
between released adipokines, receptors, and EDCs in adipose tissue and pancreas. ERs, estrogen receptors, GPR30, G 
protein-coupled estrogen receptor 1, PBDE, polybrominated diphenyl ether, TBT, tributyltin, RXR, retinoid X receptor, 
PPAR, peroxisome proliferator-activated receptor, POPs, persistent organic pollutants, BFRs, brominated flame 
retardants and MetS, metabolic syndrome. (Borrewod from Swedenborg , et al., 2009;43:1-10 (100))  
 
 
 
Knockout of sex steroid pathway components, for instance the FSH receptor, the aromatase, the 
estrogen receptor (ER), and the androgen receptor (AR), show that sex steroids are required to 
regulate adipocyte hypertrophy and hyperplasia, and that they influence the sex-specific remodeling 
of specific adipose depots (89, 90). 
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Together with peptide hormones such as growth hormone (GH), sex steroids mobilize lipid stores 
and help to counteract the actions of insulin and cortisol that promote lipid accumulation in adults. 
Therefore, imbalances in these hormones are often observed in genetic, clinical and physiological 
conditions, including Cushing’s syndrome, polycystic ovary syndrome (PCO), GH-deficiency, 
menopause, alcoholism and depression, conditions that are correlated with dyslipidemia and 
obesity. Consistent with this, anti-androgenic therapies for prostrate cancer and PCO syndrome 
produce weight gain, whereas estrogenic hormone replacement therapy is generally protective 
against the changes in body fat remodeling seen with age and menopause in women (103). Notably 
dietary compounds such as isoflavonoids modulate ER signaling and have been shown to have 
similar positive effects on adipose tissues. As an example, nutritional levels of genistein and 
daidzein have been shown to reverse fat accumulation in post-menopausal women and 
ovariectomized rodent models (104-107).  
 
Homeostasis is a central feature of all endocrine systems. However, this homeostasis or balance 
needs to be set up or programmed before the system will work correctly, and for many of the 
endocrine systems this programming takes place largely during foetal/neonatal development (108). 
Regarding the interference with the programming of metabolic set points, hypothalamic output 
plays an important role, because of its involvement in implementing adaptive responses that 
establish metabolic set points and regulate overall metabolic efficiency. The control over these 
adaptive processes lies in the hypothalamus-pituitary-thyroid axis that determines systemic thyroid 
hormone output. Thyroid hormones exerts widespread effects on metabolism and sets the basal 
metabolic rate (89).  
Another critical factor of the hypothalamic output is the regulation of glucocorticoid hormone 
signaling that mediates stress responses and metabolic functions in peripheral tissues. 
Glucocorticoids play an important role in promoting adipocyte differentiation, and disruption of  
glucocorticoid signaling during critical periods in life (e.g., perinatal) can affect long-term 
metabolic programming and the response to physiological challenges (109, 110). 
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2.5 In vitro metabolism 
In vitro studies are a good tool for getting mechanistic information regarding the effects of a 
compound. However, lack of metabolism of test substances is one of the limitations of many in 
vitro assays for endocrine disruption, and also one of the reasons why in vitro research do not stand 
stronger in the regulation of chemicals.   
Metabolism occurs especially in the liver, but also in extra hepatic tissues (111, 112), and can be 
divided into phase I and phase II metabolism. Phase I metabolism involves the oxidation, reduction 
or hydrolysis of the parent compound into a more polar substance. The key enzymes for phase I 
oxidation are the isoforms of the CYP family of enzymes (113). However, CYP enzymes can often 
be induced or inhibited by exogenous chemicals that may exert endocrine effects through this 
mechanism. Phase I metabolism has been shown to metabolise xenobiotics to both more and less 
active or toxic compounds (114-116).  Phase II metabolism often involves the further conjugation 
of the metabolite with polar molecules, such as sulphate, amino acids, glutathione or glucuronic 
acid, generating metabolites that are more soluble and thus more easily eliminated (112).  
It is well established that information on the metabolism of a substance is important in the 
evaluation of its toxic potential. With regard to endocrine disruptors, one also needs to consider that 
metabolism of the xenobiotic can alter, not only its own potency, but also the toxic potential of 
other substances. Hormones, and in particular steroid hormones, are formed or metabolised by 
enzymes that participate in the metabolism of xenobiotics. A chemical that is metabolised by these 
enzymes may, by mere interaction with the enzyme, act as a competitor for the hormone or 
hormone precursor and therefore disturb hormone levels and hormonal equilibrium.  
A number of in vitro systems are available for studying metabolism. They include both cellular 
(tissue slices, isolated and cultured hepatocytes, liver cell lines) and subcellular (microsomes, 
recombinant enzymes) systems (117). 
Depending on the study, different factors can influence the choice of in vitro metabolising system. 
However, it is well known that there are many differences in the metabolic capacity between 
species and also differences within the same species associated with age, gender, nutrition, genetic 
predisposition, environmental factors and others. In regards to risk assessment for EDCs, it would 
be most relevant to use metabolising systems based on materials from humans. However, in every 
day research using materials from animals compared to humans would most likely be easier both in 
terms of amount of material assessable, and currently also financially more favourable. Therefore, it 
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is relevant to get as much data as possible in order to make valid comparisons and extrapolations 
between results from different species.   
 
 
2.6 Assessing mixtures  
Humans are exposed to a mixture of various chemicals some of which may have endocrine 
disrupting activity, and it is conceivable that the overall effect of exposure to many compounds 
simultaneously will result in more severe effects than observed for each individual chemical. Risk 
assessment of toxicological effects is currently based on determination of the effects of single 
compounds, i.e. the lowest observed adverse effect levels (LOAELs) and the no observed adverse 
effect levels (NOAELs) or no observed adverse effect concentration (NOAEC). However, even 
though the exposure scenario may be complex, the need to consider mixture effects when assessing 
the risk associated with not just endocrine disrupters but all types of chemicals has been widely 
recognised (118, 119). Increasing numbers of studies specifically involving chemicals with 
common modes of action, but also with mixtures composed of chemicals with dissimilar modes of 
action, show that many chemicals work together to produce combination effects that are larger than 
the effects of each mixture component by itself (120).   
The prediction of mixture effects is complicated, but different models are available. Mixtures of 
compounds displaying a linear concentration-response relationship may be predicted using effect 
summation. The assumption behind this is that the total effect of the mixture is equal to the 
summation of the effect of the single compounds at a given concentration. However, most 
compounds display non-linear concentration-response curves and for these compounds two models 
are currently used: The concentration (or dose) addition’ (CA) and ‘independent action’ (IA) 
models. Both models assume that the compounds in the mixtures do not interact (physically, 
chemically, or biologically), meaning that one compound does not influence the toxicity of the other 
compounds (120). 
The CA model has generally proved applicable to mixtures of compounds known to have similar 
target sites, similar mode of action and that only differs in their individual potency. The mixture 
effects are predicted by summing up the concentrations of the individual chemicals adjusted for 
their relative potency (121). It is assumed that all compounds in the mixture behave as if they were 
a dilution of one another. This means that any concentration of any compound must be considered, 
 32 
Background
also compounds present in concentrations below their NOAEC, because it adds to the mixture 
concentration, and combination effects can result as long as enough compounds are present to sum 
up to a sufficiently high total concentration (119). 
The IA model is generally said to be applicable for mixtures of compounds having different target 
sites or modes of action. The IA model uses the individual effects of the mixture components to 
calculate the expected mixture effect. This means that compounds present at doses below their 
individual effect thresholds or NOAECs will not contribute to the mixture effect. NOAEC is the 
highest test concentration that does not provoke any statistically significant effect, and it is a 
measure highly sensitive to experimental design issues. If the NOAEC is a true zero effect 
concentration, then it will not contribute to the mixture effect. However, if the NOAEC displays a 
small but significant (although maybe not statistically) effect, this effect could in a mixture with 
enough components sum up to have a significant effect, and then the IA model would underestimate 
the effect (120). 
However, the theoretical use of IA and CA is based on previous knowledge of chemical mode of 
action, and studies suggest that toxic effects of mixtures in an intact organism are far too 
complicated to be predicted from knowledge of mode of action alone. Secondary modes of action, 
such as uptake kinetics, transportation, metabolism and excretion of the chemicals are processes 
that are not considered by the models, but can have large impacts on the combined effects (121). 
In terms of risk assessment it is currently debated which reference model should be used. Recent 
data suggest that the IA model does not provide a considerably better prediction of a mixture effect 
than the CA model when measuring on mono-species test systems, and studies have shown that the 
CA model can be applicable both for similar as well as dissimilar acting endocrine disrupters (122, 
123). Additionally, several in vitro studies have demonstrated that endocrine disrupters can generate 
additive mixture effects both on the ER (124-126) and the AR (127, 128), even when they are 
present at levels under their NOAEC (123, 129).  
Currently, work is being done with the aim of creating useful guidelines for the implementation of 
assessment of mixture effects in risk assessment of EDCs (130), but so far there is good evidence 
that EDCs, at least them with similar effects, produce combination effects that can be predicted 
using the CA model (120).  
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3 Aims of the studies 
As mentioned in the introduction of this thesis, the overall purpose of the PhD project was broad 
and aimed to gain more knowledge regarding the mechanisms of EDCs. 
Using a panel of in vitro assays different groups of EDCs including both single compounds as well 
as mixtures were investigated in three different studies, each with a different aim. 
 
1) Effects of nutrition relevant mixtures of phytoestrogens on steroidogenesis, aromatase, 
estrogen and androgen activity.  
This study examined the effects of different mixtures of PEs on steroid hormone production, 
aromatase activity, estrogenic activity and interaction with the androgen receptor, using a 
panel of four in vitro assays. The overall aim was to evaluate the endocrine disrupting 
potential of various PEs and mixtures of PEs naturally occurring in Western/Scandinavian 
food. 
 
2) Use of external metabolising systems when testing for endocrine disruption in the T-screen 
assay 
In this study the use of in vitro metabolising systems in connection with in vitro testing for 
endocrine disruption was addressed.  
The aim of the study was threefold a) to test different in vitro systems for biotransformation 
of ten known EDCs, b) to determine possible changes in the endocrine disrupting ability of 
the EDCs after biotransformation using the T-Screen assay as a model, and finally c) to 
investigate the endogenous metabolic capacity of the applied cell line (GH3 cells).  
The overall purpose of the study was to find a potential method for the incorporation of 
metabolism into in vitro testing for endocrine disruptors. 
 
3) Effects of mixtures of phytoestrogens on adipocyte differentiation, and PPARα and PPARγ 
activation in vitro 
In this study the same kind of mixtures of PEs as tested in study 1) as well as a few single 
PEs were examined for their effects on different obesity parameters in vitro. Specifically, 
the PEs were tested for their ability to affect the differentiation of preadipocytes into mature 
adipocytes, as well as their ability to activate the PPARα and γ receptors.  
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The overall aim of this study was to gain a better understanding of the mechanisms involved 
in the suspected link between exposure to EDCs, here phytoestrogens, and development of 
obesity and obesity-related diseases.  
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4 Methods  
This section gives a general description of the in vitro methods used in the studies presented in 
paper I to III (Appendix 1). A more detailed protocol for the different in vitro assays is found in the 
respective papers (Appendix 1).  
 
Table 1: Overview of the in vitro assays applied in the different studies  
In vitro assay Test compounds Purpose Paper
AR reporter gene 
assay 
PEs and mixtures of PEs   
(genistein, daidzein, equol, formonetin, 
biochanin A, enterolactone, enterodiol, 
pinoresinol, lariciresinol, secoisolariciresinol, 
matairesinol and coumestrol) 
Detect interaction with 
the AR (AR agonist or 
antagonist) 
I 
MCF-7 cell 
proliferation assay 
 
PEs and mixtures of PEs (as in the AR assay) Detect estrogenic or anti-estrogenic effects 
I 
H295R 
steroidogenesis 
assay 
 
PEs and mixtures of PEs  (as in the AR assay) Detect effects on steroid 
hormone synthesis 
I 
Aromatase assay PEs and mixtures of PEs  (as in the AR assay) Detect inhibition of the 
aromatase enzyme 
I 
T-Screen assay 5 azole fungicides: prochloraz, ketoconazole, 
miconazole, tebuconazole and epoxiconazole; 
3 parabens: butyl-, ethyl- and methyl paraben, 
and 2 phthalates: dimethyl phthalate (DMP) 
and diethyl phthalate (DEP).  
Detection of TR 
agonistic or antagonistic 
abilities  
II 
PPAR 
transactivation 
assay 
PEs and mixtures of PEs  (as in the AR assay) 
Detect PPAR α and/or γ 
agonist or antagonist 
effects 
III 
3T3-L1 
adipogenesis assay  
PEs and mixtures of PEs  (as in the AR assay) 
Detect effects on 
differentiation of 
preadipocytes into 
adipocytes 
III 
In vitro 
metabolising 
systems 
5 azole fungicides: prochloraz, ketoconazole, 
miconazole, tebuconazole and epoxiconazole; 
3 parabens: butyl-, ethyl- and methyl paraben, 
and 2 phthalates: dimethyl phthalate (DMP) 
and diethyl phthalate (DEP).  
In vitro 
biotransformation of test 
compounds before 
further in vitro testing 
II 
 
4.1  AR reporter gene assay 
In a reporter gene assay, the general principle is that ligand-bound nuclear hormone receptors bind 
specific response element sequences on the DNA and initiate transcription of a downstream gene 
(131).  
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The cell-based AR reporter gene assay investigates the ability of EDCs to interact directly with the 
AR or to interfere with the interaction of natural or synthetic androgens with the AR. The AR 
reporter gene assay uses the fact that the AR is a transcription factor that induces transcription of 
target genes after binding to an androgen response element (ARE) in their promoter. In the applied 
assay the ARE is linked to the gene of the easily measurable protein, the firefly luciferase, making 
the promoter activity and luciferase expression AR regulated. 
In general, reporter gene assays provide a quick and accurate tool to determine and quantify 
hormone-induced transcriptional activity. However, the results of a reporter gene assay are 
influenced by factors like the use of cell line, promoter regions, and response element constructs, 
which one should take into account when comparing results from different studies (132). 
 
4.2 MCF-7 cell proliferation assay 
The MCF-7 cell proliferation assay is based on the MCF-7 human breast cancer cell line, which 
growth is estrogen dependent. Test chemicals with estrogen activity bind to the ER and activate the 
transcription of estrogen-responsive genes, which leads to proliferation of MCF-7 cells.  
Proliferation of the cells is therefore an indication of the presence of estrogen or an estrogen like 
compound, and the cell proliferation assay can be used for determining both estrogenic as well as 
antiestrogenic activity (132, 133).  However, besides expression the ERs, the MCF-7 cells also 
express CYP enzymes, including the aromatase, as well as other receptors, including the androgen, 
progesterone, glucocorticoid and retinoid receptors. Substances that can bind to these exogenous 
receptors can antagonise estrogen-induced cell proliferation. As a result, care should be taken when 
interpreting results from studies of compounds with unknown or multiple mechanisms of action 
(132). Because the MCF-7 cells also express the aromatase enzyme, effects on aromatase can be 
assessed by using testosterone as substrate. However, in this thesis, the purpose of using the MCF-7 
cell proliferation assay was only for the detection of estrogenic effects. 
 
4.3 H295R Steroidogenesis assay 
The steroidogenesis assay is an in vitro model for the investigation of effects on steroid hormone 
synthesis. The assay is based on the H295R human adrenocortical carcinoma cell line, which 
expresses genes that encode for all the key enzymes for steroidogenesis (Figure 2) (134). This is a 
unique property because in vivo expression of these genes is tissue and developmental stage-
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specific with typically no single tissue or developmental stage expressing all of the genes involved 
in steroidogenesis (135). The H295R cells represent a unique in vitro system in that they have the 
ability to produce all the steroid hormones found in the adult adrenal cortex and the gonads 
allowing testing for effects on both corticosteroid synthesis and the production of sex steroid 
hormones such as androgens and estrogens. However, in the current PhD project, the assay was 
only used to detect effects on the production of testosterone, estradiol and progesterone. 
Nevertheless, depending on the setup of the assay protocol, experiments can be conducted to study 
the effects of chemicals on specific enzymes and intermediate hormones.  
The goal of using the assay is to provide an answer with regard to the potential of a chemical to 
induce or inhibit the production of the steroid hormones. The assay is not intended to identify 
substances that affect steroidogenesis due to effects on the hypothalamic-pituitary-gonadal (HPG) 
axis (135).   
 
4.4 Aromatase Assay 
As previously mentioned, the aromatase enzyme is responsible for the conversion of testosterone to 
estrogen. Aromatase activity is expressed in several tissues and cells including the placenta, 
granulosa cells, Sertoli and Leydig cells, adipose tissue, and several sites in the brain (136). 
 
Estradiol/Estrone
Androstendione
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 – Aromatasse enzyme reaction.  The conversion of androgens to estrogens requires the consumption of three 
molecules of NADPH and O2 for each molecule of estrogen formed, accompanied with the release of water. [The figure 
is modified from (137)]   
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There are many available aromatase assays. The aromatase assay applied, in the study presented in 
this thesis, used human placental JEG-3 choriocarcinoma cells and tritium labeled [1β-3H] androst-
4-ene-3,07-dione. Figure 4 illustrates the principle of the applied aromatase assay. 
The aromatase activity is quantified by the loss of the 1β-3H of the substrate into the aqueous phase 
of the reaction mixture during aromatization. The tritium atom in the β position of the substrate is 
incorporated into water during the aromatization reaction, and aromatase activity can be determined 
by measuring 1β-3H  from the tritiated water (136). 
   
4.5 T-Screen assay  
In addition to the well-documented estrogen and androgen pathways, there are other hormonal 
systems susceptible to disruption, including the thyroid axis. Thyroid hormone receptors (THRs) 
bind to short repeated sequences of DNA called thyroid hormone responsive elements (TREs), but 
in contrast to steroid hormone receptors, THRs bind DNA in the absence of hormone, and in 
general, binding of THR alone to DNA leads to repression of transcription, whereas binding of the 
THR with hormone activates transcription (2).  
In vertebrates, thyroid hormones (THs) are essential for postembryonic development, such as 
establishing the central nervous system in mammals and metamorphosis in amphibians. The 
regulation of TH delivery to tissues and cells during development and in the adult represents a very 
complex web of feedback systems, providing redundant and compensatory regulatory responses to 
maintain TH signalling in the face of specific deficiencies in circulating levels of THs (138). 
The interest in the thyroid receptor (TR) and the THs (T3 and T4) has arisen because they play a 
role in the control of development (e.g., metamorphosis in amphibians and brain development in 
mammals), and chemicals may alter their synthesis, transport and catabolism (139-144). Increasing 
numbers of studies are showing that xenobiotics may act at the THRs, and more and more 
chemicals are suspected of being able to interfere with the TR function (145). Compounds such as 
polybrominated diphenyl ethers (146) and PCB’s have been shown to have the potential to interfere 
with the TR function (147) and some of these chemicals seem to suppress transcription that is 
linked to TR activation (148).  
The T-screen assay is an in vitro assay, which can be used for the detection of agonistic and 
antagonistic properties of compounds at the level of the TR. The assay is a proliferation assay based 
on the growth of GH3 cells, which is a rat pituitary tumor cell line. The cell line growth is 
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dependent on the TH 3,3’,5-triiodo-thyronine (T3) and the cells have a high expression of TRs. The 
growth stimulatory effect of T3 is mediated by specific, high-affinity TRs that upon binding of THs 
bind to TREs in the cell nucleus ultimately leading to gene expression (149). Thus the T-screen 
assay can be used for in vitro detection of agonistic and antagonistic properties of compounds at the 
level of the TR, but it will not catch effects on TH levels resulting e.g., from impairment in TH 
synthesis pathway.  
 
4.6 3T3-L1 adipogenesis assay  
Different in vitro systems exist for studying adipocyte differentiation. One of the most frequently 
employed cell lines is the 3T3-L1 cell line. The 3T3-L1 is a mouse embryonic fibroblast pre-
adipocyte cell line. The 3T3-L1 cells are derived from the original 3T3-Swiss albino cell line, and 
the 3T3-L1 adipogenesis assay is a well established in vitro model of adipocytes for studying 
signaling pathways involved in adipocyte differentiation, and obesity or obesity related parameters 
in vitro. The preadipocyte 3T3-L1 cells have a fibroblast-like morphology during the growth phase. 
However, under appropriate conditions, the cells differentiate into an adipocyte-like phenotype 
where the preadipocyte converts to a spherical shape, accumulates lipid droplets, and progressively 
acquires the morphological and biochemical characteristics of a mature adipocyte (150). The cell 
line is considered a model for white adipose tissue, although the numerous fat droplets formed when 
the cells are fully differentiated is characteristic of brown fat cells, where as white adipocytes only 
contain a single lipid droplet (151). The effects of the test compounds on adipocyte differentiation 
can be measured by scoring the amount of lipid droplets formed in the 3T3-L1 adipocytes using Oil 
Red O staining.  
 
4.7 PPAR transactivation assay 
Adipogenesis and the many different mechanisms involved in the regulation of adipocyte 
differentiation is complex. However, one of the transcription factors shown to play a key role in 
adipocyte differentiation is the PPAR family (152-156). The PPAR α/γ transactivation assays are 
reporter gene assays used for the detection of the ability of a compound to activate the PPAR α 
and/or γ receptor and thereby a sort of measurement of a compound’s ability to work as an agonist 
or antagonists of the different PPAR receptors. The effect of a compound on PPAR transactivation 
is assessed by adding different concentrations of test compound to the cells (NIH-3T3 cells), which 
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have been transiently transfected with a plasmids expressing, in our assays, the ligand binding 
domain of the mouse PPARα or PPARγ coupled to Gal4, and a plasmid containing an UAS 
(Upstream Activation Sequence) linked luciferase reporter construct. (The applied GAL4-UAS 
system is a well known system consisting of two parts: the GAL4 gene, encoding the yeast 
transcription activator protein Gal4, and the UAS, a short section of the promoter region, to which 
Gal4 specifically binds to activate gene transcription). 
 
4.8 In vitro metabolising systems 
In this PhD project, different in vitro systems for biotransformation of known endocrine disrupting 
chemicals were tested. In total, three different in vitro metabolising systems were tested using 
cryopreserved human hepatocytes, human liver S9 mix, and PCB-induced rat microsomes, 
respectively. Generally, for all the test systems, the test compounds were metabolised by incubating   
the compounds with either cryopreserved hepatocytes, liver S9 mix or PCB-induced rat 
microsomes, respectively. To evaluate the ability of the selected test system to metabolise the 
different test compounds, samples were analysed using HPLC. The extent of metabolic 
transformation of the different compounds were assessed by measuring the amount of the parent 
compounds before and after treatment with the different metabolising agents, expressed as the 
recovery rate (percentage) of the parent compounds.  
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5 Results 
The results of the different in vitro assays with the respective compounds and mixtures are 
presented in paper I-III. This section will give a summary of the results obtained during this PhD 
thesis. The only results not presented in the papers are the results of the in vitro metabolising study 
using the human cryopreserved hepatocytes.  
 
5.1 Endocrine disrupting effects in vitro of individual phytoestrogens and 
mixtures - Paper I and III 
Figure 5 presents an overview of the different PEs and PE-mixtures that were tested in paper I and 
III: Mix 1 composed of the isoflavonoid metabolites genistein, daidzein and equol; Mix 2 composed 
of the two isoflavonoids formononetin and biochanin A; Mix 3 composed of the lignan metabolites 
enterolactone and enterodiol; Mix 4 containing the four lignans secoisolariciresinol, matairesinol, 
lariciresinol and pinoresinol, and a total mixture including all 12 selected PEs.  
Overall, the individual PEs in each of the five mixtures studied in papers I and III are the same. 
However, in paper I the proportions of the single PEs in the mixtures were in equimolar 
concentrations. That is, the design of the mixtures was not based on effective doses, as different in 
vitro assays were used, and each chemical could have very different effect in each assay.  
In paper III, the proportions of the individual PEs in the mixtures were not equimolar 
concentrations, but were based on the amount and number of the different classes (e.g., 
isoflavonoids lignans and coumestans) of PEs naturally found in Scandinavian food (157). 
The studies presented in paper I and III examined the endocrine disrupting potential of the different 
PEs and PE-mixtures testing their effects on steroid hormone production, aromatase activity, 
estrogenic activity, interaction with the AR, as well as whether they could affect the ability of 
preadipocyte 3T3-L1 cells to differentiate into adipocytes, and also their ability to activate PPAR α 
and/or PPARγ.  
 
The experiments with the steroid synthesis assay showed that at the highest concentration (10-5M) 
all compounds/mixtures tested caused an increase in the estradiol production (Fig. 2, paper I). 
Furthermore, increasing concentrations of mix 1 (genistein, daidzein and equol), mix 2 
(formononetin and biochanin A), the total-mixture as well as genistein alone caused dose-dependent 
reduction in the testosterone production although not statistically significant for mix 1 (Fig. 3, paper 
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I).  In contrast to this, coumestrol and mix 3 caused a slight but significant increase in testosterone 
production (Table 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total-Mix
(n=12)
Mix 1
Isoflavonoids
Metabolites
Mix 2
Isoflavonoids
Parent compounds 
Mix 3
Lignans
Metabolites 
Mix 4
Lignans
Parent compounds
Coumestans
Metabolite 
Genistein
Daidzein
Equol
Formononetin
Biochanin A
Enterolactone
Enterodiol
Secoisolariciresinol
Matairesinol
Lariciresinol
Pinoresinol
Coumestrol
 
Figure 5 - Overview of the different phytoestrogens and mixtures studied in papers I and III 
The selected PEs consist of both parent compounds (biochanin A, formononetin, secoisolariciresinol, metairesinol, 
lariciresinol, pinoresinol, and coumestrol) and metabolites (genistein, daidzein, equol, enterodiol and enterolactone). 
The different mixtures and the total mixture are presented in black boxes, and the compounds, which were (also) tested 
individually, are represented in light gray (dotted) boxes.  
 
 
To elucidate the mechanism behind the increased levels of estradiol, the tested compounds at the 
highest concentration (10-5 M) were studied in combination with a specific aromatase inhibitor, 4-
androsten-4-ol-3,17-dione (4-AOD). The results of these experiments revealed that the increased 
levels of estradiol following PE exposure was reduced to background levels following treatment 
with 100nM or 1µM of 4-AOD. Of the three single compounds tested, genistein was the compound 
found to have the most pronounced effect on the steroid hormone production in the H295R cells.  
In the MCF-7 proliferation assay, performed at the Danish Cancer Society, estrogenic activity was 
observed for the isoflavone metabolites in mix 1 with the effect at the highest concentrations being 
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comparable to the maximal growth stimulation obtained with estradiol. In comparison the precursor 
plant isoflavones in mix 2 were less potent showing only a growth stimulatory effect at the second 
highest concentration tested (the highest concentration of mix 2 was cytotoxic). No effects were 
observed for the lignans in mix 3 and 4 (Table 2).  
The mixture of all the PEs (total-mix) showed an estrogenic activity comparable to the maximal 
effect obtained with estradiol.  
 
Table 2 – Summery of the endocrine disrupting effects observed in the in vitro studies 
presented in paper I 
Steroid hormone production 
(H295R cell assay) 
 
Androgen 
activity 
Estrogen 
activity 
(MCF-7 
cell assay) 
 E
st
ra
di
ol
  
      
   
 
Te
st
os
te
ro
ne
 Aromatase 
activity  
(JEG-3 cells) 
Mix 1 - ↑ ↑ - ↑↓# 
Mix 2  -   ( ↑ )* ↑ ↓ ↑ 
Mix 3 - - ↑ ↑ ↑ 
Mix 4 - - ↑ - ↑  
Totalmix - ↑ ↑ ↓ ↑ 
Coumestrol - ↑ ↑ ↑   ↑¤ 
Genistein - ↑ ↑ ↓ - 
Daidzein - ↑ ↑ - - 
Equol - ↑ ↑ - - 
- : no effect.  
#:  inhibition at the lowest concentration, but increased activity was observed at higher concentrations. 
¤:  only at the second highest concentration (1μM) 
*:  only at the second highest concentration (1μM), cytoticity was found at the highest concentration  
     tested (10μM). 
 
The experiments with the single compounds from mix 1 were conducted in order to evaluate 
whether some of the single compounds could account for the observed mixture effects or whether 
combination effects were present. The isoflavone metabolites in mix 1 all resulted in stimulation of 
MCF-7 cell growth with genistein being the most potent one (potency: genistein > equol > 
daidzein). The stimulatory effect of genistein alone was comparable to the effects observed with 
mix 1 and might contribute greatly to the effect of the PEs in mix 1. Coumestrol alone was also 
found to have an estrogenic activity with the stimulatory effect at 100 nM (the third highest 
concentration) being comparable to that of 100 pM estradiol (Table 2).  
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None of the tested PEs showed any antiestrogenic effect on MCF-7 cell growth, which was tested 
by the presence of 17β-estradiol. 
To establish the mechanism behind the growth stimulatory effects observed for the MCF-7 cells, 
expression of the estrogen inducible progesterone receptor (PR) A and B proteins, as well as the 
ERα protein was assessed using Western blot analysis. The PR gene is an estrogen-regulated gene 
and the expression of the two forms of PR protein A and B is often used as a marker for the 
presence of functional ERα (29). Because the MCF-7 cells express extremely low level of ERβ (30), 
the expression of ERβ was not measured. 
The addition of estradiol to the MCF-7 cells gave an increase in PR expression and a decrease in 
ERα expression (Fig. 5 in paper I). Addition of Mix 1, as well as coumestrol resulted in increased 
expression of PR up to the level observed for 100 pM estradiol (Fig. 5 in paper I), indicating that 
the PEs can act as potent estrogens via ERα. Furthermore, the antiestrogen ICI 182,780 could 
completely inhibit the stimulation of the PR expression (Fig. 5 in paper I), further supporting an 
ERα-mediated effect of the PEs.  
 
Table 3 – Overview of the effects found on PPAR activation and lipid accumulation  
           PPARα activation              PPARγ activation 
Compounds Agonism Antagonism Agonism Antagonisme 
Effect on lipid accumulation
Mix 1 - + + + ↓ 
Mix 2 # - - + + ↓ 
Mix 3 - + - + ↓ 
Mix 4 - - - + - 
Totalmix - - + + - 
Coumestrol - + - + ↓ 
Genistein ND + * ND 
ND 
+ * ND ↓ 
Daidzein ND + * ND 
ND 
+ * ND ↓ 
- : no effect. 
ND: not determined 
# cytotoxic at the highest (100 μM) concentration tested.  
* Shown in Rickett et al., 2005 (158) 
 
 
In the aromatase assay, a general weak effect of the PEs was seen at low concentrations. Mix 1 
inhibited the aromatase activity at the lowest concentration (10-10 M), but a weak increase in 
enzyme activity was observed at 10-9 M and at 10-6 M, an approximately 1.3-fold increase in 
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activity was seen (Table 2). For mix 2, 3, 4 and for coumestrol aromatase activity was increased at 
10-6 M and also at 10-5 M for mix 2 and mix 4 (Table 2 in papar I and for an overwiew Table 2 in 
the thesis). 
None of the tested PEs or mixtures showed any agonistic or antagonistic effects in the AR assay 
(Table 2). 
 
DMSO (background) TBT 10 nM TBT 100 nM 
 
Genistein 50 μM Genistein 75 μM Genistein 25 μM 
 
 Figure 6- Effect of tributyltin (TBT) and genistein on lipid accumulation in the 3T3-L1 adipocytes. 
 The 3T3-cells were treated with different concentrations of TBT (nM) or genistein (μM). The background was cells    
 
 supplemented with 0.1% DMSO.  After 6 days exposure during the differentiation period the adipocytes were stained  
 with Oil Red O and the amount of lipid accumulation was analyzed by microscopic inspection and several phototropic  
  images from each well were taken (magnification, x40). The images shown are from one representative experiment out   of at least three independent experiments. 
 
 
Table 3 gives a summery of some of the results presented in paper III regarding the effects found on 
PPAR activation and lipid accumulation. The effects of the PEs on adipocyte differentiation were 
measured by scoring the amount of lipid droplets formed in the 3T3-L1 adipocytes. The three tested 
single PEs (coumestrol, daidzein and genistein) all significantly decreased lipid accumulation, with 
genistein being the most potent inhibitor showing effect at all tested concentrations (25, 50 and 75 
μM) (Figure 6). Coumestrol showed effect at the two highest concentrations 50 and 75 μM and 
daidzein had significant effect only at 75 μM (Fig. 2A in paper III).  
Genistein were also tested in combination with the PPARγ antagonist GW9662, to examine if any 
possible effect of genistein on lipid accumulation could be influenced by the presence of a PPARγ 
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antagonist. The co-treatment resulted in an impairment or neutralization of the decreasing effect at 
25 μM and 50 μM, giving only a significant decrease at 75 μM, the highest concentration tested 
(Figure 7). 
Of the five mixtures mix 1, mix 2 and mix 3 also showed a significant decrease in lipid 
accumulation (Table 3). However, for mix 2 the effect was only statistically significant at 50 μM, 
the second highest concentration, but the effect at 75 μM was comparable to the effect observed at 
50 μM (Fig. 2B in paper III). Neither mix 4 nor the total-mix had any significant effect on the lipid 
accumulation in the 3T3-L1 adipocytes (Table 3). 
PPARγ has been shown to play a key regulatory role in adipocyte differentiation (154, 159) and to 
be necessary for lipid accumulation in adipocytes in mice (160-162). In our study using the PPAR 
transactivation assay the PEs and mixtures were tested in seven concentrations from 0 to 100 μM. 
Mix 1, mix 2, and the total-mix showed some PPARγ agonistic effect, with mix 2 being the most 
potent of the three having effect at a concentration of 6.25 μM up to 50 μM (Fig.5A in paper III). 
The highest concentration of 100 μM was found to be cytotoxic for mix 2 (Table 3). 
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0
20
40
60
80
100
120
140
DMSO Genistein 25  Genistein 50  Genistein 75 
μM
Li
di
p 
ac
cu
m
ul
at
io
n 
(%
 o
f  
co
nt
ro
l)
Genistein
Genistein+GW
*
*
*
*
 
Figure 7- –Effect of the PPARγ antagonist GW9662 on the effect of genistein. 
The 3T3-L1 preadipocytes were treated with different concentrations (μM) of genistein either alone or in the presence 
of 1μM GW9662 (GW). The control was cells supplemented with 0.1% DMSO or 0.1% DMSO plus 1μM GW9662, 
respectively.  After 6 days exposure during the differentiation period, the adipocytes were stained with Oil Red O and 
the amount of lipid accumulation was analyzed by microscopic inspection and several phototropic images from each 
well were taken including five to twelve random fields images from each well photographed under phase contrast 
(magnification, x40). Images were analyzed in ImageJ and data are shown as the mean ± SD from one representative 
experiment out of three independent experiments.  
* Statistically significantly different from control. (P< 0.05). 
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When the mixtures were tested in combination with a PPARγ-selective agonist, a decrease in 
activity was observed for all mixtures, mix 3 being the most potent showing significant decrease in 
almost all tested concentrations (Fig.5B in paper III). 
For coumestrol alone, no effect was seen in the agonist assay, but in combination with the PPARγ-
selective agonist a significant decrease in activity was observed at 50 and 100 μM (Fig.5 in paper 
III). Overall the tested PEs and mixtures all showed PPARγ antagonistic effects, although in 
varying degrees (Table 3).  
In the PPARα assay, none of the mixtures nor coumestrol alone had any PPARα agonistic effect 
(Table 3). Contrary, for mix 3 and mix 4, a decrease in activation was observed in the PPARα 
agonist assay. When testing the PEs in combination with a known PPARα agonist, the only 
antagonistic effect observed was a weak effect with mix 3 at the two highest concentrations as well 
as a significant decrease in activity at the highest concentration of mix 1 (Table 3).  
For coumestrol alone, a significant decrease in activity was also observed in the antagonist assay at 
the highest concentration, but this decrease was also observed in the PPARα agonist assay (Table 
3). Therefore, this effect could be due to a beginning cytotoxic effect even though cytotoxicity was 
only found for coumestrol at 50 μM and 100 μM in one out of five independent cytotox-
experiments. 
 
Altogether, the results from the studies presented in paper I and III show that the mechanisms 
underlying the endocrine disrupting effects of the PEs are many and complex. Additionally, many 
PEs as well as nutrition relevant mixtures of PEs have an inhibiting effect on lipid accumulation in 
vitro, which could suggest a beneficial effect with regard to obesity. However, the concentrations 
tested in the 3T3-L1 adipocyte assay were much higher than what is normally found in humans. 
Additionally, based on our current results, as well as the fact that the roles of the different players in 
adipogenesis and lipolysis is not yet understood, the influence of PEs on adipogeneisis and 
development of obesity is still unclear.  
The current studies cannot be used to conclude, if it is the effects of genestein and/or coumestrol 
alone that account for most of the endocrine disrupting effects observed with the total PE mix. 
However, the results from mix 2 in the various in vitro assays indicate that it is not only the 
mammalian metabolites but also the precursor plant isoflavones that have the ability to act as potent 
endocrine disrupters. 
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5.2 Use of external metabolizing systems when testing for endocrine 
disruption in vitro – Paper II 
The overall aim of Paper II was to test different in vitro metabolising systems for biotransformation 
of known endocrine disrupting chemicals to find a potential method for the incorporation of 
metabolic and toxicokinetic aspects into in vitro testing for endocrine disruptors. 
Table 4 gives a summery of the results obtained with two of the in vitro metabolising systems 
applied. 
 
Table 4 - Metabolism of 10 selected test compounds using different in vitro metabolising systems 
 Recovery of parent compound (%) 
Compound human S9-mix rat microsomes 
Ketoconazol 96% 53% * 
Miconazol 97% 85% * 
Epoxiconazol 110%  95% 
Tebuconazol 96% 86% * 
Prochloraz 94% 86% * 
Dimethyl phthalate ~0% a  < 1% a 
Diethyl phthalate ~0% a < 1% a 
Methylparaben ~0% a < 1% a 
Ethylparaben ~0% a < 1% a 
Butylparaben ~0% a < 1% a 
Recovery of the parent compounds (%) after using the indicated in vitro metabolizing method. 
a Indicates that the P-value could not be calculated because the amount of remaining parent compound was  
below the detection limit.  
* Statistically significant difference between the amounts of parent compound in the samples before and after  
the applied method of metabolism, tested by to-tailed T-test (p<0.05). 
 
 
The LC-MS analysis of the S9 extracts for the azole fungicides showed no indication of any 
metabolic transformation during the incubation with the human liver S9 mix (Table 4). The 
parabens and phthalates on the other hand had almost been completely metabolized, with a recovery 
of the parent compounds from the S9 extracts of less than 1 % for both parabens and phthalates 
(Table 4).  
When using the PCB-induced rat microsomes the results for the parabens and phthalates was the 
same as seen with the human S9 mix. An extensive metabolic transformation of the parabens and 
the phthalates was observed, again with a recovery rate of the parent compounds of less that 1% 
(Table 4). However, in contrast to the human S9 mix, the rat microsomes were able to metabolize 
the tested amount of azole fungicides to some extent. A statistically significant difference between 
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the amount of parent compound before and after treatment with the rat microsomes was seen for 
four out of five azole fungicides (Table 4).   
 
An additional aim of the study presented in paper II was to determine the endogenous metabolic 
capacity of the cell line applied in the T-screen assay. 
The cells used in the T-screen assay are the GH3 cells. The results from the analysis of the 
metabolic capacity of the GH3 cells showed a statistically significant difference between the 
amount of parent compound before and after incubation with the GH3 for the two tested phthalates 
DMP and DEP. No significant transformation of the parabens or azole fungicides was found.   
 
   Table 5 - Effects of the 10 parent compounds as well as the S9 extracts of the 3 parabens,  
   and the 2 phthalates in the T-Screen assay 
 Effect in the T-screen assay 
Compound Parent compound Human S9 metabolic extract 
Ketoconazol Antagonist # Not tested 
Miconazol Antagonist # Not tested 
Epoxiconazol - Not tested 
Tebuconazol Antagonist # Not tested 
Prochloraz Antagonist # Not tested 
Dimethyl phthalate (DMP) - (antagonist)* 
Diethyl phthalate (DEP) - - 
Methylparaben Agonist - 
Ethylparaben Agonist - 
Butylparaben Agonist Agonist 
     - : no effect. 
       # : the effect was only seen at the highest concentration tested, so a cytotoxic effect could be the cause 
    * only at the three highest dilutions 
 
Regarding any possible changes in the thyroid receptor activity of the selected EDCs, after 
biotransformation, the general picture for the parent compounds was an antagonistic effect of the 
azole fungicides, while the parabens had an agonistic effect (Table 5). After biotransformation 
using the human S9 mix, the metabolic extract from butylparaben showed a significant agonistic 
effect (Table 5). A significant agonistic was also seen for the metabolic extract from methylparaben, 
however, the effect was only significant at the second lowest dilution and was therefore judged to 
be a chance finding. For the S9-extracts from the 2 phthalates a statistically significant reduction of 
the T3 induced cell proliferation was observed for the DMP extract at the three highest dilutions 
(Table 5). 
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The extracts from the 5 azole fungicides were not tested as these compounds had shown very low 
metabolic transformation after treatment with the human liver S9 mix (Table 4). 
Overall, we did not find a marked difference in the effects observed for the parent compounds and 
the effects of the tested metabolic extracts in the selected in vitro assay. However, based on the 
results from the current study, our conclusion is that the GH3 cells show some metabolic capability 
in relation to the two tested phthalates DMP and DEP, but almost none towards the tested azole 
fungicides and parabens.  
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6 Discussion  
The focus of this PhD thesis with the title “Mechanistic evaluation of endocrine disrupting 
chemicals” has been on different in vitro studies of a few groups of already known endocrine 
disrupting compounds. The overall aim has been to gain more knowledge or information on the 
many different mechanisms that are either known to or that can have the potential to play a role in 
the adverse effects of EDCs. An additional focus point has been to improve some of the limitations 
of in vitro assays for endocrine disruption, specifically the lack of metabolism of test substances, 
and the lack of knowledge regarding the endogenous metabolic capacity of the different cell lines 
applied in the various in vitro assays. 
 
6.1 The studies on phytoestrogens and phytoestrogen mixtures  
6.1.1 Effects of PEs on steroidogenesis, aromatase, and estrogen activity 
As previously mentioned, many of the studies presented as part of this thesis include testing of 
different mixtures of PEs. In this regard, it should be emphasised that the in vitro studies in this 
PhD project were not designed with the aim of making predictions of mixture effects.  
Two different types of PE-mixtures have been studied, although, the single PEs in each of the five 
mixtures studied in papers I and III are the same. The mixtures in this project were either designed 
to be equimolar concentrations as in paper I or based on exposure data as in paper III. Although the 
the mixtures were designed to represent PEs naturally occurring in Western food, the proportions of 
the compounds in the mixtures were not representative of the concentrations found in the diet, and 
the design of the mixtures was not based on effective doses, as different in vitro assays were used, 
and each compound could have very different effect in each assay. Therefore, the results of the 
studies cannot be used to conclude on additivity. 
In paper III the proportions of the single PEs in the mixtures were not equimolar concentrations, but 
were based on the amount and number of the different classes (e.g. isoflavonoids lignans and 
coumestans) of PEs naturally found in Scandinavian food (157). These mixtures are therefore very 
relevant in relation to human food consumption. 
However, it would have been very interesting being able to make some kind of predictions and 
modelling of mixture effects, and this should be kept in mind for future experiments.   
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Through our diet, we are exposed to many different and complex mixtures of PEs. The overall aim 
of the study presented in paper I was to evaluate the endocrine disrupting potential of twelve 
different PEs and mixtures of PEs naturally occurring in Western/Scandinavian food. Until recently 
many studies have typically been based on single or a small number of individual compounds, or on 
single dietary compounds like soy or flaxseed. The question we wanted to address was whether the 
effects of the individual PE compounds are modified when they are combined with other PEs from 
various classes. One example is the study by Power et al., (2006) where it was found that the 
isoflavone genistein alone promoted growth of MCF-7 human breast cancer xenografts, but when 
genistein was given in combination with the mammalian lignans enterolactone and enterodiol, no 
tumour growth-promoting effect was observed (41). 
In the study presented as part of this thesis, the twelve selected PEs were tested alone or in mixtures 
in a battery of in vitro bioassays. In the steroid synthesis assay (H295R), all tested PEs and PE-
mixtures caused an increase in the estradiol production. Furthermore, the mixture consisting of the 
isoflavonoids formononetin and biochanin A, as well as the total-mix containing all twelve PEs 
caused a dose-dependent reduction in the testosterone production. Genistein alone also caused a 
dose-dependent reduction in the testosterone production in the H295R cells, and the effect of 
genistein was in general comparable to the effects observed for mix 1, which contained the 
isoflavonoid metabolites genistein, daidzein, and equol.  
The observed reduction in the testosterone production might be a result of an inhibitory effect of the 
isoflavones on some of the steroidogenic enzymes involved in testosterone biosynthesis (see Figure 
8). This would be in agreement with other studies including a study by Ohno et al. (2002), which 
showed that genistein, daidzein, formononetin and biochanin A strongly inhibited 3β-
hydroxysteroid dehydrogenase (3β-HSD) activity and at high concentrations (12.5 and or 25µM) 
also inhibited P450c21 activity (163). Also Le Bail et al. (2000) have shown that genistein, 
daidzein, formononetin and biochanin A are 3β-HSD and/or 17β-HSD inhibitors (Figure 8), and 
that the inhibitory effect of some of the PEs are related to small structural differences, which can 
explain the diversity of effects seen for the different PEs (40). 
 
In the MCF-7 cell proliferation assay, the isoflavonoids and coumestrol had a growth stimulatory 
effect on the MCF-7 cells, whereas the lignans had no effect. The most pronounced effects were 
seen with mix 1 (genistein, daidzein, and equol) and the total-mix, as well as with the selected 
single compounds. Overall, the effect of genistein and, at the highest concentration also daidzein 
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was comparable to the effect observed for mix 1. Coumestrol alone had a significant growth 
stimulatory effect on the MCF-7 cells, with an effect comparable to that of estradiol at a 1000 fold 
lower concentration. The growth stimulatory effect of the isoflovonoids and coumestrol are in 
agreement with what previous studies have shown (40, 164) and our Western blot analysis showed 
that both the isoflavonoids and coumestrol increased the expression of the estrogen inducible PR A 
and PR B proteins, supporting an ERα mediated effect.   
Le Bail et al. (40) and others (165) have found that many of the PEs show biphasic regulation 
effects on the cell proliferation of MCF-7 cells, stimulating growth at lower concentrations and 
inhibiting growth at higher concentrations. This was also seen with coumestrol in the study 
presented in paper I. Furthermore, studies also showed that the stimulatory effects at lower 
concentrations correlate with the affinity of the PEs for the ER, supporting our result from the 
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Figure 8 – Potential effects of isoflavonoids on steroiodgenic enzymes found by us and others 
The figure shows an overview of the effects found by us and others for PEs, specifically the isoflavonoids, on the 
different enzymes in the steroid synthesis pathway. Overall, the studies presented in this thesis showed a general 
increase in aromatase activity for the PE-mixtures. However, the observed effects of the PEs and the mechanisms 
behind them can be influenced by the specific tissues or cell lines used, as well as the tested concentrations. 
 
 
Western blot analysis, but that the growth inhibition induced at higher concentrations is probably 
not mediated through ERα (40, 165). The mechanisms behind the growth inhibitory effect seen at  
 55
Discussion
higher concentrations is currently not understood, but might involve inhibition of one or more of the 
enzymes involved in the steroid synthesis (e.g., the aromatase and/or  3β-HSD and 17β-HSD)  (40, 
165).  
Overall, the studies presented in this thesis, both the aromatase assay with the JEG-3 cells as well as 
the steroidogenesis assay with the H295R cells, showed a general increase in aromatase activity for 
the PE-mixtures, and the use of 4-AOD proved that the observed effects were due to an increase in 
aromatase activity (Figure 8). This is in contrast to the many studies that indicate that several PEs 
inhibit the aromatase enzyme (40, 50-52). However, in the study by Le Bail et al. (40), it was found 
that isoflavonoids and compounds, which presented the phenolic B ring in the 3 position on the 
pyran ring, are better 3ß-HSD and/or 17ß-HSD inhibitors than aromatase inhibitors. 
Nevertheless, there are studies supporting our observations as both genistein and coumestrol have 
previously been found to induce aromatase activity (53-55). However, it should be taken into 
consideration, that the effects observed, and the mechanisms underlying them, may be influenced 
by the specific tissues or cell lines used. Coumestrol and genistein induced aromatase activity in 
breast cancer cells (SK-BR-3) through a non-genomic action of ERα (53), whereas the genistein 
increased aromatase activity observed in endometrial stromal cells (ESC) did not seem to be 
mediated through an ER pathway (55). Again, genistein, flavone, and quercetin have been shown to 
inhibit phosphodiesterase in several tissues (166, 167), and induction of aromatase activity by 
genistein, flavone, and quercetin in H295R cells have been suggested to be mediated through the 
cAMP-dependent protein kinase A (PKA) second messenger pathway (54).   
 
6.1.2 Effects of mixtures of PEs on PPAR activation, and adipocyte differentiation  
The hypothesis that there could be a link between exposure to endocrine disrupting chemicals and 
the development of obesity is being supported by more and more studies. However, the potential 
contribution of environmental factors to the development of both obesity and type 2 diabetes is far 
from understood. The aim of the study presented in paper III was to evaluate the different PEs and 
PE-mixtures, shown previously in paper I to have different endocrine disrupting effects, for effect 
on parameters involved in obesity using in vitro assays. The different mixtures and selected single 
compounds were evaluated for potential effects on adipocyte differentiation and for their ability to 
activate the PPARα and PPARγ receptors.  
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The isoflavones, genistein and daidzein have previously been shown to have both PPARα and 
PPARγ agonistic effects (158) and some PEs including genistein have also previously been studied 
for their effect on adipogenesis (168-170). In our study, genistein was found to have a decreasing 
effect on lipid accumulation in the 3T3-L1 cells. This effect was also observed for coumestrol and 
daidzein, though not as potent as seen for genistein (Fig 2A in paper III). For mix 1 containing 
genistein, daidzein and equol, a decrease in lipid accumulation was found as well, the effect being 
comparable to that of genistein. Genistein alone, but also in combination with the naturally 
occurring phytoalexin resveratrol and the flavonol quercetin has previously been shown to decrease 
lipid accumulation in 3T3-L1 cells with the decreasing effect being enhanced when the compounds 
were combined compared to the effect of the individual compounds (168, 171). Because of the 
design of the misture study it cannot be concluded, whether it is genistein that is contributing 
mostly to the effect observed with mix 1. However, the overall decreasing effect of mix 1 is in 
accordance with what others have reported for genistein (168, 171, 172), and also supported by a 
study on the effects of equol by Rachon et al.,(2007), who found that dietary equol decreased 
weight gain, intra-abdominal fat accumulation, and plasma leptin and triglyceride levels in 
ovariectomized rats (173).  
When genistein was tested in combination with the PPARγ antagonist GW9662 the effect of 
genistein on lipid accumulation was weakened, but not totally blocked. This suggests that the effect 
genistein exerts on lipid accumulation in the 3T3-L1 is only partly dependent on PPARγ and that 
lipid accumulation in the 3T3-L1 is mediated by or dependent on other players than PPARγ. One 
possibility is that the effect of genistein is mediated through the estrogen receptor (ER). This would  
be in agreement with other studies showing a possible ERα mediated effect of genistein on adipose 
tissue (170) as well as the reported effect of estrogen on lipid accumulation in 3T3-L1 adipocytes 
(174).  
In addition to mix 1, two other mixtures showed an effect on adipocyte differentiation. Mix 2 
(formononetin and biochanin A) and mix 3 (enterolactone and enterodiol) significantly decreased 
lipid accumulation, though not to the same degree as observed with mix 1. To our knowledge, there 
are currently only few studies on the effect of formononetin, biochanin A, enterolactone and/or 
enterodiol on adipogenesis. One such study is by Shen et al., who found that biochanin A and 
formononetin stimulated lipid accumulation in 3T3-L1 cells at low concentrations (1- 5 μM for 
biochanin A and 3- 30 μM for formononetin, respectively) (175). However, Shen et al. (175) also 
found that genestein stimulated lipid accumulation at 15 μM, a result that is different from what we 
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and others (168, 171, 172) have found. It is known from other types of studies with PEs that many 
of the PEs show a biphasic concentration-effect curve as also mentioned previously. The difference 
between the effects found by Shen et al. (175) and others might be due to a difference in the 
concentrations, as Shen et al. (175) generally have tested lower concentrations. 
In regard to the effects of the PEs mixtures on PPAR activation, the overall picture is a PPARγ 
antagonistic effect, with mix 3 (the lignan metabolites) being the most potent. A PPARγ agonistic 
effect was also seen for mix 1, mix 2 and the total-mix, with mix 2 showing the strongest effect of 
the three (Fig.5 in paper III). The PPARγ activation seen for mix 1 are in agreement with previously 
shown PPARγ activity of genistein and daidzein (158), the main components of mix 1. The 
PPARγ activation by mix 2 points to PPARγ agonistic activities of either formononectin and/or 
biochanin A. Interestingly, these two compounds also inhibited lipid accumulation in 3T3-L1 
preadipocytes indicating similarities to genistein and daidzein. In contrast, decreases in lipid 
accumulation were seen for mix 3 (lignans, mainly enterolactone) which showed no 
PPARγ activiation suggesting that other players besides PPARγ are involved in 3T3-L1 adipocyte 
differentiation. 
No significant activation of PPARα was observed for any of the mixtures and only slight 
antagonistic effects were seen at high concentrations with mix 1 and 3 as well as with coumestrol 
alone (Fig. 4 in paper III).  
A parallel between the results found on lipid accumulation in the 3T3-L1 cells and the effects found 
on PPAR activation cannot be drawn for various reasons. One main reason is that, although much 
progress has been made in regards to understanding adipocyte differentiation and all the different 
mechanisms underlying the development of adipocytes and adipose tissue, it is complex and still 
not fully understood. Different studies have shown that, not only PPARγ but also PPARα could 
play a role in adipocyte differentiation (155, 156). PPARα is not expressed at significant levels in 
white fat, but it is expressed in brown fat (Figure 9) (176, 177). Data by Brun et al. (155) indicate 
that, while PPARα possesses some adipogenic potential, PPARγ is a more effective inducer of 
adipocyte differentiation. However, even though PPARγ is likely to be the predominant receptor in 
regulation of differentiation of white fat, PPARα and PPARγ may both contribute to the 
development of brown fat (Figure 9). So, even though PPARγ is thought to play a big role in 3T3-
L1 adipocyte differentiation, other pathways are involved as well. Recent work by Choi et al., 
(2010)  
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suggests that activation of the PPARγ receptor is required for the adipogenic effects of chemicals 
that bind to the receptor (179). However, the potent effects of organotins on adipogenesis are 
attributed to dual agonistic activity for PPARγ and RXR, although there is some debate on whether 
these effects on adipogenesis are primarily due to interactions with PPARγ or RXR (180-183). 
Tributyltin (TBT) is a known inducer of lipid accumulation in the 3T3-L1 cells, and is also included 
as a positive control compound in the study presented in paper III. Le Maire et al. have recently 
shown that the activation of the PPAR-RXR heterodimers by TBT is primarily through its 
interaction with RXR (182). Overall, based on the result of the study presented in paper III, the 
different PE mixtures had more effect on PPARγ than PPARα, with some mixtures showing PPARγ 
agonistic effects while others had more PPARγ antagonistic effects. To my knowledge, nothing is 
known regarding the interaction between the different PEs and RXR, and such information would 
be relevant in terms of explaining or interpreting the observed effects of the PEs on adipocyte 
differentiation and lipid accumulation.   
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6.2 The use of in vitro metabolising systems in connection with in vitro testing 
of EDCs 
This study, presented in paper II, on in vitro metabolising systems only focused on metabolism 
through phase I and not phase II metabolism, and it was not the aim of the study to identify the 
different metabolites.  
As mentioned in the result section, the results of the in vitro metabolising study using the human 
cryopreserved hepatocytes are not presented in any of the papers. The reason for this is that our 
efforts to metabolise the xenobiotics using cryopreserved human hepatocytes failed as the 
hepatocytes died even though the protocol was followed according to the manufactur’s instructions.  
Several attempts were made with cryopreserved human hepatocytes. The results from the first run 
were very uneven and generally inconclusive. A new order of cryopreserved human hepatocytes 
was placed, and this time we measured the number of living cells. It turned out that the number of 
live cells was so low (less that 3%) that the cell number was too low to run the experiments. A third 
order of cryopreserved human hepatocytes was placed. This time we also had a very low number of 
live cells, less than 10%. The low number of living cells could explain the uneven and inconclusive 
results gathered from the first run, where we had not measured the number of living cells, before 
starting the experiment. The post-thaw viability promised by the supplier of the hepatocytes was at 
least 70%. After having revised a total of three new batches of cryopreserved human hepatocytes all 
with viability less than 10%, it was decided not to pursue with the cryopreserved human hepatocyte 
metabolism assay. 
When working with in vitro systems, one is working with isolated systems not whole organisms. 
Therefore, when looking and evaluating the effects or results obtained from the different test 
systems, it is important to know how a particular compound is metabolised, both in vivo (in the 
animal) and in the different in vitro systems (cell models). In that regard, it is important to have 
information concerning the endogenous metabolic capacity of the different cell lines used in the 
various in vitro assays now available for the testing of compounds’ endocrine disrupting potential. 
A point of interest in the study presented in paper II was therefore, to investigate the endogenous 
metabolic capacity of the cells used in the applied in vitro assay, which in the current study was the 
T-screen assay. For the ten selected test compounds representing three different classes of 
compounds: azole fungicides, parabens and phthalates, we found a significant difference between 
the amount of parent compound before and after incubation with the GH3 cells for the two 
phthalates. This could suggest that the GH3 cells, employed in the T-screen assay, have some 
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metabolic capability in regard to the two tested phthalates, DMP and DEP. In general, such 
information concerning the metabolic fate of a compound in a given test system, is important when 
evaluating the results. In the current study, we did not find a marked difference in the effects 
observed for the parent compounds and the effects of the tested metabolic extracts.  
Regarding the aim of looking at different in vitro systems for biotransformation of known endocrine 
disrupting chemicals in connection with testing their effects in in vitro assays, two in vitro 
metabolising systems were tested. Human liver S9 mix, and PCB-induced hepatic rat microsomes.  
The basis for choosing human liver S9 was initially that we wanted to compare the results from the 
human liver S9 assay with results from an assay using a rat based in vitro metabolising system. 
Both test systems gave an almost complete metabolic transformation of the tested parabens and 
phthalates, with a recovery rate of the parent compounds of less than 1%. 
A difference was found between the human S9 and rat microsome assay systems. When using the 
PCB-induced rat microsomes, a statistically significant difference between the amount of parent 
compound before and after treatment with the microsomes was seen for four out of the five azole 
fungicides tested. When using the human liver S9, no significant metabolic transformation of the 
azole fungicides was detected. This variation could be due to differences in metabolism between 
humans and rats or it could be due to a general higher metabolic activity of the rat microsomes 
compared to the human S9 fraction. The use of PCB mixtures is a known and well established 
method to induce the activity of the different liver enzymes. The induction with PCB can only be 
done before the rat (or other animal) liver enzymes are recovered, and can be used in connetion with 
recovery of liver enzymes from humans. The applied human liver S9 mixtures were made from 
pooled livers from both male and females in the ages from 28 to 77 years of age. So, although the 
use of human liver enzymes would seem more relevant in regards to a human exposure scenario, at 
least one question that comes into mind is how representative these human livers and liver enzymes 
are of a healthy human population? Overall, there is reason to believe that a higher metabolic 
activity of the rat microsomes could be one reason of the difference in metabolism between the 
human liver S9 and the PCB induced rat microsomes. However, it is well known that there are 
many differences in the metabolic capacity between species and also differences within the same 
species associated with age, gender, nutrition, genetic predisposition, environmental factors and 
others.  
In regards to risk assessment for endocrine disrupting effects and human exposure, it would seem 
most relevant to use metabolising systems based on materials from humans. However, using 
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materials from animals compared to humans would most likely be easier and cheaper, particularly 
because getting enough amount of research material from animals would be less of a challenge. 
Therefore, it is relevant to get as much data as possible in order to make valid comparisons and 
extrapolations between results from different species. Another reason for the difference observed 
between the human S9 and rat microsome metabolising systems could be due to different binding of 
test compounds to proteins in the enzyme fractions. The azole fungicides are the most apolar of the 
ten test compounds and they might bind to proteins or lipids making them less accessible for the 
metabolising enzymes. Several EDs are known to bind strongly to serum proteins and when this 
occurs in vivo, it affects the internal target tissue concentrations of the chemical involved (184). 
Such binding can occur with components of the metabolising systems like S9 or components in 
culture media such as proteins in serum added to the media thereby resulting in both variable in 
vitro data, but also in differences in the results obtained in in vivo and in vitro assays.  
The focus of this study was on getting qualitative data, i.e., to see if the test compounds could be 
metabolised by the different in vitro metabolising systems tested and to get information on the 
metabolic capability of the cells in the selected in vitro assay. However, additional studies focusing 
on determining the metabolic fate of known endocrine disrupters in more detail and identifying 
metabolites would be relevant. 
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7 Conclusions and perspectives 
The challenge with understanding the effects of EDCs, and the mechanisms behind them is that 
EDCs involve many different classes of compounds, affecting different systems and pathways, and 
acting through multiple mechanisms of action, making the picture of the effects of EDCs very 
complex. The results of the studies presented in this PhD thesis have contributed to the still existing 
need for more information regarding the effects of EDCs and mechanisms behind the observed 
effects. Much focus of this PhD project has been on PEs and mixtures of PEs. The contradicting 
effects and the biphasic nature of the PEs make it difficult to get a clear picture of the effects of the 
PEs, also in relation to any possible health promoting effects. Overall more research is needed to 
help understand the mechanisms and the many different effects of PEs. 
Based on the studies conducted in this thesis, it cannot be concluded whether it is the potent effects 
of genestein and/or coumestrol alone that account for most of the effects observed with the total PE 
mix. However, based on the results from mix 2 in the different in vitro assays, it is not only the 
mammalian metabolites, but also the precursor plant isoflavones that have the ability to act as 
potent endocrine disrupters. In addition, PEs might act as ER agonists as observed in the MCF-7 
proliferation assay reported here and elsewhere, which also correlates with a possible ER mediated 
effect of PEs like genistein on lipid accumulation in 3T3-L1 adipocytes. 
Our conclusion is that many PEs, as well as nutrition relevant mixtures of PEs have an inhibitory 
effect on lipid accumulation in vitro, which could suggest a beneficial effect with regard to obesity. 
However, the role of the different players involved in adipogenesis and lipolysis, not only the 
different PPAR isoforms, but RXR and ER as well, are still not understood. Therefore, based on the 
results of the current studies, the influence of PEs on adipogenisis and their effects on the different 
pathways involved in the development of obesity remain unclear. Nevertheless, the current results 
in combination with previous studies and future experiments will hopefully bring us closer to what 
role exposure to EDCs play in the development of obesity and obesity-related diseases, like type 2 
diabetes. 
Additionally, the ability of PEs to make human cells (H295R) produce more endogenous estradiol 
should be emphasised and taken into account, when evaluating the overall effects of PEs on 
humans. 
Further studies are needed in order to investigate mixtures in relation to single compounds. 
Especially, it could be interesting to test whether the effects of lignans are additive to the effects of 
an isoflavonoid, such as genistein. Knowledge from such kind of studies would improve risk 
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assessment of possible adverse effects of the various EDCs that we may come in contact with 
through our diet.  
 
Finally, in regards to the endogenous metabolic capability of different applied cell lines, and the 
lack of metabolism in connection with in vitro tests for endocrine disruption, our conclusion, based 
on the results and data from the study presented in paper II, is that the GH3 cells, applied in the T-
screen assay, show some metabolic capability in relation to the two tested phthalates DMP and 
DEP, but none towards the tested azole fungicides and phthalates. However, additional information 
regarding the metabolic capability of other applied cell lines would be relevant, as well as 
identification of the metabolites from the different compounds and knowledge concerning the 
metabolic fate of known EDCs.  
Overall, an in vitro metabolising system using liver S9 mixtures or hepatic microsomes could be a 
convenient method for the incorporation of metabolism into in vitro tests for endocrine disrupters. 
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Phytoestrogens (PEs) are naturally occurring plant components
produced in a large range of plants. They can induce biologic re-
sponses in vertebrates by mimicking or modulating the action or
production of endogenous hormones. This study examined mix-
tures of 12 food relevant PEs for effects on steroid hormone produc-
tion, aromatase activity, estrogenic activity, and for interaction with
the androgen receptor. The results show that a mixture of all tested
PEs increased estradiol production and decreased testosterone pro-
duction in H295R human adrenal corticocarcinoma cells, indi-
cating an induced aromatase activity. Furthermore, exposure of
the H295R cells to isoflavonoids caused a decrease in testosterone
production, and various mixtures of PEs significantly stimulated
MCF-7 human breast adenocarcinoma cell growth and induced
aromatase activity in JEG-3 choriocarcinoma cells. The estrogenic
effect in the MCF7 cells of the isoflavonoid mixture and coumestrol
was supported by an observed increase in progesterone receptor
protein expression as well as a decreased ERα expression.Overall,
the results support that nutrition-relevant concentrations of PEs
both alone and in mixtures possess various endocrine disrupting
effects, all of which need to be considered when assessing the effects
on human health.
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INTRODUCTION
Phytoestrogens (PEs) are a diverse group of naturally occur-
ring plant compounds that because of their structural similarity
with estradiol, have the ability to cause estrogenic or/and antie-
strogenic effects (1).
The broad classes of PEs include the isoflavonoids (genistein,
daidzein, formonetin, biochanin A, and equol) found predom-
inantly in soya beans and red clover, the lignans (enterolac-
tone, enterodiol, pinoresinol, lariciresinol, secoisolariciresinol,
matairesinol) found particularly in flax seed and fruits, and the
coumestans (coumestrol) found in red clover and a variety of
other plants. Several of the PEs are ingested as precursors and
then converted by the microflora in the mammalian gut. Lignans,
for instance, are metabolized by intestinal bacteria to form the
mammalian lignans known as enterodiol and enterolactone (2).
The major isoflavonoids daidzin and genistin are metabolized in
mammals to form the active compounds daidzein and genistein.
Daidzein is further metabolized to the compound equol (3).
Many of the metabolites have been shown to have more
pronounced effects compared to the mother compound (3,4).
Several in vivo studies have indicated that PEs may elicit
cancer-preventing effects in laboratory animals exposed to a
cancer-inducing agent (3,5,6). Furthermore, epidemiological
data suggests that a diet rich in phytoestrogens decreases the
risk of breast cancer, among others, because the breast cancer
incidence is much lower in Asian populations in comparison
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with Western populations (7). However, other studies, both an-
imal and in vitro, have shown that the effects of phytoestrogens
may increase cancer risk (8–11).
The vast majority of experimental studies in vitro and in vivo
have typically been based on a single diet (containing primarily
soy or flaxseed) or on single or a small number of individual
components. However, PEs occur in complex matrices in our
diet and it is relevant to conduct experimental designs in order
to evaluate the effect of mixtures of these compounds. The se-
lection of PEs for the current study was based on a Scandinavian
epidemiological study, estimating the intake of a number of PEs
in the Swedish population (12). Western diet contains several
more lignans than the traditionally studied isoflavones.
The extent of the metabolism of PEs by the intestinal bacteria
appears to be highly variable among individuals; for example,
only one-third to one-half of the population can metabolize the
soy isoflavone daidzein to equol (13,14). PEs are weak estro-
gens, but may also function as estrogen antagonists by blocking
the binding of the much more potent endogenous estrogen to its
receptor. In addition, it has been shown that PEs can affect the
synthesis or metabolism of steroid hormones, for example, by
affecting the aromatase activity. Aromatase activity is impor-
tant for the balance between the endogenous testosterone and
17ß-estradiol, and changes in this balance may be beneficial or
adverse in relation to proliferation of, for example, breast cancer
tumor cells, as 17ß-estradiol is considered the main determinant
of proliferation of estrogen-dependent breast cancer cells (15).
The major site of aromatase dependent estradiol synthesis is in
the ovary in premenopausal women and in peripheral tissues
in postmenopausal women (such as the adrenals) (16). Many
papers have referred to the inhibitory effects of PEs on the aro-
matase activity (4,17–19), but it cannot be generalized that these
compounds elicit inhibitory effects, and it has been found that
some PEs in fact induce aromatase activity (20–22). The avail-
able literature provides conflicting findings as to the effects of
PEs, which probably results from the multiple mechanisms
of action of these compounds. The complexity of the influence
of PEs at the cellular and molecular level is further increased
by the fact that their effects are dependent on the dose, the class
to which they belong, the presence or absence of endogenous
estrogens, their different affinity for the estrogen receptor (ER)α
and ERß receptor, and the type of tissue or cell considered (19).
The aim of this study was to evaluate the endocrine disrupt-
ing potential of different PEs and mixtures of PEs naturally
occurring in Western/Scandinavian food. The proportions of
the different compounds in the mixtures were in equimolar
concentrations; so although representing PEs naturally occur-
ring in Western food, the proportions of the compounds in the
mixtures are not a representative of the concentrations found in
the diet. The PEs were analyzed in a panel of in vitro bioassays,
designed to look for effects on 1) steroid hormone production in
human adrenal corticocarcinoma cells (H295R), 2) aromatase
activity in human JEG-3 choriocarcinoma cells, 3) estrogenic
activity using the human MCF-7 cell proliferation assay, and 4)
FIG. 1. Overview of the different phytoestrogens (PEs) and mixtures tested
in the in vitro assays. The selected PEs consists of both mother compounds
(biochanin A, formononetin, secoisolariciresinol, matairesinol, lariciresinol,
pinoresinol, and coumestrol) and metabolites (genistein, daidzein, equol, en-
terodiol, and enterolactone). The different mixtures and the total mixture are
presented in boxes, and the compounds, which were (also) tested alone, are
represented in dotted line boxes.
interaction with the androgen receptor (AR) in a reporter gene
assay. The design of mixtures was not based on effective dose,
as 4 different in vitro assays were used, and each chemical
could have very different effect in each assay. In addition only
genistein, daidzein, equol, and coumestrol were tested as single
compounds. The results of this study, therefore, cannot be used
to conclude on additivity. An overview of the different PEs and
mixtures are presented in Fig. 1.
MATERIALS AND METHODS
Test Compounds
The 12 PEs used and their data are listed in Table 1. The
mixtures were made by mixing the PEs in equimolar concentra-
tions. Thus a 10 µM concentration of mixture 1 is composed of
3.33 µM of each of the 3 PEs, genistein, daidzein, and equol.
Mixture 2 is composed of the 2 isoflavonoids, formononetin and
biochanin A; and mixture 3 is composed of enterolactone and
enterodiol. Mixture 4 is a mixture of the 4 lignans secoisolar-
iciresinol, matairesinol, lariciresinol, and pinoresinol. Coume-
strol was part of the total mixture but was also tested alone, as
it was the only coumestan included in the study. An overview
of the different PEs and mixtures included in the study is given
in Fig. 1.
[1β-3H]Androst-4-ene-3,17-dione was from PerkinElmer
(Boston, MA), and both 4-androstene-3,17-dione (4-AD) and 4-
androsten-4-ol-3,17-dione (4-AOD) were from Sigma Aldrich
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(Milwaukee, WI). The test compounds were dissolved in
dimethyl sulfoxide (DMSO).
Steroid Synthesis Assay (H295R)
The H295R cells are human adrenocortical carcinoma cells.
The cell line has been characterized in detail and shown to
be a useful tool for the study of adrenocortical function and
steroidogenesis, as it express all the key enzymes necessary for
steroidogenesis and is able to produce many steroid hormones,
glucocorticoids, and mineralocorticoids.
H295R cells were obtained from the American Type Cul-
ture Collection (ATCC, CRL-2128; ATCC, Manassas, VA) and
grown in 75 cm2 flasks at 37◦C with 5% CO2. The cells were
maintained in a 1:1 mixture of DMEM/F12 (Sigma) supple-
mented with 1.2g/l Na2CO2, 5.0 ml/l of ITS + premix (BD
Bioscience), and 12.5 ml/l NU-serum (BD Bioscience). Cells
were grown until almost confluent and seeded in 24-well cell
culture plates at a density of 300,000 cells/ml. After a 24 h
attachment period, the medium was removed, and new media
containing the test compounds was added. Each test compound
or mix was tested in triplicate. After incubation for 48 h, the
media was removed and stored at –20◦C until hormones were
measured. Prochloraz (known inhibitor of testosterone/estradiol
synthesis) was used as positive control, and DMSO was used
as vehicle control. As positive control for aromatase inhibition,
the H295R cells were exposed to 100 nM/1 µM of the steroidal
aromatase inhibitor 4-AOD. Cytotoxicity was evaluated in each
well by the use of a Live/Dead kit (following instructions sup-
plied by the manufacturer, Molecular Probes, Invitrogen A/S,
Taastrup, Denmark) and AlamarBlue (Serotec, Kidlington, UK).
Fluorescence was measured after 1, 2, and 3 h (excitation 10
nm/emission 10 nm) using a PerkinElmer luminescence spec-
trophotometer, equipped with a microtiter plate reader.
The hormones were extracted from the medium by solid
phase extraction using IST Isolute C18 SPE columns of 200 mg
(Mikrolab Aarhus). The medium samples (800 µl) were diluted
twofold with purified water and applied to columns precondi-
tioned and rinsed with methanol and water, respectively. Inter-
fering substances were eluted with 2 ml methanol:water (20:80
vol/vol), and the steroids were eluted with 2∗2.4 ml methanol.
Subsequently, the solvent was evaporated and samples were
resuspended in 200 µl Diluent (PerkinElmer Life Sciences,
Wallac). Testosterone and estradiol were measured in the ex-
tracts using Delfia kits from PerkinElmer Life Sciences, Wallac,
for each tested compound/mixture. The H295R assay was re-
peated 3 times in the concentration range 10–10 to 10–5 M, and
furthermore twice with 5 concentrations within the range 10–6 to
10–5 M, to study this concentration range in detail.
MCF-7 Cell Proliferation Assay
The MCF-7 (MCF-7-BUS) cell line was kindly provided by
Ana Soto (Boston, MA). The cells were maintained in DMEM
(Gibco, supplied by Invitrogen A/S, Taastrup, Denmark) with-
out phenol red, supplemented with 10% heat-inactivated fetal
calf serum (FCS) (Life Technologies, Bethesda, MD), 6 ng/ml
bovine insulin (Novo Nordic, Bagsværd, Denmark), 4 mM glu-
tamine, 20 mM HEPES and 1 mM sodium pyruvate (all from
Invitrogen). Cells were subcultivated by trypsination once a
week and were incubated in a 5% CO2 humidified incubator at
37◦C. For experiments, MCF-7 cells (2.5 × 104) were seeded
into 24-well plates (1.9 cm2 wells) and left to attach for 24 h
before initiating 5 days exposure to PEs. At the onset of ex-
posure, FCS in the medium was replaced with serum depleted
of steroids by dextrane-coated charcoal treatment (DCC-FCS)
(23), and the medium was supplemented with 2.5 × 105 U peni-
cillin and 31.25 µg/l streptomycin (DCC medium). Cells were
exposed to PEs in the combinations and doses shown in Fig. 4.
Effects on proliferation of the PEs were tested in the absence
and presence of 17β-estradiol (Sigma) in order to detect both
estrogenic and antiestrogenic effects. A suboptimal stimulatory
concentration of estradiol (1 pM) was used to enable detection
of either antiestrogenic effects or additive estrogenic effects in
TABLE 1
Information on test compounds
Compund MW Supplier CAS no. Purity(%)
Coumestrol 267.0 Fluka, Sigma-Aldrich 479-13-0 >95
Genistein 270.2 Sigma-Aldrich 446-72-0 98
Daidzein 254.2 Sigma-Aldrich 486-66-8 98
Equol 242.3 Sigma-Aldrich 94105-90-5 99
Formononetin 268.3 Fluka BioChemika, Sigma-Aldrich 485-72-3 >99
Biochanin A 284.3 Sigma, Sigma-Aldrich 491-80-5 >99
Enterolactone 298.3 Fluka BioChemika, Sigma-Aldrich 78473-71-9 >95
Enterodiol 301.2 Fluka, Sigma-Aldrich 80226-00-2 >95
Lariciresinol 360.0 Arbo-Nova, Finland 27003-73-2 >95
Pinoresinol 358.4 Arbo-Nova, Finland 487-36-5 >95
Matairesinol 358.4 Arbo-Nova, Finland 580-72-3 >95
Secoisolarici resinol 362.4 Fluka BioChemika, Sigma-Aldrich 29388-59-8 >95
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the same assay. Exposure to 100 pM estradiol (resulting in max-
imal stimulation of cell growth) was used as a positive control
for estrogenic effects, and exposure to 1 pM estradiol + 1 nM
ICI 182,780 was used as a control for antiestrogenic effects. Ve-
hicle (DMSO) was added to the control cultures. Exposure was
sustained for 5 days (Day 0 to 5), with replacement of medium
and compounds on Day 0, 1, and 4. On Day 5, the cells were
rinsed in phosphate buffered saline (PBS), and a crystal violet
colorimetric assay staining DNA was used to obtain an indirect
measure of the cell number (24). The obtained optical density
for each sample was expressed as a relative value in percent of
the DCC control culture.
Western Analysis
Expression of ERα, 67 kDa, progesterone receptor (PR A,
81 kDa and PR B, 116 kDa) and β-actin (42 kDa) was deter-
mined by Western analysis. The MCF-7 cells were grown in
control medium for 2 days before exposure to vehicle (DMSO),
100 pM estradiol, 1 µM Mix 1 or 1 µM Mix 1 plus 100 nM
ICI 182,780, 100 nM coumestrol, and 100 nM coumestrol plus
100 nM ICI 182,780. After 3 days, whole cell extracts were
prepared by harvest in RIPA buffer (100 nM NaCl; 20 mM
Trizma-base; 0.1% Triton X-100; 0.5% sodium desoxycholate;
0.1% sodium dodecyl sulphate; 1 mM ethylenediaminetetra-
acetic acid, pH 8.0). 10 µg cell extracts were separated by
SDS-PAGE and immuno detected as described previously (25).
Three independent experiments were performed.
Aromatase Assay
The aromatase assay was performed in human JEG-3 chori-
ocarcinoma cells (no. HTB-36; ATCC, Manassas, VA) as de-
scribed in (26), with minor modifications. The test compounds
were dissolved in DMSO. Cells were seeded in 24-well cul-
ture plates (Nunc) at 4 × 104 cells/well in 1 ml culture medium
for 2 days. Day 3, at approximately 80% confluence, serum-free
medium ± test compound and/or control were added (max 0.1%
DMSO).
After 18-h incubation (Day 4), medium was carefully re-
moved, cells were washed with PBS and 0.5 ml substrate
medium without serum containing 0.2 µCi [1β-3H]androst-4-
ene-3,17-dione, and 10 nM unlabelled 4-AD was added. After
2 h of incubation, the aromatization was terminated by plac-
ing the 24-well plates on ice. A total of 300 µl of the culture
medium was withdrawn and extracted; and to remove remain-
ing substrate, 150 µl of the aqueous phase was treated with
100 µl dextran-charcoal in PBS (5%; Sigma Aldrich). The
positive solvent control (PSC) was cells incubated for 18 h
(Day 4) without test compounds, and after cell wash added
0.5 ml substrate medium without serum containing 0.2 µCi
[1β-3H]androst-4-ene-3,17-dione and 10 nM unlabeled 4-AD
and 0.1% DMSO.
The determined aromatase activity was subtracted from back-
ground level (culture media alone minus cells), corrected to cell
protein concentration, and related to the PSC.
For protein determination, cells were lyzed with 0.5 ml 1X
lysis buffer (5x lysis buffer, Reporter Gene Assay, Roche 1897
675, Denmark) for 20 min under mixing at RT. After quick-
spin centrifugation, 40 µl was applied for protein determination
in parallel with bovine serum albumin standards (10–6 to 10–4
g) in lysis buffer using 40 µl lysis buffer as blank. A total of
50 µl of Fluorescamin solution (100 mg Fluorescamin dissolved
in 200 ml Acetonitril) was added, and the plate was incubated for
20 min. while mixing at room temperature in a fume hood. The
protein concentration was then determined using a fluorometer
at 355/460 nm wavelength.
In parallel, the 4-AOD was used as an aromatase inhibitor
control at 10 µM [effective concentration (EC) of 100%] and 10
nM [50% EC (EC50)]. All compound and control incubations
were performed in triplicate in at least 3 independent assays.
In each assay, all data were related to the positive control (me-
dia + substrate: labeled and unlabeled 4-AD), which were set
to 100%. Cell cytotoxicity was determined on the cell culture
media Day 4 using the cytotoxicity detection kit (LDH) from
Roche (Mannheim, Germany) as described previously (27).
AR Reporter Gene Assay
Effects of PEs on AR activity were tested in a gene assay
based on transiently transfected Chinese hamster ovary (CHO)
cells. The assay was performed as previously described by (28)
with minor modifications. The cells were seeded in microtiter
plates at a density of 5 × 103 cells per well and incubated at
37◦C in a humidified atmosphere of 5% CO2/air. After 24 h,
the PEs to be tested were added and dissolved in culture me-
dia. The test solutions were prepared from stock solutions in
DMSO (final concentration in the media was 0.1%) with or
without 0.1 nM of the positive control R1881 (NEN, Boston,
MA). Hydroxyflutamide (Schering-Plough, Berlin, Germany)
was included as a positive control in every experiment. Chem-
icals were tested at 8 concentrations within the range of 1–
50 µM. Shortly after addition of test compounds, each well was
transfected with a total of 75 ng cDNA consisting of the human
AR expression vector pSVAR0 and the MMTV-LUC reporter
plasmid (both provided by Albert Brinkmann, Erasmus Univer-
sity, Rotterdam, The Netherlands) in a ratio of 1:100 using 25 µl
of the nonliposomal transfection reagent FuGene (Boehringer,
Mannheim, Germany).
After an incubation period of 24 h, the media was aspirated,
and the cells were lysed. Five microliters of a substrate contain-
ing 1 mM luciferin (Sigma) and 1 mM ATP in lysis buffer was in-
jected automatically and the chemiluminescence was measured
over a 1-s interval after an incubation time of 2 s. After 24 h in-
cubation, cytotoxicity was measured by replacing the pSVAR0
expression vector with the constitutively active AR expression
vector, pSVAR13, as described in (28). Cytotoxicity was de-
fined as the ability of the compounds to affect the transcription
process in the cell. Furthermore, the cytotoxicity was also mea-
sured using AlamarBlue (Serotec, Kidlington, UK). The AR
assay was repeated 3 times for each test compound/mixture.
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Statistical Analysis
Steroid synthesis and AR reporter gene assay. Data were
examined for normal distribution and homogeneity of variances.
Effects of PEs on steroid synthesis and AR activation/inhibition
were analyzed with a 1-way parametric analysis of variance
(ANOVA); and if ANOVA results were significant (P< 0.05),
Dunnett’s tests were used to compare the means between the
controls and the means of the different concentrations.
MCF-7 cell proliferation. Levene’s test was used to analyze
for homogeneity of variance in all experiments, and log trans-
formation of data was performed in case of unequal variance.
A linear model of analysis of variance, followed by 2-sided,
pairwise t-tests with Bonferroni’s correction was used to detect
differences between treatments. Results were considered signif-
icant when P< 0.05. Calculations were performed using SAS,
version 8.2 (SAS institute, Cary, NC). For mixture 2, cytotoxi-
city at approximately 10 µM resulted in large SDs, as the cells
in some wells had died, whereas others had only initiated the
death process. The large SDs for this data point confounded
statistical analysis of the rest of the data set, which is why the
data point was removed from the data material before statistical
analysis.
Aromatase assay. The statistical analysis was performed in
SPSS 14.0 (SPSS, Inc., Chicago, IL). Due to unequal of vari-
ances and relatively few data points per concentration, nonpara-
metric statistics was performed. The Kruskal–Wallis test was
used to compare differences between different concentrations,
and the Jonckheere–Tepstra test was used to analyze for a lin-
ear trend between concentrations and response. If one or both
tests showed a significant difference (P ≤ 0.05), the Mann–
Whitney test was used to compare the difference between each
test concentration and the respective control.
The EC50 was calculated by fitting dose-response data to
a 3-parameter sigmodal Hill curve using Sigma Plot (SPSS,
Chicago, IL) as described previously (26).
RESULTS
The PEs alone or in the different mixtures was tested in the
in vitro panel for endocrine activity. The different mixtures and
single PEs tested can be seen in Fig. 1.
Effects on Steroid Production in H295R Cells
Experiments in the H295R cells showed that none of the
PEs had any effect on the synthesis of testosterone or estra-
diol in the low concentration range from 10–10 M to 10–7 M
(data not shown). At the highest concentration (10 µM), all
compounds/mixtures tested caused an increase in the estradiol
production (Fig. 2). Furthermore, the highest concentration of
the isoflavonoids in Mix 2 (formononetin and biochanin A) and
the total mixture caused a significant decrease in the testosterone
production (Fig. 3). Additional examination of the concentra-
tions ranging from 1–10 µM revealed that increasing concen-
trations of Mix 1 (genistein, daidzein, and equol), Mix 2 (for-
FIG. 2. Effect of phytoestrogens (PEs) on estradiol production in the H295R
cells. In vitro effects of PEs on estradiol production in human adrenocortical
carcinoma cells (H295R) are shown. Data represent the mean ± SD for 3 inde-
pendent experiments. + and ++ represent 100 nM and 1 µM of the aromatase
inhibitor 4-androstene-4-ol-3,17-dione, respectively. Proch, 3 µM prochloraz.
∗
, Statistically significantly different from control (P< 0.05).
FIG. 3. Effect of phytoestrogens (PEs) on testosterone production in the
H295R cells. In vitro effects of PEs on testosterone production in human adreno-
cortical carcinoma cells (H295R) are shown. Data represent the mean ± SD for
3 independent experiments. + and ++ represent 100 nM and 1 µM of the
aromatase inhibitor 4-androstene-4-ol-3,17-dione, respectively. Proch, 3 µM
Prochloraz. ∗, Statistically significantly different from control (P< 0.05).
D
o
w
n
lo
ad
ed
 B
y:
 [
Ta
xv
ig
, 
Ca
mi
ll
a]
 A
t:
 0
7:
03
 4
 J
an
ua
ry
 2
01
0
EFFECTS OF NUTRITION RELEVANT MIXTURES OF PHYTOESTROGENS 127
FIG. 4. Effects of phytoestrogens (PEs) exposure on MCF-7 cell proliferation.
Results are expressed as cell number in percent of the dextrane-coated charcoal
(DCC) control culture ± SD. Cells were exposed to PEs for 5 days. Estradiol
(E2) treatment served as a positive control in all experiments. The effect of
genistein, daidzein, and equol was further compared to the effect of 1 µM of
Mix 1. An indirect measure of the cell number was obtained using a crystal violet
colorimetric assay. Figure shows results from representative experiments with
triplicate measures. For each PE mix, 3 independent experiments in triplicate
were performed and gave comparable results. ∗, Denotes significantly different
from the DCC control; #, Indicates a cell number equal to the E2-treated culture.
mononetin and biochanin A), the total mixture, and genistein
alone caused a dose-dependent reduction in the testosterone pro-
duction, although not statistically significant for Mix 1 (Fig. 3).
Exposure to secoisolariciresinol, matairesinol, lariciresinol, and
pinoresinol (Mix 4) to enterolactone and enterodiol (Mix 3) as
well as to coumestrol did not reduce the testosterone production
in H295R cells. On the contrary, coumestrol and Mix 3 caused a
slight but significant increase in testosterone production (Fig. 3).
To elucidate the mechanism behind the increased levels of
estradiol, the tested compounds, at the highest concentration
(10 µM), were studied in combination with a specific inhibitor
of aromatase, 4-AOD. The results of these experiments revealed
that the increased levels of estradiol following PE exposure
was reduced to background levels following treatment with
100 nM or 1 µM of 4-AOD (Fig. 2). Of the 3 single com-
pounds tested, genistein was the compound that had most effect
on the steroid hormone production in the H295R cells. No sig-
nificant cytotoxic effects were observed for the PEs in the tested
concentrations.
MCF-7 Cell Proliferation
Figure 4 shows the effect of PE exposure on MCF-7 cell
proliferation using the setup for detection of estrogenic effects.
The results are expressed as cell number in percent of the DCC
control culture. Significant stimulatory effects were observed
with the isoflavone metabolites from 10 nM (Mix 1), whereas
the precursor plant isoflavones were less potent (Mix 2) and
only resulted in growth stimulation at 1 µM. For Mix 2, cy-
totoxicity occurred at 10 µM. Exposure to 1–10 µM Mix 1
resulted in MCF-7 cell growth stimulation comparable to the
maximal growth stimulation obtained with estradiol. No effects
were observed with any concentrations of the lignans (Mix 3
and 4). The mix of all tested PEs (total mix) resulted in stimu-
lation of MCF-7 cell growth at concentrations from 100 nM to
10 µM. In 2 out of 3 independent experiments, significant
growth stimulation was observed already at 10 nM. At 1 µM, the
effect was comparable to the maximal effect obtained with estra-
diol. Experiments with selected single compounds were con-
ducted in order to investigate whether single compounds could
account for the observed mixture effects or whether combination
effects were present. The isoflavone metabolites in Mix 1 all re-
sulted in growth stimulation of MCF-7 cell growth (potency:
genistein > equol > daidzein). The potent stimulatory effect
of genistein alone was comparable to the effects observed with
Mix 1 and may have marked detection of any potential mixture
effect of the PEs in Mix 1. Coumestrol stimulated cell growth at
concentrations from 1 nM to1 µM and the stimulatory effect at
100 nM was comparable to that of 100 pM estradiol. At 1–10
µM, coumestrol appeared to be cytotoxic after prolonged ex-
posure (5 days), following an initial growth stimulation at these
concentrations. None of the tested PEs showed antiestrogenic
effects on MCF-7 cell growth (data not shown).
Effect of Mix 1 and Coumestrol on PR and ER Expression
To establish the mechanism behind the growth stimulatory
effects observed for the MCF-7 cells, expression of the PR
and ERα protein was assessed using Western blot analysis.
PR protein is expressed in 2 forms, PR A and PR B, and the PR
gene is an estrogen-regulated gene, the expression of which is
often used as a marker for the presence of functional ERα (29).
It should also be mentioned that MCF-7 cells express extremely
low level of ERβ (30), and therefore expression of ERβ was not
measured.
Addition of estradiol in this experimental setup showed an
expected increase in PR expression and decrease in ERα ex-
pression (Fig. 5). Addition of Mix 1 as well as coumestrol re-
sulted in increased expression of PR up to the level observed for
100 pM estradiol (Fig. 5), indicating that the PEs can act as
potent estrogens via ERα. Furthermore, the antiestrogen ICI
182,780 could completely inhibit the stimulation of the PR
expression (Fig. 5), again supporting an ERα-mediated effect
of the PEs. As expected, estradiol downregulated the ERα ex-
pression (31), and Mix 1 and coumestrol also reduced ERα
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FIG. 5. Effect of Mix 1 and coumestrol on progesterone receptor (PR) and
estrogen receptor alpha (ERα) expression. Expression of ERα (67 kDa), the
PR A (81 kDa) and PR B (116 kDa), and β-actin (42 kDa) determined by
Western analysis. The MCF-7 cells were grown in medium with 10% steroid
depleted FCS and exposed for 3 days to vehicle (DMSO, control), 100 pM
estradiol (E2), 1 µM Mix 1 or 1 µM Mix 1 plus 100 nM ICI 182,780 (ICI),
or 100 nM coumestrol and 100 nM coumestrol plus 100 nM ICI. 10 µg cell
extracts were separated by SDS-PAGE as described in Materials and Methods.
expression. Downregulation of ERα protein with the PEs was
not reversed by ICI treatment, as this antiestrogen in itself down-
regulates ER expression (31).
Aromatase activity. In general, weak effects of the PEs were
observed at low concentrations. Mix 1 inhibited the aromatase
activity at the lowest concentration (10–10 M), but a weak
increase in enzyme activity was observed at 10–9 M, and at
10–6 M an approximately 1.3-fold increase in activity was seen
(Table 2). For Mix 2, 3, 4, and coumestrol, the aromatase activity
was significantly increased at 1 µM and also at 10 µM for Mix
2 and Mix 4. No effect on the aromatase activity was observed
for the single compounds of Mix 1, genistein, daidzein, and
equol and neither for the mixture of all PEs (Table 2).
Androgenicity (AR–assay). None of the tested PEs exerted
any agonistic or antagonistic effects in the androgen reporter
assay in the tested concentration range (data not shown).
DISCUSSION
Through our diet, we are exposed to many different and com-
plex mixtures of PEs. The overall aim of this study was to eval-
uate the endocrine disrupting potential of 12 different PEs and
mixtures of PEs naturally occurring in Western/Scandinavian
food. As mentioned previously, many of the conducted
experimental studies have typically been based on single or
a small number of individual compounds, or on single diet com-
pounds such as soy or flaxseed. However, focus has now been
brought on the question of what happens to the effect of the
individual PE compounds when they are combined with other
PEs from different classes. One such example is the study by
Power et al. (5) in which it was found that the isoflavone genis-
tein alone promoted growth of MCF-7 human breast cancer
xenografts; but when genistein was given in combination with
the mammalian lignans enterolactone and enterodiol, no tumor
growth-promoting effects were observed.
In this study, the 12 selected PEs were tested alone or in mix-
tures in a panel of 4 in vitro bioassays. In the steroid synthesis
assay (H295R), all tested PEs and mixtures caused an increase
in the estradiol production. Furthermore, Mix 2, consisting of
formononetin and biochanin A, and the total mix containing all
12 PEs caused a dose-dependent reduction in the testosterone
production. Genistein alone also caused a dose-dependent re-
duction in the testosterone production in the H295R cells, and
the effect of genistein was in general comparable to the ef-
fects observed for Mix 1. The observed reduction in the testos-
terone production might be a result of an inhibitory effect of
the isoflavones on some of the steroidogenic enzymes involved
in testosterone biosynthesis. This is in agreement with a study
(32) that showed that genistein, daidzein, formononetin, and
biochanin A strongly inhibited 3β-hydroxysteroid dehydroge-
nase (3β-HSD) activity and at high concentrations (12.5 and or
25 µM) also inhibited P450c21 activity. Also Le Bail et al. (4)
showed that genistein, daidzein, formononetin, and biochanin A
are 3β-HSD and/or 17β-HSD inhibitors and that the inhibitory
effect of some of the PEs are related to small structural differ-
ences, which can explain the diversity of effects seen for the
different PEs.
In the MCF-7 cell proliferation assay, the isoflavonoids and
coumestrol had growth stimulatory effect on the MCF-7 cells,
whereas the lignans had no effect. The most pronounced effects
were seen with Mix 1 and the total mix as well as with the
selected single compounds. Overall, the effect of genistein, and
at the highest concentration, also daidzein, was comparable to
the effect observed for Mix 1. Coumestrol alone also had a sig-
nificant growth stimulatory effect on the MCF-7 cells, with an
effect comparable to that of estradiol at 1,000-fold lower con-
centration. The growth stimulatory effect of the isoflovonoids
and coumestrol are in agreement with what previous studies
have shown (4,33). Concomitant with the growth stimulation,
both the isoflavonoids and coumestrol increased the expression
of the estrogen inducible PR A and PR B proteins, supporting
an ERα-mediated effect. Le Bail et al. (4) and others (34) have
found that many of the PEs show biphasic regulation effects
on the cell proliferation of MCF-7 cells, stimulating growth at
lower concentrations and inhibiting growth at higher concen-
trations, as seen with coumestrol in this study. Furthermore,
studies have also shown that the stimulatory effects at lower
concentrations correlate with the affinity of the PEs for the ER,
supporting our result from the Western blot analysis, but that the
growth inhibition induced at higher concentrations is probably
not mediated through ERα (4,34). Altogether, this further adds
to the difficulty of getting a clear picture of the effects of the
PEs, also in relation to any possible health promoting effects.
Finally, this study (both with the JEG-3 and the H295R cells)
showed a general increase in aromatase activity for the PE-
mixtures, and the use of 4-AOD proved that the observed effects
were due to an increase in aromatase activity. This is in contrast
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to the many studies that have indicated that several PEs inhibit
the aromatase enzyme (4,17–19). However, in another study
(4), it was found that isoflavonoids and compounds, which pre-
sented the phenolic B ring in the 3 position on the pyran ring,
are better 3ß-HSD and/or 17ß-HSD inhibitors than aromatase
inhibitors.
Nevertheless, there are studies supporting our observations,
as both genistein and coumestrol have previously been found to
induce aromatase activity (20–22). However, it should be taken
into consideration that the effects observed, and the mechanisms
underlying them, may be influenced by the specific tissues or
cell lines used. Coumestrol and genistein induced aromatase
activity in breast cancer cells (SK-BR-3) through a nonge-
nomic action of ERα (20), whereas the genistein increased
aromatase activity, observed in the endometrial stromal cells
(ESC), did not seem to be mediated through an ER-mediated
pathway (22). Induction of aromatase activity by genistein,
flavone, and quercetin in H295R cells (21) again indicates that
the effects seen in the H295R cells could be mediated through
the cAMP-dependent protein kinase (PKA) second messenger
pathway.
Altogether, the mechanisms underlying the different en-
docrine disrupting effects of the PEs are many and complex.
Based on this study, it cannot be concluded if it is the potent
effects of PEs such as genestein and/or coumestrol alone that
account for most of the effects observed with the total PE mix.
However, based on the results from Mix 2 in the various in vitro
assays, it is not only the mammalian metabolites but also the
precursor plant isoflavones that have the ability to act as potent
endocrine disrupters. In addition, PEs might act as ER agonists
as observed in the MCF-7 assay reported here and elsewhere,
but the ability of PEs to make human cells (H295R) produce
more endogenous estradiol should be emphasized and taken
into account.
Further studies are needed in order to investigate mixtures in
relation to single compounds. Especially, it could be interesting
to test whether the effects of lignans are additive to the effects of
an isoflavonoid such as genistein. Knowledge from these kinds
of studies will help us in risk assessment of possible adverse
effects of the different mixtures of PEs that we may come in
contact with through our diet.
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Although, it is well-established that information on the metabolism of a substance is important in the
evaluation of its toxic potential, there is limited experience with incorporating metabolic aspects into in vitro
tests for endocrine disrupters. The aim of the current study was a) to study different in vitro systems for
biotransformation of ten known endocrine disrupting chemicals (EDs): ﬁve azole fungicides, three parabens
and 2 phthalates, b) to determine possible changes in the ability of the EDs to bind and activate the thyroid
receptor (TR) in the in vitro T-screen assay after biotransformation and c) to investigate the endogenous
metabolic capacity of the GH3 cells, the cell line used in the T-screen assay, which is a proliferation assay used
for the in vitro detection of agonistic and antagonistic properties of compounds at the level of the TR.
The two in vitro metabolizing systems tested the human liver S9 mix and the PCB-induced rat microsomes
gave an almost complete metabolic transformation of the tested parabens and phthalates. No marked
difference the effects in the T-screen assaywas observed between the parent compounds and the effects of the
tested metabolic extracts. The GH3 cells themselves signiﬁcantly metabolized the two tested phthalates
dimethyl phthalate (DMP) and diethyl phthalate (DEP). Overall the results and qualitative data from the
current study show that an in vitro metabolizing system using liver S9 or microsomes could be a convenient
method for the incorporation of metabolic and toxicokinetic aspects into in vitro testing for endocrine
disrupting effects.
© 2010 Elsevier Inc. All rights reserved.
Introduction
Both in vivo and in vitro tests are presently being proposed for the
testing of endocrine disrupting activity of different compounds. The in
vivo or animal tests are currently necessary because it is not possible to
model the complex responses of a whole body to endocrine disrupters
(EDs), including biotransformation. Biokinetic processes, like
absorption, distribution, biotransformation and excretion, determine
the relation of the administered and the internal dose. For in vivo
animal studies, regulatory toxicokinetic studies can determine the
relation between the administered dose via the oral, dermal or
inhalation route and the actual dose at the point of interest for example
a speciﬁc organ or cell When carrying out in vitro studies the same
biokinetic information is crucial when relating the administered in
vitro dose to the internal dose (i.e. free concentration) reaching the
cellular targets.
It is well-established that information on the metabolism of a
substance is important in the evaluation of its toxic potential. For
example, the determination of metabolic stability can provide
information on the potential for bioaccumulation and whether a
chemical is likely to be converted to a more or less active form. With
regard to endocrine disruptors, one also needs to consider that
metabolism of the xenobiotic can alter not only its own potency but
also the toxicokinetics of other substances. Hormones and in
particular steroid hormones are formed or metabolized by enzymes
that participate in the metabolism of xenobiotics. A chemical that is
metabolized by these enzymes may, by mere interaction with the
enzyme, act as a competitor for the hormone or hormone precursor
and therefore disturb hormone levels and hormonal equilibrium.
However, so far there is little or no experience with incorporating
metabolic and toxicokinetic aspects into in vitro tests for endocrine
disrupters, which is in contrast to other areas of toxicity testing such
as the genotoxicity area.
Metabolism occurs especially in the liver, but also in extra-hepatic
tissues (Combes, 1992; Coecke et al., 2006), and can be divided into
phases I and II. Phase I metabolism involves the oxidation, reduction
or hydrolysis of the parent compound into a more polar substance.
The key enzymes for phase I oxidation are the isoforms of the CYP
family of enzymes (Werck-Reichhart and Feyereisen, 2000). However,
CYP enzymes can often be induced or inhibited by exogenous
chemicals that may exert endocrine effects through this mechanism.
Phase I metabolism has been shown to metabolize xenobiotics to both
more and less active compounds (Setchell, 1988; Wong et al., 1995;
Coldham et al., 2002). Phase II metabolism often involves the further
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conjugation of the metabolite with polar molecules, such as sulphate,
amino acids, glutathione or glucuronic acid, generating metabolites
that are more soluble and thus easily eliminated (Combes, 1992;
Coecke et al., 2006). In the current study focus will only be on
metabolism through phase I.
A number of in vitro systems are available for studying metabolism.
They include both cellular (tissue slices, isolated and cultured hepatocytes
or liver cell lines) and subcellular (microsomes, recombinant enzymes)
systems (Guillouzo, 1998).
The aimof the current studywas a) to studydifferent in vitro systems
for biotransformation of ten known endocrine disrupting chemicals
(EDs), b) to determine possible changes in the ability of the EDs to bind
and activate the thyroid receptor (TR) in the in vitro T-screen assay after
biotransformation and c) to investigate the endogenous metabolic
capacity of the GH3 cells, the cell line used in the T-screen assay.
The GH3 cells employed in the T-screen assay is a rat pituitary
tumor cell line. The cell line growth is dependent on the thyroid
hormone (TH) 3,3′,5-triiodothyronine (T3) and it has a high
expression of TR. The growth stimulatory effect of T3 is mediated by
speciﬁc, high-afﬁnity TRs that upon binding of THs bind to thyroid
hormone responsive elements (TREs) in the cell nucleus ultimately
leading to gene expression (Hinkle and Kinsella, 1986). Thus the
T-screen assay can be used for in vitro detection of agonistic and
antagonistic properties of compounds at the level of the TR.
The interest in the TR and the thyroid hormones (T3 and T4) has
arisen because they play a role in the control of development (e.g.
metamorphosis in amphibians and brain development in mammals),
and chemicals may alter their synthesis, transport and catabolism
(Capen, 1997; Cheek et al., 1999; DeVito et al., 1999; Kato et al., 2000;
Zhou et al., 2001; Craft et al., 2002). Increasingly, more evidence is
accruing showing that xenobiotics may act at the thyroid hormone
receptors, and more chemicals are suspected of being able to interfere
with the thyroid receptor function (Zoeller et al., 2005). Compounds
such as polybrominated diphenyl ethers (Hallgren et al., 2001) and
PCB's have been shown to have the potential to interfere with the
thyroid receptor function (Gauger et al., 2004) and some of these
chemicals seem to suppress transcription that is linked to thyroid
receptor activation (Fritsche et al., 2005).
The ten compounds selected for the current study were 5 azole
fungicides: prochloraz, ketoconazole, miconazole, tebuconazole and
epoxiconazole; 3 parabens: butyl-, ethyl- and methyl paraben, and 2
phthalates: dimethyl phthalate (DMP) and diethyl phthalate (DEP).
The compounds were selected from a preliminary study of 20
compounds. The 10 compounds were selected based both on
analytical parameters involving their ease of detection in the HPLC
analysis but also as examples of compounds with known endocrine
disrupting effects on different hormone systems.
Materials and methods
Test compounds
The ten tested compounds and their data are listed in Table 1. For
the in vitro assay all compounds were dissolved in dimethylesulfoxide
(DMSO). MS-grade acetonitrile (99.9%), MS-grade methanol (99.9%)
and MS-grade formic acid (98%) was purchased from Sigma-Aldrich
(Milwaukee, WI, USA). DMSO, 99.8%was purchased fromMerck KGaA
(Darmstadt, Germany). Milli-Q qualitywater was supplied fromwater
puriﬁcation system from Millipore (Billerica, MA, USA).
In vitro metabolizing systems
Human liver S9. The human liver S9 (Product number X008023)
was purchased from Celsis (Brussels, Belgium) The purchased liver S9
was a pooled human mixed gender fraction. The pooled fraction was
from ten individuals, ﬁve females and ﬁve males, in the age between
28 and 81 years old. The original stock had a protein concentration of
23 mg/mL. The procedure for human liver S9 assay was based on
preliminary experiments for optimization of protein concentration as
well as the instructions provided by the supplier (Celsis).
The liver S9 fraction was diluted in Tris buffer to a concentration of
20 mg/mL. Glass test tubes were placed into an ice bath and 50 μL of
diluted S9 was added followed by 320 μL of Tris buffer. 5 μL of 100×
(20 mM for the phthalates and 10 mM for all the other test
compounds) test article stock was added and the test tubes were
placed into a 37 °C shakingwater bath, alongwith a 3.4 mg/mLNADPH
solution, shaking at 150 rpm for 5 min. 125 μL of the 3.4 mg/mL
NADPH solution was then added to each test tube, and the reaction
timer was started at the addition of NADPH to the ﬁrst sample. Total
reactionmixture was exactly 0.5 mL in each tube giving a ﬁnal protein
concentration of 2.0 mg/mL in sample. The sampleswere incubated for
60 min. After incubation the reaction was stopped by adding 1.5 mL
ice-cold methanol and all samples were placed in a−20 °C freezer for
1 h, before the samples were centrifuged at 16,000×g, 4 °C and the
supernatantswere transferred to new tubes and stored at−20 °C until
they were analysed on the HPLC.
Samples containing NADPH solution and DMSO (0.1%) were used
as background. Furthermore samples containing only NADPH solution,
DMSO (0.1%) and S9 were used as negative controls. Reference
sampleswere identical to the test samples, butwith the addition of test
compound after the methanol induced inactivation. The background
and the negative controls samples contain no test compounds but all
other components such as cell media, NADHP and DMSO in the same
concentration as the maximum amount of DMSO found in the test
solutions and the for the negative control samples they also contain S9
or microsomes. The reference samples contained all components
including test compound, but because the test compoundswere added
after inactivation of the enzymes with cold methanol, we would not
expect any metabolism of the test compound to occur. All samples
were run in triplicates.
PCB-induced hepatic rat microsomes. The polychlorinated biphenyl
(PCB)-induced hepatic rat microsomes were prepared from adult
male Wistar rats (age 7–8 weeks, weight ~200 g) as described in
(Frandsen et al., 1994; Frederiksen and Frandsen, 2002). Four rats
were used to prepare a pool of PCB-induced hepatic rat microsomes.
PCB (Aroclor 1254, 500 mg/kg, dissolved in corn oil) was injected
intraperitoneally 5 days before termination as described in (Frandsen
et al., 1994; Frederiksen and Frandsen, 2002). The metabolism assay
using the PCB-induced rat microsomes was run as described above
with the human lever S9 fraction with a ﬁnal protein concentration of
2 mg/mL.
In the current study the primary interest was only Phase I
metabolism and therefore NADPH (phase I oxidation) was the only
exogenous cofactor added, both in the S9 and microsome study.
Table 1
Information on test compounds.
Compound MW Supplier CAS no.
Prochloraz 376.67 Dr.Ehrendorfer GmBH, Augsburg
Germany
67747-09-5
Miconazole 479.14 Sigma-Aldrich (St. Louis, MO, USA) 22832-87-7
Ketoconazole 531.4 Sigma-Aldrich (St. Louis, MO, USA) 65277-42-1
Tebuconazole 307.8 Sigma-Aldrich/(Riedel-de Haën) 107534-96-3
Epoxiconazole 329.76 Dr.Ehrendorfer GmBH, Augsburg
Germany
106325-08-8
Ethyl paraben 166.18 Sigma-Aldrich (St. Louis, MO, USA) 120-47-8
Butyl paraben 194.23 Sigma-Aldrich (St. Louis, MO, USA) 94-26-8
Methyl paraben 152.15 Sigma-Aldrich (St. Louis, MO, USA) 99-76-3
Dimethyl phthalate
(DMP)
194.19 Sigma-Aldrich (St. Louis, MO, USA) 131-11-3
Diethyl phthalate
(DEP)
222.24 Sigma-Aldrich (St. Louis, MO, USA) 84-66-2
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The endogenous metabolic capacity of the GH3 cells
For the evaluation of the endogenous metabolic capacity of the
GH3 cells all 10 compounds were tested in triplicates at a single
concentration of 30 μMusing the standard assay protocol as described
in (Taxvig et al., 2008). At the end of the assay time period (4 days)
the exposure of the GH3 cells and potential further metabolism of the
test compounds was stopped by adding 3× volume of ice-cold
methanol in relation to the cell suspension volume (e.g. 300 μL
methanol to 100 μL cell suspension) to all the samples.
The samples were transferred to test tubes and placed in a−20 °C
freezer for 1 h, before the samples were centrifuged at 16,000×g, 4 °C
and the supernatants were transferred to new tubes and stored at
−20 °C until they were analysed on the HPLC.
LC–MS/MS analysis
The LC–MS/MS analyses were conducted on an 1100 series LC
coupled to a MSD ion trap SL mass spectrometer (Agilent Technologies,
Palo Alto, CA, USA) using positive and negative electrospray ionisation
depending on the analysed compounds. A sample volume of 0.5 μL was
injected onto a Gemini RP C18 column (3 μm, 150×2.0 mm,
Phenomenex, Torrance, CA, USA). Analytes were determined using a
gradient of water containing 0.01% formic acid (solvent A) and
acetonitrile (solvent B): 0 min: 5% B, 1.0 min: 5% B, 2.0 min: 60% B,
8.0 min: 100% B, 15.5 min: 100% B and 16.0 min: 5% B. The ﬂow rate was
constant at 0.2 ml/min and column was 50 °C. The mass spectrum was
scanned from 100m/z to 1000 m/z (a mass spectrum is intensity vs.m/z
(mass-to-charge ratio)). Analytes were semi quantiﬁed using external
standard calibration. Semi quantiﬁcation was based on the total sum of
the dominant ions for each analyte. Ketoconazole (positive ionisation),
extracted ions: m/z 531; 532; 533; 266; 267; Miconazole (positive
ionisation), extracted ions: m/z 415; 417; 419; Epoxyconazole (positive
ionisation), extracted ions: m/z 330; 331; 332; Tebuconazole (positive
ionisation), extracted ions: m/z 308; 309; 310; Prochloraz (positive
ionisation), extracted ions: m/z 376; 378; 380; 308; 310; Dimethyl
phthalate (positive ionisation), extracted ions: m/z 163; 195; 217; 411;
Diethyl phthalate (positive ionisation), extracted ions: m/z 149; 177;
223; 245; 467;Methyl paraben (negative ionisation), extracted ions:m/z
151; Ethyl paraben (negative ionisation), extracted ions: m/z 165; Butyl
paraben (negative ionisation), extracted ions:m/z 193.
The T-screen assay
The rat pituitary cell line GH3 obtained from American Type
Culture Collection, ATCC, were cultured and the assay carried out as
described in (Taxvig et al., 2008).
All 10 mother compounds were tested in triplicate (0, 10, 375,
1000, 3000, 10,000 and 30,000 nM) and were tested both in the
absence or presence of 0.1 nM T3 to test for agonistic and antagonistic
potency. A T3 concentrations response curve from 0 to 10 nM was
included in each assay (Fig. 1). The human S9 metabolic extracts from
the 3 parabens and the 2 phthalates were also tested for effect in the
T-screen assay. The extractswere tested in ﬁve dilutions (dilution 1/16
to 1, with dilution 1/16 being the extract sample that was the most
diluted). As for the mother compounds the extracts were tested both
alone and in combination with 0.1 nM T3.
Statistical analyses
All data showing normal distribution and homogeneity of variance
were analysed by one-way analyses of variance (ANOVA) and, if
signiﬁcant, followed by the post hoc test, Dunnett's test. Signiﬁcance
was judged at pb0.05.
The HPLC data was evaluated for statistical signiﬁcance using a
two-tailed T-test (pb0.05).
Results
In vitro metabolizing systems
Human liver S9 and rat microsomes. The LC–MS analysis of the S9
extracts for the azole fungicides showed no indication of any
metabolic transformation during the incubation with the human
liver S9 mix (Table 2). The parabens and phthalates on the other hand
had almost been completely metabolized. The recovery of the parent
compounds from the S9 extracts were less than 1% for both parabens
and phthalates (Table 2).
Fig. 1. Effect of T3 the on proliferation of GH3 cells. Solvent control (0.1% DMSO) was set
to 0%. Data represent mean±SD for three independent experiments.
Table 2
Metabolism of the 10 selected test compounds by use of human S9-fraction.
Recovery of parent compound (%) Signiﬁcance (p-value)
Ketoconazol 96% 0.68
Miconazol 97% 0.38
Epoxiconazol 110% 0.47
Tebuconazol 96% 0.66
Prochloraz 94% 0.26
Dimethyl phthalate ~0% – a
Diethyl phthalate ~0% – a
Methylparaben ~0% – a
Ethylparaben ~0% – a
Butylparaben ~0% – a
Recovery of the parent compounds (%) after incubation with human S9 according to the
protocol described in the Material and methods section.
a Indicates that the P-value could not be calculated because the amount of remaining
parent compound was below the detection limit. Statistically signiﬁcant difference
between the amounts of parent compound in the samples before and after incubation
with S9 was tested by two-tailed T-test (pb0.05).
Table 3
Metabolism of the 10 selected test compounds treatment with rat microsomes.
Recovery of parent compound (%) Signiﬁcance (p-value)
Ketoconazol 53% b0.01⁎
Miconazol 85% 0.02⁎
Epoxiconazol 95% 0.06
Tebuconazol 86% b0.01⁎
Prochloraz 86% 0.02⁎
Dimethyl phthalate b1% – a
Diethyl phthalate b1% – a
Methylparaben b1% – a
Ethylparaben b1% – a
Butylparaben b1% – a
Recovery of the parent compounds (%) after incubation with PCB-induced rat
microsomes as described in the Material and methods section.
⁎ Statistically signiﬁcant difference between the amounts of parent compound in the
samples before and after incubation with rat microsomes using a two-tailed T-test
(pb0.05).
a The compound was below the detection limit.
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When using the PCB-induced rat microsomes the results for the
parabens and phthalates was the same as seen with the human S9
mix. An extensive metabolic transformation of the parabens and the
phthalates was observed, with a recovery rate of the parent
compounds of less that 1% (Table 3). However, in contrast to the
human S9 mix, the rat microsomes were able to metabolize the tested
amount of azole fungicides to some extent. A statistically signiﬁcant
difference between the amount of parent compound before and after
treatment with the rat microsomes was seen for four out of the ﬁve
azole fungicides (Table 3).
Effects in the T-screen assay
Parent compounds. The effect on the proliferation of GH3 cells of
the ten selected test compounds is illustrated in Figs. 2 and 3. For all
ﬁve azole fungicides, except epoxiconazole, a signiﬁcant decrease in
the GH3 cell proliferation was observed at the highest concentration
(30,000 nM), both when tested alone and in combination with T3
(Figs. 2A and B). This effect could be due to a cytotoxic effect, as others
have demonstrated cytotoxicity at these concentrations (at and above
25,000 nM), for some of the same chemicals (Ghisari and Bonefeld-
Jorgensen, 2005).
For miconazole a signiﬁcant decrease in the T3-induced cell
growth was observed with the second highest concentration
(10,000 nM) (Fig. 2A). Furthermore, ketoconazole alone showed a
decreasing effect on the cell proliferation at 6000 nM and above
(Fig. 2B).
The three parabens, butyl paraben, ethyl paraben and methyl
paraben, all showed TR agonistic effect, with butyl paraben being the
most potent of the three (butyl parabenNethyl parabenNmethyl
Fig. 2. Effects of the 5 azole fungicides: prochloraz, ketoconazole, miconazole, tebuconazole and epoxiconazole in the T-screen assay. The GH3 cells were treated with different
concentrations of the 5 compounds A) in the presence of 0.1 nM T3 or B) alone. Data represent mean±SD. The concentrations listed on the right are in nM. *Statistically signiﬁcantly
different from control (Pb0.05).
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paraben) showing signiﬁcant effect from 3 μM and above (Fig. 4B).
None of the tested parabens had any TR antagonistic effect in vitro
(Fig. 4A).
For the two tested phthalates, DMP and DEP, no effect was seen
neither alone nor in combination with T3 (Figs. 3A and B).
Metabolic extracts from the human liver S9 assay. The extracts from
the 3 parabens and the 2 phthalates after incubationwith the human S9
were tested for effect in the T-screen assay. The extracts from the 5 azole
fungicides were not tested as these compounds had shown very low
metabolic transformation after treatment with the human liver S9 mix
(Table 2).
The metabolic extract from butyl paraben showed a signiﬁcant
agonistic effect at the three lowest dilutions of the extract: 1/16, 1/8 and
1/14 (Fig. 4). Themetabolic extract frommethyl paraben also showed a
signiﬁcant agonistic but only at the second lowest dilution (1/8 diluted).
As seen for the parent compounds, none of the paraben extracts had any
antagonistic effect on the TR (Fig. 4).
For the S9-extracts from the 2 phthalates DMP and DEP a
statistically signiﬁcant reduction of the T3 induced cell proliferation
was observed for the DMP extract at the three highest dilutions
(Fig. 4).
The endogenous metabolic capacity of the GH3 cells
Table 4 lists the results from the analysis of the samples after the
parent compounds have been incubated the GH3 cells according to
the protocol for testing of compounds in the T-screen assay.
A statistically signiﬁcant difference between the amount of parent
compound before and after incubation with the GH3 cells had taken
place was found for the two phthalates, suggesting some metabolic
capability of the GH3 cells in regard to DMP and DEP.
Fig. 3. Effects of the 3 parabens and 2 phthalates: methyl-, ethyl- and butyl paraben, DMP and DEP in the T-screen assay: The GH3 cells were treated with different concentrations of
the compounds A) in the presence of 0.1 nM T3 or B) alone. Data represent mean±SD. The concentrations listed on the right are in nM. *Statistically signiﬁcantly different from
control (Pb0.05).
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Discussion
In vitromethods are a valuable and important tool for screening of
many compounds for potential endocrine disrupting effects. However,
when working with in vitro systems one is working with isolated
systems not whole organisms. Therefore, when looking and
evaluating the effects or results obtained from the different test
systems, it is important to know how a particular compound is
metabolized both in vivo (in the animal) and in the different in in vitro
systems (cell models). In that regard it is important to have
information concerning the endogenous metabolic capacity of the
different cells used in the many different in vitro assays now available
for the testing of a compounds endocrine disrupting potential. A focus
point of the current study was therefore to investigate the
endogenous metabolic capacity of the cells used in the applied in
vitro assay, which in the current study was the T-screen assay. For the
10 selected test compounds representing 3 different classes of
compounds: azole fungicides, parabens and phthalates, we found a
signiﬁcant difference between the amount of parent compound
before and after incubation with the GH3 cells for the two phthalates.
This could suggest that the GH3 cells have some metabolic capability
in regard to the two tested phthalates, DMP and DEP. In general, such
information concerning the metabolic fate of a compound in a given
test system, is important when evaluating the results. In the current
study we did not ﬁnd a marked difference in the effects observed
for the parent compounds and the effects of the tested metabolic
extracts.
One other objective of the current study was to look at different in
vitro systems for biotransformation of known endocrine disrupting
chemicals before testing for their effects in in vitro assays. Two in vitro
metabolizing systems were tested in the current study. Human liver
S9 mix and PCB-induced hepatic rat microsomes. Both test systems
gave an almost complete metabolic transformation of the tested
parabens and phthalates, with a recovery rate of the parent
compounds of less than 1%.
A difference was found between the human S9 and rat microsome
assay systems. When using the PCB-induced rat microsomes a
statistically signiﬁcant difference between the amount of parent
compound before and after treatment with the microsomes was seen
for four out of the ﬁve azole fungicides tested. When using the human
liver S9 we were not able to detect any signiﬁcant metabolic
transformation of the azole fungicides. This variation could be due
to differences in metabolism between humans and rats or it could be
due to a general higher metabolic activity of the rat microsomes
compared to the human S9 fraction. It is well known that there are
many differences in the metabolic capacity between species and also
differences within the same species associated with age, gender,
nutrition, genetic predisposition, environmental factors and others.
The basis for choosing human liver S9 was initially that we wanted to
compare the results from the human liver S9 assay with results from
an assay using a rat based in vitro metabolizing systems.
In regards to risk assessment for endocrine disrupting effects and
human exposure it would seem most relevant to use metabolizing
systems based on materials from humans. However, using materials
coming from animals compared to humans would most likely be
easier and cheaper, particularly because getting enough amounts of
research material from animals would be less of a challenge.
Fig. 4. Effects of the S9 extracts from methyl-, ethyl- and butyl paraben, and from DMP and DEP in the T-screen assay. GH3 cells treated with different dilutions of the extracts A) in
the presence of 0.1 nM T3 or B) alone. Data represent mean±SD. *Statistically signiﬁcantly different from the solvent control (Pb0.05).
Table 4
The endogenous metabolic capacity of the GH3 cells.
Recovery of parent compound (%) Signiﬁcance (p-value)
Ketoconazol 85% 0.13
Miconazol 83% 0.11
Epoxiconazol 96% 0.63
Tebuconazol 105% 0.63
Prochloraz 90% 0.12
Dimethyl phthalate 64% b0.01⁎
Diethyl phthalate 45% b0.01⁎
Methylparaben 100% 0.97
Ethylparaben 95% 0.32
Butylparaben 96% 0.71
Recovery of the parent compounds (%) after the compounds had been incubation with
the GH3 cells according to the protocol for the T-screen assay as described in the
Material and Methods section.
⁎ Statistically signiﬁcant difference between the amounts of parent compound in the
samples before and after T-screen assay termination was tested by two-tailed T-test
(pb0.05).
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Therefore, it is relevant to get as much data as possible in order to
make valid comparisons and extrapolations between results from
different species.
Another reason for the difference observed between the human S9
and rat microsome metabolizing systems could be due to different
bindingof test compounds toproteins in the enzyme fractions. The azole
fungicides are themost apolar of the 10 test compounds and theymight
bind to proteins or lipids making them less assessable for the
metabolizing enzymes. Several EDs are known to bind strongly to
serumproteins, andwhen this occurs in vivo, it affects the internal target
tissue concentrations of the chemical involved (Safe et al., 1997). Such
binding can occurwith components of themetabolizing systems like S9
or components in culture media such as proteins in serum added to the
media thereby resulting in both variable in vitro data, but also in
differences in the results obtained in in vivo and in vitro assays.
It was not an aim of the current study to get any quantitative
information on the metabolic fate of the selected test compounds as
we were not going to identify the metabolites from the different
compounds. We were interested in getting qualitative data, to see if
the test compounds could be metabolized by the different in vitro
metabolizing systems tested and to get information on the metabolic
capability of the cells in the selected in vitro assay. However, additional
studies focusing on determining the metabolic fate of known
endocrine disrupters in more detail and identifying metabolites
would certainly be relevant.
Based on the results and data from the current study our
conclusion is that the GH3 cells show some metabolic capability in
relation to the two tested phthalates DMP and DEP but none towards
the tested azole fungicides and phthalates. Furthermore, an in vitro
metabolizing system using liver human S9 or hepatic rat microsomes
could be a convenient method for the incorporation of metabolic and
toxicokinetic aspects into in vitro tests for endocrine disrupters.
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Abstract 
Many studied phytoestrogens (PEs) have been reported to exhibit anti-adipogenic effects in 
adipocytes and anti-proliferative and pro-apoptotic activities in several cell types. The current study 
examines different mixtures of twelve food relevant PEs, hereunder both isoflavones, lignans and 
coumestrol, for effects on adipogenesis in the 3T3-L1 preadipocyte cell line as well as their effect 
on PPAR α and γ in a transactivation assay. Overall the results shoved that the different PE 
mixtures had more effect on PPARγ activation than on PPARα. Furthermore, the tested single PEs 
as well as the nutrition relevant mixtures of PEs had a decreasing effect on lipid accumulation in 
vitro, which suggests that PEs can affect pathways known to play a role in the development of 
obesity. However, based on the results of the current study as well as the fact, that the role of 
different players in adipogenesis and lipolysis is not fully understood, the influence of PEs on 
adipogenesis, and pathways involved in development of obesity, remains unclear. Nevertheless, the 
current study adds to an increasing understanding of what effects exposure to different endocrine 
disrupting chemicals can exert on the different pathways playing a role in the development obesity.  
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1.     Introduction 
It is now well documented that numerous environmental chemicals can interfere with complex 
endocrine signalling pathways and cause adverse effects (Diamanti-Kandarakis et al., 2009). The 
centre of attention for endocrine disrupting chemicals (EDCs) has been broadened by the 
knowledge that multiple organ systems can be affected by EDCs. One of the new emerging  modes 
of action for EDCs is that exposure to EDCs may play a role in obesity. Different reports have 
played a part in starting the hypothesis that there could be a link between environmental chemical 
exposure and the development of obesity. Some of the work supporting this hypothesis is studies 
describing excess weight gain in animals treated developmentally with certain EDCs, including 
diethylstilbestrol (DES) and bisphenol A (BPA) (Howdeshell et al., 1999; Newbold et al., 2005; 
Rubin and Soto, 2009) as well as data from epidemiologic studies showing a possible association 
between serum dioxin levels and the onset and incidence rate of diabetes (Longnecker and 
Michalek, 2000). 
Additionally, in one of our own studies, we found that diisobutyl phthalate (DiBP), butylparaben, 
and rosiglitazone reduced plasma leptin and/or insulin levels in 21-day old male and female fetuses 
after exposure of pregnant rats from gestation day (GD) 7–21 (Boberg et al., 2008). 
The purpose of the current study was to evaluate 12 different phytoestrogens (PEs), naturally 
occurring in Western/Scandinavian food. We previously investigated the endocrine disrupting 
abilities of these PEs on different endpoints such as steroidogenesis as well as estrogen and 
androgen activity, and found different effects including estrogen activity in MFC-7 cells, as well as 
increased estradiol production in the H295R steroidogenesis assay (Taxvig et al., 2010). Here we 
examined whether any of these naturally occurring PEs could affect the ability of preadipocyte 3T3-
L1 cells to differentiate into adipocytes and the subsequent accumulation of lipid droplets, and 
 3
studied how  the PEs affected  transactivation of peroxisome proliferator-activated receptors 
(PPARs).  
The need to develop new effective strategies in controlling obesity has become more acute because 
obesity leads to a wide range of negative impacts on health. This has lead to progress in 
understanding the process of adipocyte differentiation. Adipose tissue growth involves formation of 
new adipocytes from precursor cells, further leading to an increase in adipocyte size. The transition 
from undifferentiated fibroblast-like preadipocytes into mature adipocytes constitutes the adipocyte 
life cycle, and a better understanding of how size and number of adipocytes is regulated may be 
required to improve understanding and treatment of obesity (Rayalam et al., 2008). Different in 
vitro systems exist for studying adipocyte differentiation. One of the most frequently employed cell 
lines is the 3T3-L1 cell line. The 3T3-L1 is a mouse embryonic fibroblast pre-adipocyte cell line, 
and the 3T3-L1 differentiation assay is a well established in vitro model of adipocytes to study 
signaling pathways involved in adipocyte differentiation, as well as pathways playing a role obesity 
or obesity related  diseases. The preadipocyte 3T3-L1 cells have a fibroblast-like morphology 
during the growth phase. However, under appropriate conditions, the cells differentiate into an 
adipocyte-like phenotype, where the preadipocyte converts to a spherical shape, accumulates lipid 
droplets, and progressively acquires the morphological and biochemical characteristics of a mature 
white adipocyte (Gregoire et al., 1998). 
Adipogenesis and the many different mechanisms involved in the regulation of adipocyte 
differentiation is complex. However, one of the transcription factors shown to play a key role in 
adipocyte differentiation is the PPAR family. Generally the PPARs are a group of nuclear receptor 
proteins that function as transcription factors regulating the expression of genes that play essential 
roles in cellular differentiation, development, and metabolism. PPARγ is primarily expressed in 
adipose tissue, and promotes adipocyte differentiation and activates transcription of genes involved 
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in lipid storage and control of insulin sensitivity (Auwerx, 1999; Ferre, 2004; Shen et al., 2006; 
Tontonoz et al., 1994). PPARα is predominantly expressed in tissues with high rates of 
mitochondrial and peroxisomal fatty acid catabolism, such as liver, brown adipose tissue, heart, 
skeletal muscle, kidney, and intestinal mucosa. PPARα  ligands have been shown to be 
hypolipidemic, to improve insulin sensitivity and to reduce adiposity, through a direct regulatory 
action on lipid metabolism (Guerre-Millo et al., 2000; Yoon, 2009), and different studies have also 
shown that PPARα could have a role in adipocyte differentiation (Brun et al., 1996; Yu et al., 
1995). Therefore, a second interest point for the current study was to test the different mixtures of 
the 12 PEs for their effect on PPAR α and γ, to see if they had any ability activate PPAR α and/or γ 
in a transactivation assay.  
The selection of PEs for the current study was based on a Scandinavian epidemiological study, 
estimating the intake of a number of PEs in the Swedish population (Hedelin et al., 2006). The 
proportions of the single PEs in the mixtures were based on the amount and number of the different 
classes (e.g. isoflavonoids lignans and coumestans) of PEs naturally found in Scandinavian food 
(Hedelin et al., 2006). Therefore, the design of the mixtures was based on representing PEs 
naturally occurring in Western food, but the proportions of the compounds in the mixtures were not 
representative of the concentrations found in the diet, and the design of the mixtures was not based 
on effective doses.  
Five different mixtures were tested: Mix 1 composed of the isoflavonoid metabolites genistein, 
daidzein and equol, Mix 2 composed of the two isoflavonoids formononetin and biochanin A; Mix 
3 composed of the lignan metabolites enterolactone and enterodiol; Mix 4 containing the four 
lignans secoisolariciresinol, matairesinol, lariciresinol and pinoresinol, and finally a total mixture 
including all 12 selected PEs. An overview of the different PEs and mixtures is presented in Figure 
1. Additionally the single compound coumestrol was also tested in the PPAR transactivation assay, 
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and in the 3T3-L1 assay, coumestrol, genistein, and daidzein were also tested as single compounds 
as well tributyltin (TBT), which was included because of its reported positive effects in the 3T3-L1 
differentiation assay (Collins, 2005; Grun et al., 2006; Inadera and Shimomura, 2005).  
The experiments involving the PPARγ antagonist GW9662, was included to examine if any 
possible effects on lipid accumulation in the 3T3-L1 cells could be influenced by the presence of a 
PPARγ antagonist. Rosigiltazone is a known PPARγ agonist and was also run in the 3T3-L1 assays 
as a reference compound, because it is known to induce adipocyte differentiation.    
 
2.    Methods and Materials 
2.1    Test compounds  
Genistein (CAS 446-72-0), daidzein (CAS 486-66-8), equol (CAS 66036-38-2), formononetin 
(CAS 485-72-3), biochanin A (CAS 491-80-5), enterolactone (CAS 78473-71-9), enterodiol (CAS 
80226-00-2), secoisolarici resinol (CAS 29288-59-8), and coumestrol (CAS 479-13-0) were all 
purchased from Sigma-Aldrich (Milwaukee, WI, USA). Matairesinol (CAS 580-72-3), lariciresinol 
(CAS 27003-73-2), and pinoresinol (CAS 487-36-5) were purchased from Arbo-Nova, Finland. 
Rosiglitazone (BRL 49653) cas no. 122320-73-4 was from Cayman Chemicals (cat no. 71740). WY 
14,643, cas no. 50892-23-4, was from Calbiochem (cat no. 681725). Phosphate Buffered Saline 
(PBS Tablets; Oxoid, Cat no BR1400G)Biotin (CAS 58-85-5), Calcium pantothenate (CAS 137-08-
06), Dexamethasone (CAS 50-02-2), Isobutylmethylxanthine (IBMX) (CAS 28822-58-4), Insulin 
(CAS 11070-73-8), Tributyltin chloride (TBT) (CAS 1461-22-9), Oil Red O (CAS 1320-06-5), 
Sodium dihydrogen phosphate, NaH2PO4 (CAS 7558-80-7), Sodium hydrogenphosphate, Na2HPO4 
(CAS 7558-79-4), Calcium chloride (CAS 10043-52-4), Magnesium chloride hexahydrate, 
MgCl26H2O (CAS 7791-18-6), 2-Propanol (CAS 67-63-0), Formaldehyde (CAS 50-00-0), and 
GW9662 (CAS 22978-25-2) all from Sigma Aldrich (Milwaukee, WI, USA). The test compounds 
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were dissolved in dimethyl sulfoxid (DMSO, CAS 67-68-5) also from Sigma Aldrich. The twelve 
phytoestrogens used, their data, estimated daily intake, and their proportions in the different 
mixtures are listed in Table 1.  
 
2.2    Adipocyte differentiation assays 
3T3-L1 cells (ATCC number: CL-173) were cultured in a humid atmosphere at 37˚C and 95% 
air/5% CO2 in DMEM (Gibco-Invitrogen, Paisley, UK) supplemented with 1% 
Antibiotic/Antimycotic (PSF), 10% (vol/vol) calf serum (FBS) and 1 mM sodium pyruvate 
(Invitrogen). When starting the assay cells were switched from growing in 10 cm culture dished 
(Falkon) to 6 well culture plates (Falcon) and the media were also switched to DMEM with 10% 
FBS. The cells were cultured in the 6-well plates to confluence and exposed to the induction 
cocktail: 1 μg/ml insulin, 600 nM dexamethasone, 500 μM isobutylmethylxanthine (IBMX) (MDI 
cocktail) as well as 33 μM biotin and 17 μM calcium pantothenate. In the experiments where 
rosiglitazone was giving during the during the induction period the cells were exposed to 0.5 μM 
rosiglitazone in addition to the MDI induction cocktail. After 48 hr in the medium with the added 
induction substances the medium was replaced with differentiation medium containing 33 μM 
biotin, 17 μM calcium pantothenate and 1 ug/ml insulin as well as the respective test compounds or 
test mixtures. The phytoestrogens and mixtures were tested duplicates in three concentrations: 25, 
50 and 75 μM. Included as a background control on each test plate was a well with 0.1% DMSO 
instead of test compound. The differentiation medium with test compounds were changed every 2 
days until day 6 where the plates were stained with Oil red O. For the assays including the PPARγ 
antagonist GW9662 a final concentration of 1 μM GW9662 was added to each well every 6 hour 
for the 6 days the cells were exposed to test compound.  
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For the Oil Red O staining each well was washed with 2 mL PBS and then fixed with 10% 
formaldehyde (0.4 g sodium phosphate; 0.65 g disodium hydrogen phosphate dissolved in 10 mL 
formaldehyde and 90 mL distilled water) for 15-20 min. After the formaldehyde treatment, the 
wells were washed with PBS and then stained for 15 min with 2 mL/well filtered Oil Red O 
solution (0.36 g Oil Red O added to 100 mL 60% isopropanol) After 15 min. the staining solution 
was removed and the wells were rinsed once with 2 mL/well 60% isopropanol for 30 sec. followed 
by washing 3 times with 2 mL/well PBS. 
After the last wash 2 ml PBS was left in each well to prevent it from drying out before 
photographing was completed.  The Oil Red O stained wells were inspected under a microscope and 
five to twelve random field images from each well were photographed under phase contrast. These 
images were analyzed in ImageJ, where they were converted into high-contrast black and white 
images to visualize the lipid droplets and score them as percentage area per field using the ImageJ 
software.  
All compounds and mixtures were run in three independent experiments and data are shown as the 
mean ± SD from one representative experiment. 
 
2.3    PPARα and PPARγ  transactivation assay 
The NIH-3T3 cells (ATCC number: CL-1658) were maintained in phenol red-free DMEM/F12 
(Gibco, Paisley, UK) with 10 % charcoal-filtered calf serum (Biological Industries Ltd, Israel) and 
1 % Antibiotic/Antimycotic (PSF) (PAA Laboratories GmbH, Austria) at 37˚C in 5 % CO2/air. To 
examine the effect of the test compounds on ligand-induced PPAR transactivation, cells were 
transiently transfected with a plasmid expressing the ligand binding domain of mouse PPARα or 
PPARγ coupled to Gal4 and a plasmid containing an UAS linked luciferase reporter construct, 
4xUAS-TK-luc. Used as positive controls was the specific PPARα agonist WY14.643 or the 
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PPAR -selective agonist rosiglitazone. On day 1 of the experiment, cells were counted and 
transferred to 96-well cell culture plates (PerkinElmer, Massachusetts, USA) at a density of 7000 
cells per well. After 20 hours, cells were transfected with the luciferase reporter plasmid 4xUAS-
TK and either gal4-DBD_mPPARαLBD or gal4-DBD_mPPARγLBD expression vectors using 
FuGene® (Roche. Mannheim, Germany) as a transfection reagent. One hour before transfection 
medium was changed: FuGene and serum-free medium was mixed using 4.5 μL FuGene in 10 μL 
medium per well and added to a mixture of the plasmids with a total cDNA content of 75 ng per 
well. Plasmids were mixed in a 1:2 ratio for gal4-DBD_mPPARαLBD and 4xUAS-TK-luc and a 
ratio of 1:1 for gal4-DBD_mPPARγLBD and 4xUAS-TK-luc. These ratios and cDNA 
concentrations had been selected as the optimal for each receptor giving the highest activation level 
compared to other plasmid ratios and DNA contents. The FuGene-cDNA mixture was incubated for 
30 minutes before being added to the cells. 5 hours after transfection, media was removed and new 
media containing test compounds was added and left for incubation at 37˚C in 5 % CO2/air over 
night (22 h). All test compounds and mixtures were tested in triplicate in concentrations from 0 to 
100 μM (0; 3.13; 6.25; 12.5; 25; 50, and 100 μM), with a maximal concentration of DMSO below 
0.3 % which had previously been found not to be cytotoxic. 
Cytotoxicity was evaluated in each well by incubating the cells with resazurin solution (CAS 
62758-13-8, Sigma Aldrich; Milwaukee, WI, USA) for 2 h followed by measuring fluorescence 
(excitation wavelength 560 nm/emission. 590 nm) on a Wallac Victor 1420 multilabel counter 
(PerkinElmer Life Sciences). 
Each test compound and mixture was run in three to five independent experiments and data are 
presented as the mean ± SD from three comparable independent experiments. 
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2.4    Statistical analyses  
All data were tested for homogeneity of variance and normal distribution. Data were analyzed by   
one-way analyses of variance (ANOVA) and, if significant, followed by Dunnett’s post hoc test. 
Significance was judged at p < 0.05. 
 
3.    Results 
3.1   Effects of naturally occurring PEs on adipogenesis in 3T3-L1 cells  
The 3T3-L1 preadipocyte cell line was used as an in vitro model for studying adipogenesis and 
specifically to look at the effect of nutritionally relevant concentrations and mixtures of PEs on the 
differentiation of 3T3-L1 preadipocytes, a process in which PPARγ is thought to play a major role. 
The 3T3-L1 cells were grown to confluence and induced to differentiate into adipocytes by 
treatment with a mixture containing isobutylmethylxanthine (IBMX), dexamethasone, and insulin 
(MDI cocktail). After 2 days in the induction medium the medium was changed to adipogenesis 
differentiation medium containing biotin, calcium pantothenate and insulin as well as the respective 
test compounds or test mixtures. The effects of the PEs on adipocyte differentiation were measured 
by scoring the amount of lipid droplets formed in the 3T3-L1 adipocytes using Oil Red O staining 
(Figure 5). Along with the different PEs and mixtures, TBT was also included in the assays, as TBT 
previously has been shown to be a potent inducer of lipid accumulation in these 3T3-L1 adipocytes 
(Grun et al., 2006; Inadera and Shimomura, 2005). As presented in Figure 2A, all three selected 
single PEs (genistein, daidzein, and coumestrol) significantly decreased lipid accumulation, with 
genistein being the post potent inhibitor showing effect at all tested concentrations (25, 50 and 75 
μM). Coumestrol showed effect at the two highest concentrations 50 and 75 μM and daidzein had 
significant effect only at 75 μM (Fig 2A).  
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For the five different mixtures tested mix 1 (genistein, daidzein and equol), mix 2 (formononetin 
and biochanin A) and mix 3 (enterolactone and enterodiol) also showed significant decrease in lipid 
accumulation (Fig 2B). However, for mix 2 the effect was only statistically significant at 50 μM, 
the second highest concentration but the effect at 75 μM were comparable to the effect observed at 
50 μM (Fig 2B). Neither mix 4 (secoisolariciresinol, matairesinol, lariciresinol and pinoresinol) nor 
the total-mix had any significant effect on the lipid accumulation in the 3T3-L1 adipocytes (Fig 
2B). 
Rosiglitazone is a known PPARγ agonist and the single compounds genistein, daidzein and 
coumestrol as well as mixture 1, 2 and 3 were also tested for the effect on rosiglitazone induced 
differentiation. Rosiglitazone alone showed a concentration dependent increase in lipid 
assumulation (Figure 3A). When the 3T3-L1 celle were induced to differentiate by standard MDI 
adipogenic treatment in the presence of 0,5 μM rosiglitazone (Rosi), all three single PEs as well as 
the tested PE-mixtures showed a significant ability to decrease the rosiglitazone induce lipid 
accumulation in the 3T3-L1 cells as seen in figure 3B (the results for mix 2 and mix 3 are not 
presented, but were comparable with the effects seen in figure 2B).   
In figure 5 are shown representative pictures of the Oil Red O staining from both the experiments 
using standard MDI induction and from the experiments with induction in the presence of 0.5 μM 
rosiglitazone.  
 
3.1.1 Effect of PEs  in combination with a PPARγ antagonist on 3T3-L1 differentiation   
PPARγ has been shown to play a key regulatory role in adipocyte differentiation (Hu et al., 1995; 
Tontonoz et al., 1994) and to be necessary for lipid accumulation in adipocytes in mice (Barak et 
al., 1999; Kubota et al., 1999; Rosen et al., 1999).  
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In the current study we found that treatment of the 3T3-L1 with TBT in combination with the 
PPARγ antagonist GW9662 did not significantly influence the effect of TBT on lipid accumulation 
in the 3T3-L1 adipocytes (Fig 4A). These results are in accordance with results from a previous 
study by Inadera and Shimomura (Inadera and Shimomura, 2005) where it was found that induction 
of aP2 (adipocyte protein 2) - a well known marker of adipocyte differentiation - by TBT was 
unaffected by co-treatment of TBT with the PPARγ antagonist GW9662, suggesting that the effect 
of TBT on 3T3-L1 differentiation is not PPARγ-dependent.  
In the present study genistein and the mixture containing all 12 PEs were also tested in combination 
with GW9662, to examine if any possible effect of genistein or the mixture on lipid accumulation 
could be influenced by the presence of a PPARγ antagonist. For genistein which alone significantly 
decreased lipid accumulation at all tested concentrations the co-treatment with GW resulted in an 
impairment or neutralization of the decreasing effect at 25 μM and 50 μM, giving only a significant 
decrease at 75 μM, the highest concentration tested (Fig. 4B), indicating that other players besides 
PPARγ are involved in 3T3-L1 differentiation. For the total-mix, which alone had shown no effect, 
the co-treatment with GW9662 had no effect (data not shown).  
 
3.2 Effect of PE-mixtures on the activation of PPARα and PPARγ 
Transactivation of PPARα and PPARγ was examined in a reporter gene assay by adding different 
concentrations of test compound or mixture to cells transiently transfected with expression plasmid 
for the ligand binding domain of either mouse PPARα or PPARγ coupled to Gal4 and a plasmid 
containing an UAS linked luciferase reporter construct (UAS-TK-luc).  
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PPARα 
None of the mixtures or coumestrol alone had any PPARα activating effect (Fig. 6A and Table2). 
Contrary, for Mix 3 (enterolactone and enterodiol) and mix 4 (secoisolariciresinol, matairesinol, 
lariciresinol and pinoresinol) a decrease in activation was observed in the PPARα (Fig. 6A).   
For coumestrol alone a significant decrease in activity was observed at 100 μM (Fig 6A), which  
could be due to a beginning cytotoxic effect even though cytotoxicity was only found for 
coumestrol at 50 μM and 100 μM in one out of five independent cytotox-experiments (data not 
shown). The response observed for the positive control the PPARα agonist WY14.643 was 382 % 
of the background control (data not shown).  
 
 PPARγ 
 
In the PPARγ assay, mix 1 (genistein, daidzein and equol), mix 2 (formononetin and biochanin A) 
and the total-mix showed some activating effect, with mix 2 being the most potent of the three 
shoving an activating effect at a concentration of 6.25 μM up to 50 μM, whit a maximum around 
200% of the background control (Fig. 6B and Table 2). For comparison the response observed with 
the positive control rosiglitazone was 8583% of the background control (data not shown) 
The highest concentration of 100 μM was found to be cytotoxic for mix 2. 
For coumestrol alone no effect was, seen (Fig 6B).  
 
   
 
4. Discussion 
 
There are only limited data on the possible role of EDCs in the development of obesity in humans.  
Several pregnancy cohort studies have examined chemicals in relation to childhood or adult BMI or 
height. In general, findings from these studies are inconsistent. Different studies on associations 
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between levels of dichlorodiphenyldichloroethylene (DDE) and PSB and endpoints such as BMI 
and growth outcomes have reported both positive associations as well as either negative or null 
associations (Blanck et al., 2002; Gladen et al., 2004; Gladen et al., 2000; Karmaus et al., 2009; 
Ribas-Fito et al., 2006; Verhulst et al., 2009). However, despite conflicting results from 
epidemiological studies, the hypothesis that there could be a link between exposure to endocrine 
disrupting chemicals and the development of obesity is being supported by more and more studies. 
The modes of action and the contribution of environmental factors to the development of both 
obesity and obesity related diseases is though, far from understood and the aim of the current study 
was to evaluate 12 different PEs, naturally occurring in Western/Scandinavian food, and previously 
shown to have different endocrine disrupting effects (Taxvig et al., 2010), for their effect on obesity 
parameters in vitro. Different mixtures but also a few single compounds were evaluated for 
potential effects on adipocyte differentiation and their ability to activate peroxisome proliferator 
activated receptor PPARα and PPARγ. The isoflavones, genistein and daidzein, have already been 
shown to have both PPARα and PPARγ agonistic effects (Ricketts et al., 2005; Shen et al., 2006) 
and some PEs including genistein have also previously been studied for their effect on adipogenesis 
(Cooke and Naaz, 2005; Liao et al., 2008; Park et al., 2008). In the present study genistein had a 
decreasing effect on lipid accumulation in the 3T3-L1 cells for all concentrations tested (25-75 
μM). This effect was seen both when differentiation induced using standard MDI treatment, but 
genistein also decreased rosiglitazone-induced adipocyte differentiation. The same effects were 
observed for coumestrol and daidzein, and in the experiments with the rosiglitazone-induced 
differentiation the effects on lipid accumulation observed for the three single PEs were comparable 
(Fig 3A). For mix 1 containing a combination of genistein, daidzein and equol a decrease in lipid 
accumulation was found as well, the effect being comparable to that of genistein, and in the 
rosiglitazone-induction experiments, the effect of Mix1 was comparable that seen for each of the 
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single compounds (Fig 3A). Genistein both alone but also in combination with the naturally 
occurring phytoalexin resveratrol and the flavonol quercetin has previously been shown to decrease 
lipid accumulation in 3T3-L1 cells with the decreasing effect being enhanced when the compounds 
were combined compared to the effect of the single compounds (Park et al., 2008; Rayalam et al., 
2007).  
The overall decreasing effect of mix 1 is in accordance with what others have reported for genistein 
(Harmon and Harp, 2001; Park et al., 2008; Rayalam et al., 2007), and also supported by a study on 
the effects of equol by Rachon et al.,(2007) (Rachon et al., 2007), which found that dietary equol 
decreased weight gain, intra-abdominal fat accumulation, and plasma leptin and triglyceride levels 
in ovariectomized rats. However, our results contradicts studies by (Cho et al., 2010) and (Relic et 
al., 2009) who found that daidzein and genistein enhanced adipogenesis, although for the Relic et 
al. study this was not shown in 3T3-L1 cells but in cultured synovial fibroblasts.     
In order to examine whether the effect of genistein was PPARγ dependent, genistein was tested in 
combination with the PPARγ antagonist GW9662. This showed that the effect of genistein on lipid 
accumulation was weakened but not totally blocked, suggesting that the effect genistein exerts on 
lipid accumulation in the 3T3-L1 is only partly dependent on PPARγ and/or that lipid accumulation 
in the 3T3-L1 is mediated or dependent on other players than PPARγ. One possibility is that the 
effect of genistein is mediated through the estrogen receptor (ER). This would  be in agreement 
with other studies showing a possible ERα mediated effect of genistein on adipose tissue (Cooke 
and Naaz, 2005) as well as the reported decreasing effect of estrogen on lipid accumulation in 3T3-
L1 adipocytes (Homma et al., 2000). Additionally, when TBT was tested in combination with the 
PPARγ antagonist GW9662, it did not affect the increase in lipid accumulation brought on by TBT. 
This is in agreement with the results of Inadera and Shimomura (Inadera and Shimomura, 2005), 
who found that combined treatment with TBT and GW9662 did not prevent the induction of the 
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well known marker of adipocyte differentiation aP2, suggesting that the effect of TBT on the 3T3-
L1 cells is PPARγ-independent, or at least that other players beside PPARγ are involved. The potent 
effects of organotins on adipogenesis have been found to be attributed to dual agonistic activity for 
PPARγ and RXR, although there is some debate on whether these effects on adipogenesis are 
primarily do to interactions with PPARγ or RXR (Hiromori et al., 2009; Inadera and Shimomura, 
2005; Kirchner et al., 2010; le Maire et al., 2009). Le Maire et al. have recently shown that the 
activation of the PPAR-RXR heterodimers by TBT is primarily through its interaction with RXR (le 
Maire et al., 2009). Our results with TBT however, are in contrast to the effects found by Kirchner 
et al. (2010), who were able to block the lipid accumulating effect of TBT in mouse adipose-derived 
stromal stem cells (mADSCs) by the addition of the potent PPARγ antagonist T0070907 (Kirchner 
et al., 2010). Whether this difference is due to a different involvement of PPARγ in lipid 
accumulation in the 3T3-L1 cells compared to the mADSCs is currently not known. 
Also mix 2 (formononetin and biochanin A) and mix 3 (enterolactone and enterodiol) significantly 
decreased lipid accumulation, though not in the same order of magnitude as observed with mix 1. 
Few studies have examined  the effect of formononetin, biochanin A, enterolactone and/or 
enterodiol on adipogenesis. One such study showed that biochanin A and formononetin stimulated 
lipid accumulation in 3T3-L1 cells at low concentrations (1- 5 μM for biochanin A and 3- 30 μM 
for formononetin, respectively)(Shen et al., 2006). However, the study by Shen et al, (2006) also 
found that genistein stimulated lipid accumulation at 15 μM, a result that is different from what we 
and others have found (Harmon and Harp, 2001; Park et al., 2008; Rayalam et al., 2007; Shen et al., 
2006). It is known from other types of studies with PEs that many of the PEs show a biphasic 
concentration-effect curve. One such example is the effect of PEs on the cell proliferation of MCF-7 
cells, where Le Bail et al.,(2000) and others have found that some of the PEs stimulated growth at 
lower concentrations but inhibited growth at higher concentrations (Le Bail et al., 2000; Taxvig et 
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al., 2010; Ying et al., 2005). As Shen et al., (2006)  have generally tested lower concentrations than 
applied in our and other studies, this may cause the observed differences in the effects found in the 
different studies (Shen et al., 2006). 
In regards to the effects of the PEs mixturets on PPAR activation, no significant PPARα activating 
effect was observed for any of the mixtures (Fig. 6A) On the contrary for mix 3 and mix 4 a 
significant decrease in PPARα activation was observed (Fig. 6A). In the assays testing for PPARγ 
activation the overall picture was an activating effect of mix 1, mix 2 and the total-mix, with mix 2 
being the most potent of the three. The PPARγ activation by mix 1 confirms the previously shown 
PPARγ activity of genistein and daidzein, the main components of mix 1, at concentrations 
comparable to those in the current study (Ricketts et al., 2005; Shen et al., 2006). The 
PPARγ activation by mix 2 points to PPARγ agonistic activities of formononectin and/or biochanin 
A, the two compounds found in mix 2, which have also previously been shown to activate 
PPARγ in concentrations from 1 to 90 μM or 100 μM (Shen et al., 2006).  
A parallel between the results found on lipid accumulation in the 3T3-L1 cells and the effects found 
on PPAR activation cannot be drawn as all the different mechanisms underlying the development of 
adipocytes and adipose tissue, are complex and far from understood. Studies have shown that not 
only PPARγ but also PPARα could have a role in adipocyte differentiation (Brun et al., 1996; Yu et 
al., 1995). PPARα is not expressed at significant levels in white fat, but it is expressed in brown fat 
(Beck et al., 1992; Issemann and Green, 1990). Data by Brun et al., (1996) indicate that while 
PPARα possesses some adipogenic potential, PPARγ is a more effective inducer of adipocyte 
differentiation (Brun et al., 1996). As can be seen from the results of the combination of TBT and 
GW9662, both ours and others (Inadera and Shimomura, 2005), even though PPARγ is thought to 
play a big role in 3T3-L1 adipocyte differentiation other pathways are involved as well. 
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Overall, based on the result of the current study, the different PE mixtures had more effect on 
PPARγ than PPARα. Our conclusion is that many PEs as well as dietary relevant mixtures of PEs 
have a decreasing effect on lipid accumulation in vitro. However, the role of different players in 
adipogenesis and lipolysis, including the different PPAR isoforms, as well as ER and RXR, is not 
yet understood. Therefore, based on the results of the current study the influence of PEs on 
adipogenisis in in vivo is unclear. To our knowledge little is known regarding the interaction 
between different PEs and RXR, and such information would be relevant to help with the 
interpretation of the observed effects of the PEs on adipocyte differentiation and lipid accumulation.   
Nevertheless, combined with future experiments the current result may add to our knowledge on 
what effects various EDCs can exert on different pathways playing a role in the development 
obesity.. 
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Figure legends 
 
Fig 1. - Overview of the different phytoestrogens and mixtures tested. 
The selected PEs consists of both mother compounds (biochanin A, formononetin, 
secoisolariciresinol, metairesinol, lariciresinol, pinoresinol, and coumestrol) and metabolites 
(genistein, daidzein, equol, enterodiol and enterolactone). The different mixtures and the total 
mixture are presented in black boxes, and the compounds, which were (also) tested alone, are 
represented in light gray boxes.  
 
Fig. 2 - Effect of the individual tested PEs and mixtures on lipid accumulation in 3T3-L1 
maturing preadipocytes. 
The 3T3-L1 preadipocytes were grown to confluence and induced to differentiate using standard 
MDI treatment as described in the material and method section. The control was cells supplemented 
with 0.1% DMSO instead of test compound. After exposing the cells to test compound for 6 days 
during the differentiation period the adipocytes were stained with Oil Red O, and the amount of 
lipid accumulation was analyzed by microscopic inspection and several phototropic images from 
each well were taken including five to twelve random fields images from each well photographed 
under phase contrast (magnification, x10). Images were analyzed in ImageJ and data are shown as 
the mean ± SD from one representative experiment out of three independent experiments. 
* Statistically significantly different from control. (P< 0.05). 
 
Fig. 3 - Effect of rosiglitazone and the PEs on rosiglitazone induced adipocyte differentiation. 
The 3T3-L1 preadipocytes were induced to differentiate by standard MDI treatment in the presence 
of 0.5 μM rosiglitazone (rosi). The 3T3-L1 cells were exposed to 1 μM and 5 μM rosi (A) or to 
coumestrol, daidzein, genistein or mix 1 (0 -75 μM). The control was cells supplemented with 0.1% 
DMSO instead of test compound. After exposing the cells to test compound for 6 days during the 
differentiation period the adipocytes were stained with Oil Red O, and the amount of lipid 
accumulation was analyzed by microscopic inspection and several phototropic images from each 
well were taken including five to twelve random fields images from each well photographed under 
phase contrast (magnification, x10). Images were analyzed in ImageJ and data are shown as the 
mean ± SD from one representative experiment out of two independent experiments. 
* Statistically significantly different from control. (P< 0.05). 
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 Fig. 4 –Effect of the PPARγ antagonist GW9662 on the effect of TBT and genistein. 
 The 3T3-L1 preadipocytes were treated with 10 nM and 100 nM TBT (A) or different 
concentrations (μM) of genistein (B) either alone or in the presence of 1μM GW9662 as described 
in the material and method section. The control was cells supplemented with 0.1% DMSO or 0.1% 
DMSO plus 1μM GW9662, respectively.  After 6 days exposure during the differentiation period 
the adipocytes were stained with Oil Red O and the amount of lipid accumulation was analyzed as 
previously described. Images were analyzed in ImageJ and data are shown as the mean ± SD from 
one representative experiment out of three independent experiments. 
Statistically significantly different from control. (P< 0.05). 
 
Fig.5 – Effect of genistein, rosiglitazone and TBT on 3T3-L1 differentiation 
The 3T3-L1 cells were cultured in the 6-well plates to confluence and exposed to standard MDI 
induction media, and then during differentiation they were exposed to 100 nM TBT, 5 μM 
rosiglitazone or 25 and 75 μM of genistein. In the lowest panel the 3T3-L1 cells were exposed to 
standard MDI induction media in the presence of 0.5 μM rosiglitazone (+ 0.5 μM Rosi), and then 
exposed to 25 or 75 μM genistein during differentiation. The control was cells supplemented with 
DMSO instead of test compound. The assay was ended by staining the cells with Oil Red O and 
photomicrographs were taken at 10x magnification.  
 
 
Fig. 6 – The effect of the PE mixtures and Coumestrol on PPAR α and γ transactivation .  
To examine the effect of the different mixtures and coumestrol on ligand-induced PPAR 
transactication, NIH-3T3 cells were transiently transfected with expression plasmid for the ligand 
binding domain of either mouse PPARα or mouse PPARγ coupled to Gal4 and a plasmid 
containing an UAS linked luciferase reporter gene (UAS-TK-luc). Results are shown as activity 
obtained relative to the activity is wells containing media only (control = 100%).  
Data represent mean ± SD of three independent experiments.   
C = cytotoxic. * Statistically significantly different from control. (P< 0.05). 
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 The table list the 12 phytoestrogens investigated in the current study with information on their molecular weight as well 
as their proportions in each of their mixtures. 
Table 1 – Information on test compounds – The phytoestrogens 
Compounds Mixture MW 
Purity 
(%) 
Daily intake* 
(μg/day) 
Proportion  
in mix 
Proportion  
in the total-mix 
Genistein 270,2 96 205 775 12385 
Daidzein 254,2 98 133 533 8520 
Equol 
 
1 
 242,2 99 1 1 16 
Formononetin 268,3 99 2 1 19 
Biochanin A 2 284,3 99 1 1 18 
Enterolactone 298,3 95 16 159 159 
Enterodiol 3 301,2 95 0.06 1 1 
Secoisolarici resinol 362,4 95 1871 252 81912 
Matairesinol 358,4 95 49 1 325 
Lariciresinol 360 95 621 6 1906 
Pinoresinol 
4 
358,4 95 268 3 908 
Coumestrol coumestan 267 95 0.1 1 5 
*  The daily intake is based on the amounts reported in the study by (Hedelin et al., 2006) 
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Table 2 – Overview of the effects found on PPAR activation and lipid accumulation 
Compounds 
PPARα transactivation PPARγ transactivation Effect on lipid accumulation 
Mix 1 - ↑ ↓ 
Mix 2 # - ↑ ↓ 
Mix 3 ↓ - ↓ 
Mix 4 ↓ - - 
Totalmix - ↑ - 
Coumestrol - - ↓ 
Genistein ND(↑*) ND (↑*) ↓ 
Daidzein ND (↑*) ND (↑*) ↓ 
- : no effect. 
ND: not determined 
# cytotoxic at the highest (100 μM) concentration tested.  
* Shown in Rickett et al., (2005) 
 
 
Total-Mix
(n=12)
Mix 1
Isoflavonoids
Metabolites
Mix 2
Isoflavonoids
Parent compounds 
Mix 3
Lignans
Metabolites 
Mix 4
Lignans
Parent compounds
Coumestans
Metabolite 
Genistein
Daidzein
Equol
Formononetin
Biochanin A
Enterolactone
Enterodiol
Secoisolariciresinol
Matairesinol
Lariciresinol
Pinoresinol
Coumestrol
Fig 1. - Overview of the different phytoestrogens and mixtures tested.
The selected PEs consists of both mother compounds (biochanin A, formononetin, secoisolariciresinol, 
metairesinol, lariciresinol, pinoresinol, and coumestrol) and metabolites (genistein, daidzein, equol, 
enterodiol and enterolactone). The different mixtures and the total mixture are presented in black boxes, 
and the compounds, which were (also) tested alone, are represented in light gray boxes. 
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Fig. 2 - Effect of the individual tested PEs and mixtures on lipid accumulation in 3T3-L1 maturing preadipocytes.
The 3T3-L1 preadipocytes were grown to confluence and induced to differentiate using standard MDI treatment as described 
in the material and method section. The control was cells supplemented with 0.1% DMSO instead of test compound. After 
exposing the cells to test compound for 6 days during the differentiation period the adipocytes were stained with Oil Red O, 
and the amount of lipid accumulation was analyzed by microscopic inspection and several phototropic images from each well 
were taken including five to twelve random fields images from each well photographed under phase contrast (magnification, 
x10). Images were analyzed in ImageJ and data are shown as the mean ± SD from one representative experiment out of three 
independent experiments. * Statistically significantly different from control. (P< 0.05).
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Fig. 3 - Effect of rosiglitazone and the PEs on rosiglitazone induced adipocyte differentiation.
The 3T3-L1 preadipocytes were induced to differentiate by standard MDI treatment in the presence of 0.5 mM 
rosiglitazone (rosi). The 3T3-L1 cells were exposed to 1 mM and 5 mM rosi (A) or to coumestrol, daidzein, genistein or 
mix 1 (0 -75 mM). The control was cells supplemented with 0.1% DMSO instead of test compound. After exposing the 
cells to test compound for 6 days during the differentiation period the adipocytes were stained with Oil Red O, and the 
amount of lipid accumulation was analyzed by microscopic inspection and several phototropic images from each well 
were taken including five to twelve random fields images from each well photographed under phase contrast 
(magnification, x10). Images were analyzed in ImageJ and data are shown as the mean ± SD from one representative 
experiment out of two independent experiments.  * Statistically significantly different from control. (P< 0.05).
Fig. 4 –Effect of the PPARγ
 
antagonist GW9662 on the effect of TBT and genistein.
The 3T3-L1 preadipocytes were treated with 10 nM and 100 nM TBT (A) or different concentrations (mM) of 
genistein (B) either alone or in the presence of 1mM GW9662 as described in the material and method section. 
The control was cells supplemented with 0.1% DMSO or 0.1% DMSO plus 1mM GW9662, respectively.  After 
6 days exposure during the differentiation period the adipocytes were stained with Oil Red O and the amount of 
lipid accumulation was analyzed as previously described. Images were analyzed in ImageJ and data are shown as 
the mean ± SD from one representative experiment out of three independent experiments.
Statistically significantly different from control. (P< 0.05).
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Fig.5 – Effect of genistein, rosiglitazone and TBT on 3T3-L1 differentiation
The 3T3-L1 cells were cultured in the 6-well plates to confluence and exposed to standard MDI induction media, and then during 
differentiation they were exposed to 100 nM TBT, 5 mM rosiglitazone or 25 and 75 mM of genistein. In the lowest panel the 
3T3-L1 cells were exposed to standard MDI induction media in the presence of 0.5 mM rosiglitazone (+ 0.5 mM Rosi), and then 
exposed to 25 or 75 mM genistein during differentiation. The control was cells supplemented with DMSO instead of test 
compound. The assay was ended by staining the cells with Oil Red O and photomicrographs were taken at 10x magnification. 
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Fig. 6 – The effect of the PE mixtures and Coumestrol on PPAR a and g transactivation . 
To examine the effect of the different mixtures and coumestrol on ligand-induced PPAR transactication, NIH-3T3 cells were 
transiently transfected with expression plasmid for the ligand binding domain of either mouse PPARa or mouse PPARg 
coupled to Gal4 and a plasmid containing an UAS linked luciferase reporter gene (UAS-TK-luc). Results are shown as activity 
obtained relative to the activity is wells containing media only (control = 100%). Data represent mean ± SD of three 
independent experiments.  C = cytotoxic. * Statistically significantly different from control. (P< 0.05).
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